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Summary 
Cystic Fibrosis (CF) is caused by mutations in the gene encoding the CF transmembrane 
conductance regulator (CFTR) protein. CFTR is the apical cAMP activated Cl- channel of 
epithelial cells. Mutations of this protein cause disruption of the electrolyte balance, leading to 
the formation of thick and sticky mucus in the lungs, and a variety of other problems. Cystic 
Fibrosis is a multifaceted disease and, despite being monogenic, its treatment is very 
challenging. Current therapies aim to modulate defective CFTR but are beneficial only to 
patients harboring a restricted number of mutations including F508del and G551D, thus 
excluding about 15% of the patients carrying so-called “unrescuable” mutations. Therefore, 
bypass therapies are of great importance to many patients who could benefit from them 
regardless of their genotype. This implies that with the increase in the number of mutations 
that are sensitive to a given therapy, the costs would diminish and the accessibility to the 
treatment should increase accordingly.  
TMEM16A (Anoctamin 1; ANO1) is the major contributor to Ca2+ activated Cl- secretion in the 
airways and is regarded as the ideal druggable channel to bypass defective CFTR dependent 
Cl- secretion. In the present work we demonstrate that TMEM16A facilitates 
compartmentalized Ca2+ store release in membrane microdomains. Modulation of intracellular 
Ca2+ by TMEM16A is necessary for proper function as well as membrane insertion of CFTR. 
We showed that cAMP-dependent and Ca2+ activated Cl- currents in airway epithelial cells 
strongly overlap due to crosstalk of intracellular signaling molecules. Intracellular Ca2+ rise 
mediated by TMEM16A triggers so-called Store Operated cAMP signaling (SOcAMPs) and 
activates Ca2+ regulated adenylyl cyclase 1 (ADCY1) and the exchange protein directly 
activated by cAMP (EPAC1). This crosstalk is compartmentalized and supports activation of 
both, TMEM16A and CFTR.  
Our tissue specific knockout model for TMEM16A showed a peculiar phenotype due to 
intracellular mucus accumulation. We found that TMEM16A is essential for ATP-dependent 
constitutive exocytosis of mucus in airways and intestine. Moreover, we demonstrate that 
TMEM16A is upregulated in inflammatory airway disease. This upregulation occurs in 
epithelial cells as well as airway smooth muscle. We concluded that the effect of TMEM16A 
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on intracellular Ca2+ signaling contributes to mucus hypersecretion and airways 
bronchoconstriction. As further shown, inhibition of TMEM16 proteins has beneficial effects in 
inflammatory airway disease by inhibiting mucus release and promoting bronchorelaxation 
and in addition, shows anti-inflammatory effects. TMEM16 inhibitors are therefore suggested 
as novel potential drugs for the treatment of CF lung disease and other inflammatory airway 
diseases.
Zusammenfassung 
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Zusammenfassung 
Mukoviszidose (Zystische Fibrose, Cystic Fibrosis, CF) wird durch Mutationen im CFTR 
(Cystic Fibrosis Transmembrane Conductance Regulator) Gen verursacht. CFTR ist der 
apikale cAMP-aktivierte Cl- Kanal in Epithelzellen. Mutationen im CFTR Protein führen zu 
einer Störung des Elektrolyttransports, was zur Bildung von hochviskösem und adhäsivem 
Schleim in Lunge und Darm sowie zu einer Vielzahl von Störungen in anderen Organen führt. 
Die Mukoviszidose ist eine vielschichtige Krankheit. Obwohl sie monogen vererbt wird, weist 
sie eine Vielzahl von zellulären Defekten und klinischen Symptomen auf. Die Behandlung der 
Erkrankung erweist sich als schwierig. Die derzeitigen Therapien zielen darauf ab, die 
Restfunktion des mutierten CFTRs zu aktivieren. Dies ist aber nur bei etwa 85 % der 
Patienten möglich. Etwa 15% der Patienten mit nicht korrigierbaren Mutationen sind von 
diesen Therapien ausgeschlossen. Daher sind neue therapeutische Ansätze erforderlich. Ein 
möglicher Ansatz besteht in der pharmakologischen Beeinflussung weiterer zellulärer 
Ionenkanäle, um den CFTR-Defekt zu kompensieren. Viele Patienten könnten von diesen 
sogenannten Bypass-Therapien unabhängig von ihrem Genotyp profitieren. Darüber hinaus 
könnte eine solche Behandlung für alle CF-Patienten zugänglich sein und die derzeit 
enormen Behandlungskosten senken. 
TMEM16A (Anoctamin 1; ANO1) ist der Hauptfaktor für die Ca2+ aktivierte Cl- Sekretion in den 
Atemwegen und gilt als idealer pharmakologischer Angriffspunkt zur Umgehung defekter 
CFTR-abhängiger Cl- Sekretion. Die vorliegende Arbeit zeigt, dass TMEM16A die Freisetzung 
von Ca2+ in Membran-Mikrodomänen erleichtert. Die Modulation von intrazellulärem Ca2+ 
durch TMEM16A ist für die korrekte Funktion sowie für die Membraninsertion von CFTR 
notwendig. Weiterhin wurde deutlich, dass sich die cAMP-abhängigen und Ca2+-aktivierten Cl- 
Ströme in Atemwegsepithelzellen aufgrund des Nebeneinanders von intrazellulären 
Signalmolekülen stark überlappen. Der intrazelluläre Ca2+-Anstieg, der durch TMEM16A 
vermittelt wird, löst das so genannte Store Operated cAMP-Signaling (SOcAMPs) aus und 
aktiviert die Ca2+ regulierte Adenylylcyclase 1 (ADCY1) und das Austauschprotein aktiviert 
durch cAMP (EPAC1). Diese kompartimentalisierten Wechselwirkungen von Signalmolekülen 
führen zusammen zur Aktivierung von TMEM16A und CFTR.  
Zusammenfassung 
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Gewebespezifische Knockout-Modelle für TMEM16A zeigen in den Atemwegen und im Darm 
aufgrund der intrazellulären Akkumulation von Schleim einen auffälligen Phänotyp. TMEM16A 
ist für die ATP-abhängige konstitutive Exozytose von Schleim in Atemwegen und Darm 
unerlässlich. Darüber zeigt die Arbeit, dass TMEM16A bei entzündlichen 
Atemwegserkrankungen hochreguliert ist. Die erhöhte Expression von TMEM16A tritt sowohl 
in Epithelzellen als auch in der glatten Muskulatur der Atemwege auf. Die erhobenen Daten 
lassen darauf schließen, dass die Wirkung von TMEM16A auf die intrazellulären Ca2+-
Signalwege zur Schleimhypersekretion und Atemwegsbronchokonstriktion beiträgt. Wie 
weiter gezeigt, hat die Hemmung der TMEM16-Proteine positive Auswirkungen auf die 
entzündliche Atemwegserkrankung durch Hemmung der Schleimfreisetzung und 
Bronchorelaxation. Darüber hinaus zeigt es entzündungshemmende Effekte. TMEM16-
Hemmer werden daher als neuartige potenzielle Medikamente zur Behandlung von CF-
Lungenerkrankungen und anderen entzündlichen Atemwegserkrankungen vorgeschlagen. 
Preface 
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Chapter 1 
Introduction  
 
Cystic Fibrosis 
Cystic Fibrosis (CF) is an autosomal recessive disorder caused by mutations in the Cystic 
Fibrosis transmembrane conductance regulator (CFTR) gene. The frequency of CF varies 
around the globe. It is particularly common among Caucasians of Northern European 
descent, with an incidence of 1 in every 2500-3000 newborns 1. CFTR is a complex cAMP-
activated chloride (Cl-) channel and regulatory protein found in the apical membranes of 
epithelial cells in all exocrine tissues. Deficient CFTR causes imbalanced transport of chloride 
and bicarbonate and leads to the formation of a thick, viscous secretion in lungs, pancreas, 
liver, intestine, and reproductive tract. CF patients also show an increased salt content in their 
sweat 2,3. Clinically, lung disease is the most severe problem in the majority of CF patients. 
However, the phenotypic spectrum of CF is complex and several organs can be affected. In 
the gastrointestinal tract, plugs of meconium appear in the distal ileum after the 17th week of 
gestation, leading to an obstruction that causes dilatation and perforation of the ileal wall, a 
condition called meconium ileus. Due to their altered composition, pancreatic secretion in CF 
is characterized by low pH, reduced volume and higher protein content. Precipitation in the 
duct lamina results in obstruction, inflammation and general fibrosis. Intrahepatic and 
extrahepatic stones, due to the accumulation of mucus in the liver, are found in around 15% 
of CF patients. Gallbladder calculi, affecting around 12% of all CF cases, often accompany 
liver pathology. Kidney stones 4, renal amyloidosis and immune complex glomerulonephritis 
occur in a large number of CF patients. Around 97% of all males with CF suffer from the 
Congenital Absence of the Vas Deferens (CAVD), while 20% of affected women have reduced 
fertility due to thickened cervical mucus. Of all the various symptoms of CF, mucus 
hyperproduction with consequent obstruction of the distal airways and submucosal glands is 
the main cause for morbidity and mortality in affected individuals 5, 6. 
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The CFTR Cl- channel 
In 1989 the CF gene was discovered by linkage analysis by Riordan et al., who located the 
gene on the long arm of chromosome 7 (7q31.2) 7. CFTR encodes a member of the ATP-
binding cassette (ABC) transporter superfamily that, unlike canonical ABC transporters, forms 
a Cl- channel 8. CFTR consists of two membrane spanning domains (MSDs) with six 
transmembrane helices each, two cytoplasmic nucleotide-binding domains (NBDs) that 
hydrolyze ATP, and a phosphorylation dependent regulatory (R) domain that allows the 
channel to open upon phosphorylation by cAMP-dependent protein kinase A (PKA) (Fig 1) 8-
10. Peculiar of CFTR is a N-terminal interfacial structure named lasso motif (represented in 
dark blue in Fig.1). It is speculated that the lasso domain interaction with the R domain 
regulates the gating of the channel 11, however no direct contact was reported 9. The 
contributions of the different domains to the functions of CFTR have been thoroughly 
investigated over the years, through study of CFTR variants containing site-directed 
mutations 11. By using Cl- channel inhibitors of different sizes, the narrowest part of the pore 
was found to be around 5.3 Å 12. 
 
Fig 1.1 Cryo-EM CFTR structure. 
Transmembrane domain 1 and 2 (TMD1, TMD2) are represented in green and blue (together with the 
respective nucleotide binding domains 1 and 2; NBD1, NBD2). The Lasso motive is in dark blue. The 
Regulatory domain (R domain) is in red. Reprinted from 
9
. 
Whereas standard ABC transporters actively transport solutes by consuming ATP, CFTR 
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possesses the unique characteristic of using ATP hydrolysis to open the channel pore, 
through which ions flow only along their electrochemical gradient. Assembly of two MSDs 
forms the pore 12-14. In patch clamp experiments the CFTR channel shows a small single-
channel conductance (6-10 pS) with a linear current-voltage (I-V) relationship. In addition the 
channel displays a time and voltage-independent gating behavior, and an anion over cation 
selectivity. Its permeability sequence is Br- ≥ Cl- ≥ I-, with a corresponding conductance 
sequence of Cl ≥ Br ≥ I 15, 16. 
There are currently 2027 known mutations of CFTR, 400 of which cause Cystic Fibrosis 
(www.genet.sickkids.on.ca). They are divided into seven classes, according to the 
mechanism by which they disrupt synthesis, trafficking, or function of CFTR (Table 1).  
 
Class Mutation type (s) Examples 
Class I: Lack of CFTR 
synthesis 
Nonsense mutation, frameshift, 
deletions. 
W1282X, R553X, 
G542X 
Class II: Defective protein 
processing 
Missense mutations and in frame 
deletions disrupt CFTR folding and 
trafficking 
F508del, N1303K 
Class III: Defective 
channel regulation or 
channel gating 
Missense mutations resulting in 
aminoacid substitutions 
G551D, G551S, 
G1349D 
Class IV: Defective 
chloride conductance 
Missense mutations resulting in 
changes to the CFTR pore region 
R117H, R334W, 
R347P 
Class V: Reduced amount 
of CFTR protein 
Missense mutations resulting in 
alternative splicing that disrupt 
mRNA processing 
2789+5G →A, 
A455E 
Class VI: Increased 
turnover of CFTR channel 
at the cell surface 
Various mutations resulting in 
unstable CFTR at the membrane 
Rescued F508del, 
120del23, N287Y 
Class VII: “Unrescuable 
mutations” 
Large deletions 
CFTRdele2,3 (21 
kb) 
 Table 1 Classes of CFTR mutations, adapted from 
17
. 
The most common CF-associated mutation belongs to Class II. It is a phenylalanine deletion 
at residue 508, named F508del-CFTR, and is present in at least one allele in about 70% of all 
patients in Europe and North America 8. CFTR bearing the F508del mutation is misfolded and 
does not progress through the normal biosynthetic pathway. Instead it is retained in the 
endoplasmatic reticulum (ER) by chaperone proteins (Hsp 70 18, Hsp 90 19, Hsp40 20) and 
undergoes premature degradation by the proteasome complex. The F508del-CFTR protein 
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shares similar biophysical properties with wild-type (wt)-CFTR: small single conductance (6-
10pS), linear I-V relationship, selectivity for anions over cations, and equivalent permeability 
sequence 21. However, the F508del mutation occurs at a critical interface, impairing the ATP-
dependent CFTR gating 21,22. Other common CF mutations, such as G542X (a Class I 
mutation, present in 5% of CF cases), affect production of the protein, while Class III 
mutations (e.g., G551D, found in 4%) lead to defective channel gating. The Class I mutations 
W1282X and R553X are each found in 2.5% of CF cases. R117H (Class IV) causes defective 
conductance and has a 1% incidence (http://www.genet.sickkids.on.ca/app).  
Progress has been made with regard to symptomatic treatments and therapies that target the 
molecular defect of CF. Several therapies for CF are based on the use of pharmacological 
chaperones (correctors), designed to overcome defective trafficking of Class II mutants, 
combined with molecules that repair the gating defect that is associated with F508delCFTR 
and other mutants in classes III and IV (potentiators).  
The identification and characterization of CFTR activators started in 2002 23. Verkman et al. 
screened 60,000 compounds to look for activators of wt-CFTR that would activate G551D-
CFTR and F508del-CFTR. Out of 57 activators of wt-CFTR only three significantly activated 
G551D-CFTR, and a few more the F508del-CFTR. The same group screened 100,000 
compounds 24 for potentiators to correct the defective F508del-CFTR gating. They were able 
to identify by high-throughput screening a collection of diverse small molecules (1000 
compounds) with high affinity for F508del-CFTR. The search for compounds continued and 
eventually led to the discovery of VRT-532 and VRT-422/VRT-325. The former potentiates 
PKA-stimulated gating of defective F508del-CFTR, the latter corrects the trafficking defect of 
F508del-CFTR25. Vertex Pharmaceuticals screened over 228,000 compounds and identified 
VX-770 (Ivacaftor), a CFTR potentiator that enhances the activity of G551D-CFTR. Treatment 
of F508delCFTRcells with 1 µmol/l of VX-770 restored the channel activity to wt-CFTR levels 
26. In addition, CFBE with genotype F508del/G551D-CFTR incubated with VX-770 (10 μmol/l) 
increased airway surface liquid (ASL) volume and ciliary beat frequency (CBF) to levels about 
half of those of wt-CFTR 21. VX-770 was the first potentiator that was tested in the clinic and it 
was approved by the US Food and Drug administration (FDA) in 2012. Ivacaftor is currently 
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used as a drug for patients (children 6 years) harboring the G551D mutation and was 
approved to treat 23 additional mutations27. Lumacaftor (VX-809), also developed by Vertex, 
is a CFTR corrector used in combination with Ivacaftor. It is marketed under the name 
OrkambiTM and used in patients homozygous for F508delCFTR28, 29. Despite great promises of 
these compounds, other studies showed controversial results. Veit et al demonstrated that 
chronic co-administration of Lumacaftor and Ivacaftor reduces biosynthesis of F508del-
CFTR30. A study conducted by Cholon et al demonstrated that chronic treatment with 
Ivacaftor negatively affects the pharmacological correction of F508delCFTR by Lumacaftor 
and VX-661 30. Costs of these drugs are another major issue: Ivacaftor and Orkambi are 
rather expensive treatments, with costs ranging between 250.000 and 300.000 US$ per 
patient and year 31. In 2018 the FDA approved Tezacaftor (VX-661), a corrector that aims to 
restore CFTR traffic to the membrane. It is sold in combination with Ivacaftor under the name 
SymdekoTM for patients having two copies of F508delCFTR 32. A recent study identified three 
correctors (type I, II, and III) that individually exhibit only marginal effects, but in combination 
robustly restored expression and function of mutant CFTR 33. These studies represent the 
proof of concept that compounds targeting distinct structural defects of CFTR can 
synergistically rescue mutant CFTR. In 2018 two new next generation correctors (VX-445 and 
VX-659) used in combination with Tezacaftor and Ivacaftor showed positive effects in CF 
patients who were heterozygous for the F508del-CFTR mutation and a minimal-function 
CFTR mutation (Phe508del–MF genotypes) or homozygous for the F508del-CFTR mutation 
(F508del–F508del genotype) 323,324. 
Despite extensive research for suitable small molecules targeting mutant CFTR, there is still a 
need for treatments all CF patients would benefit from. For this reason the so-called  
”mutation agnostic therapies”, whose aim it is to bypass the loss of the CFTR mediated Cl- 
transport, are interesting. Along this line, alternative ion channels that may compensate for 
the lack of functional CFTR have long been proposed as a treatment in CF.  
 
Alternative therapies for Cystic Fibrosis 
Many ion channels and transporters are promising non-CFTR targets. Among which are 
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TMEM16A (also called Anoctamin 1) and possibly TMEM16F (Anoctamin 6), SLC9A3, 
SLC26A9 (Solute Carrier 9A3 and 26A9) and the Epithelial Sodium Channel ENaC. 
TMEM16A and TMEM16F are part of the Anoctamins protein family, and are both plasma 
membrane localized. TMEM16A is a Ca2+ activated Cl- Channel (CaCC), present in many 
secretory epithelia, while the role of TMEM16F is somewhat controversial. In fact, TMEM16F 
is thought to be both an ion channel and phospholipid scramblase34. SLC9A3 encodes for a 
sodium-proton exchanger. Its variant rs4957061 has been associated with lung decline and 
earlier onset age of P.aeruginosa infections35 in children with CF. Interestingly SLC9A3 
interacts with CFTR via a regulatory complex of NHERF2, Ezrin and PKA. Co-binding of 
CFTR and SLC9A3 to the PDZ domains of NHERF-2 lead to PKA mediated suppression of 
SLC9A3. Disruption of CFTR might lead to excessive SLC9A3 activity, and therefore 
acidification of the ASL 36. Deletion of SLC9A3 in a CF mouse model decreased the rate of 
intestinal obstruction and reverted the intestinal pathology 37. SLC26A9 is a chloride-
bicarbonate exchanger abundantly expressed in gastric epithelial cells. Variations of this 
protein are associated with diabetes mellitus 38 and meconium ileus 39. In addition Slc26a9-
null mice displayed impaired Cl- gastric secretion 40. ENaC is the essential channel for 
electrogenic Na+ absorption in epithelial tissues41. Loss of CFTR has been linked to increased 
function of ENaC and therefore Na+ hyperabsorption has been proposed as the main reason 
for CF lung disease42. In fact numerous findings supported the concept of Na+ 
hyperabsorption43-45 as a leading cause for CF lung and intestinal disease. Na+ 
hyperabsorption causes airways dehydration, plugging with thickened mucus and impaired 
mucociliary clearance (MCC). Numerous groups, including ours, detected enhanced Na+ 
conductance in nasal ex vivo tissue and nasal cells from CF patients46. However, this model 
was challenged by other studies, which did not provide evidence for Na+ hyperabsorption in 
CF airways 47, 48. 
In recent years the protons pump ATP12A that is expressed in airway epithelial cells, 
attracted attention. Several studies demonstrated that ATP12A mediates airway H+ secretion. 
In normal conditions, H+ secretion is counterbalanced by bicarbonate transport. This is 
unbalanced in CF. Proton accumulation causes acidification of the ASL, which compromises 
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local innate immune defense by ß-defensins, thereby favoring bacterial infections 49, 50. Thus, 
inhibition of ATP12A might have a beneficial effect on CF airways.  
Targeting alternative channels, transporters or pumps may be beneficial to all patients, 
regardless of their underlying CFTR-mutation. Activating alternative Cl- channels may 
compensate for the lack of CFTR, and thus restore epithelial Cl- secretion. Activation of CaCC 
was already tested in a clinical trial with Denofusol, a P2Y2 agonist that stimulates Ca
2+ 
activated chloride secretion. Despite the potential of this approach, the inhalation of 
Denofusol was unsuccessful in a phase III clinical trial. The likely reason for the negative 
outcome might be the limited half-life time of the compound in airways, which is only 17 
minutes 51. Direct activation of TMEM16A by small molecules has not yet been examined in 
patients. However, given the broad expression of TMEM16A in smooth muscle cells and its 
role in nociception, further studies are needed to clarify the consequences of activation of 
TMEM16A. In fact, stimulation of TMEM16A results in membrane depolarization causing 
muscular contraction and potentially bronchoconstriction52. During the experimental work on 
my PhD thesis, I focused on the role of TMEM16A and TMEM16F for Cl- transport in the 
airways and other epithelial tissues. However, other members of the TMEM16 protein family 
have been shown to play a relevant role in cellular homeostasis. An overview, summarizing 
other TMEM16 proteins is given in Table 2 of Appendix I.  
 
TMEM16A and TMEM16F 
Epithelial and non-epithelial Ca2+ activated Cl- channels (CaCC) are involved in many 
physiological processes such as electrolyte/fluid secretion, smooth muscle excitability, and 
olfactory perception. The molecular identity of these channels was unknown until 2008, when 
three independent groups identified TMEM16A as the Ca2+-activated Cl- channel53-56. 
TMEM16 proteins are a family of 10 transmembrane protein members (TMEM16A to 
TMEM16K) abundantly expressed in many cell types 57. The first two members TMEM16A 
and TMEM16B function as Ca2+ activated chloride channels, while TMEM16C, D, G, J and in 
particular TMEM16F are phospholipid scramblases. Scramblases are proteins responsible for 
the translocation of phospholipids across the cell membrane. TMEM16A and TMEM16B are 
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voltage-dependent, small conductance (1-3 pS) chloride channels that are activated by an 
increase in intracellular Ca2+ above 150 nmol/l 58. They produce time dependent currents with 
a strongly outwardly rectifying current-voltage (I-V) relationship. They are characterized by a 
permeability sequence of I-≥Br-≥Cl- ≥F with a similar conductivity for I- and Cl- 53. Initial insights 
into the structure of these proteins were obtained from X-ray crystallography studies on the 
lipid scramblase of the fungus Nectria haematococca (nhTMEM16) in 2014 59. This study 
confirmed the homodimeric organization of TMEM16 proteins and identified ten membrane 
spanning helices rather than the to eight initially predicted. Most interestingly it recognized the 
presence of a dimer cavity (of unknown function) and of a subunit cavity (linked to Ca2+ 
activation) 59 (Fig 3). 
 
 
Fig 1. 2 Ribbon representation of the nhTMEM16 dimer (green and red). 
 The view is from within the membrane. Bound calcium ions are shown as blue spheres. Reprinted 
from 
59
. 
 
Further studies in 2017 purified a murine Tmem16A in the absence and presence of Ca2+, 
and determined the structure of the channel under both conditions by single-particle Cryo-
Electron Microscopy (Cryo-EM) 60. The study established the structure of the channel in both 
open and closed conformations, and proposed a mechanism of activation (Fig 4). The authors 
proved that the binding of Ca2+ alters the properties of the ion conduction path and triggers a 
rearrangement of the α-helix number six. The contact between the helix and the bound ligand 
causes the opening of the pore (Fig 1.3). 
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Fig 1. 3 Cryo-EM model for mouse TMEM16A activation. 
A) Schematic representation of Tmem16a activation upon Ca
2+
 binding. Each transmembrane unit 
consists of ten membrane-spanning αhelices. In the closed state the α6 helix is in the relaxed state, 
leaving space for the binding of (presumably) two Ca
2+
 ions to four acidic residues on α7 and α8. B) 
Formation of a -helix lead to the conformational change in α6 upon Ca
2+
 binding. Reprinted from
60
. 
 
TMEM16A is upregulated in various types of cancer such as head and neck squamous cell 
carcinoma (HNSCC) and colon cancer and is generally linked with cells hyperproliferation, 
migration, and apoptosis. TMEM16F is together with TMEM16A the most studied TMEM16 
protein, although its physiological role remain controversial. It is highly expressed among 
various cells and tissues, and it has been endowed with both Ca2+ activated phospholipid 
scrambling activity 61 and with chloride 62 and cation 63 ion channel activity. TMEM16F is also 
activated during cell swelling 64. Recent studies attributed a role of TMEM16F in mediating 
cell death through ROS-activation of the channel itself 65. TMEM16F missense mutations 
have been reported in patients with the Scott syndrome, a rare congenital bleeding disorder 
caused by a defect in a platelet mechanism required for blood coagulation 61, 66.  
TMEM16 proteins are an unusual family with dual functions. It is suggested that the 
phospholipid scrambling and the transmembrane ion flux could be mediated by the same 
pore. When TMEM16A and B were identifed as Ca2+ activated Cl- channels 67, 68, it was 
expected that the remaining members of the family would have the same properties. However 
then TMEM16F was identified as a scramblase. The structural characterization of 
nhTMEM16, a TMEM16F homologue, from the fungus Netria Hematococca, revealed the 
presence of a hydrophilic enviroment required for phospholipid scrambling, but a separate 
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pore for ion transport could not be detected 60. These results supported the hypothesis that 
phospholipid scrambling was the ancestral activity of TMEM16 proteins. Some members, 
namely TMEM16A and TMEM16B obviously have lost their ability to shuttle phospholipids 
between both membrane leaflets by narrowing the conductive pore, but maintaining the ability 
to conduct anions. In 2016 a study on the structure of a mouse Tmem16A (mTmem16A) 
unraveled how TMEM16 proteins use similar structures to accomplish different functions of 
Ca2+ activated Cl- channel and phospholipid scrambles69. The authors claimed that the helices 
constituting the polar cavity in scramblases have changed their location in channels to form a 
protein-enclosed enviroment. To unravel this duality further functional studies are required. 
The localization of TMEM16 proteins within the plasma membrane is also of interest, as they 
seem to be localized in lipid rafts 70. 
 
Membrane microdomains 
The plasma membrane mediates exchange of metabolic material and biochemical signaling. 
Therefore, highly differentiated compartments are required. The plasma membrane is defined 
as a fluid mosaic 71, in which the lipid bilayer houses several components (transmembrane 
proteins, lipids) that can freely diffuse. The lipidic component can segregate in functionalized 
microdomains, also referred as lipid rafts 72. Lipid rafts are believed to regulate signaling by 
providing concentrated microenvironments for lipid and protein components of signaling 
pathways 73. These microdomains contain higher amounts of cholesterol (3 to 5 fold increase 
compared to the surrounding lipid bilayer), and are enriched in sphingomyelin. The 
hydrophobic residues contained in the lipids are more tightly packed and saturated than the 
rest of the membrane and interact with cholesterol in gluing and stabilizing the membrane 74. 
Two kinds of lipid rafts have been described according to the presence of caveolin: caveolae 
and non caveolar or planar lipid rafts 75. Caveolae can be invaginated or detached vesicles, 
and are mainly composed of cholesterol, sphingolipids and caveolin, while non-caveolar lipid 
rafts are composed of phospholipids 76.  
Three different isoforms of Caveolin have been decribed: Caveolin 1, 2 and 3 (CAV1/2/3). 
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CAV1 and CAV2 are ubiquitously expressed while CAV3 is mostly expressed in skeletal and 
cardiac smooth muscles 77. Membrane rafts have been reported to play a significant role in 
many biological processes, including signal transduction pathways, apoptosis, viral infections, 
cell adhesion and migration, synaptic transmission, organization of the cytoskeleton, and 
plasma membrane protein sorting during both exocytosis and endocytosis. For more than 
three decades lipid rafts have been proposed to influence the homeostasis of Ca2+ signaling. 
Recently the link between Ca2+ and lipid rafts has been further elucidated. A mechanism of 
Ca2+ entry via CAV1 has been proposed 78. Evidence was provided that CAV1 containing lipid 
rafts may also contain TMEM16A and the proteins which are essential for the TMEM16A 
mediated Ca2+ activated chloride secretion 79; namely P2Y2 receptors, IP3 receptors, GPCRs, 
and part of the ER 80.  
 
Mucins and exocytosis 
Mucus hypersecretion is a hallmark of chronic airway diseases such as asthma, chronic 
obstructive pulmonary disease (COPD), and Cystic Fibrosis. Goblet cell hyperplasia and 
persistent inflammation are characteristic pathologic features and the main causes of 
pulmonary complications and mortality in CF patients 81. Under physiological conditions the 
mucus forms a barrier against bacteria, traps inhaled particles and prevents desiccation of the 
airways surfaces. Functioning as part of the innate immune system, mucus consists of a 
mixture of secreted polypeptides, water, ions and cellular debris 82, overlying the airway 
epithelial cells 83, 84. In other epithelia such as the stomach and the colon, mucus is composed 
of two layers, an adherent layer secreted by goblet cells that is impermeable to bacteria, and 
a non-adherent layer formed by accumulation of mucins released from the adherent layer, 
which traps the bacteria 85, 86. 
Mucins are the most abundant macromolecules present in mucus. They are heavily 
glycosylated proteins that can easily reach very high molecular weights and confer mucus its 
elastic and gel-forming properties. Mucins are mainly constituted of chains of oligosaccharids 
linked to a protein backbone and a high number of threonine/serine and proline rich tandem 
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repeats (TRs). The protein backbone of the mucins determines the class in which they belong 
87 (Table 2). 
 
Table 2 Class of mucins, adapted from 
88
. 
In lung, the predominant mucins are MUC5AC (airway epithelium) and MUC5AB (in 
submucosal glands), while MUC2 is predominantly produced in the gastro intestinal tract 88. 
Mucins are stored intracellularly in a highly condensed form and compacted in granules. In 
order to be properly unfolded the negative charges need to be shielded by positive ions, 
namely Ca2+ or H+ 89. After being exocytosed the mucins virtually explode and expand within a 
couple of seconds to a volume that is up to three orders of magnitude larger than the 
condensed mucins. This process depends on HCO3
-, which binds Ca2+ and H+ and forms 
CaHCO3
-, CaCO3 and H2CO3
-, which ultimately will lead to the formation of water (H2O) and 
carbon dioxide (CO2). The negative core of mucins is then exposed and will force the 
compacted mucins into open-soluble and easily transportable strings 90, 91.  
Exocytosis of mucin granules is a Ca2+ dependent event, following agonistic stimulation of 
P2Y2 receptors (via ATP or UTP), A3 adenosine receptors or protease-activated receptors 
92. 
Unlike intestinal goblet cells 93, stimulation of CFTR by cAMP in the airways does not lead to 
mucin secretion 94. Low stimulation of P2Y2 and A3 adenosine receptors induce basal 
secretion of mucin by paracrine release of ATP and adenosine (constitutive exocytosis). On 
the contrary, high levels of these ligands as well as inflammatory mediators leads to massive 
secretion called compound exocytosis. Once the receptors are activated, a signaling cascade 
triggers the formation of diacylglycerol (DAG) and triphosphoinositol (IP3) from 
phosphatidylinositol 4,5-bisphosphate (PIP2). IP3 binds to the inositol trisphosphate receptor 
(IP3R) and causes Ca
2+ release from the ER. The Ca2+ represents the key signal to trigger 
exocytosis. It is involved in both the fusion of the secretory vesicles with the plasma 
Membrane tethered 
MUC1, MUC3A, MUC3B, MUC4, MUC11, MUC12, 
MUC13, MUC16, MUC17, MUC20 
Secreted cysteine 
rich 
MUC2, MUC5AC, MUC5AB, MUC6, MUC19 
Secreted non-
cysteine rich 
MUC7, MUC8, MUC9 
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membrane 95 and in the maturation of the vesicles prior to fusion 96. 
Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) protein has been reported as one 
of the main players of exocytosis 97, 98. It was shown that MARCKS binds to the mucin 
granules together with the Vesicle-associated membrane protein 8 (VAMP8) and the Cysteine 
String Protein (CSP), and that this interaction helps to position granules in place for secretion. 
The regulation of secretory granule (SG) exocytosis depends on the interaction of the 
GTPase Rab27 with the myosin V, which mediates the anchoring of the SG to the plasma 
membrane. After stimulation, the MARCKS protein mediates the recruitment of the SG to the 
actin cytoskeleton, and its successive transport to the periphery of the cell. Consecutively the 
SGs are tethered and docked to the plasma membrane in a process mediated by the soluble 
N-ethylmaleimide sensitive factor attachment receptor (SNARE) proteins that are present on 
secretory vesicles (v-SNAREs, such as VAMP) and their target membranes (t-SNAREs, such 
as Syntaxin and SNAP-25). The v- and t-SNAREs contain-helical domains that interact to 
form a tightly coiled four-helix bundle (the core complex) that brings together the opposing 
membrane 99-101. However, this process requires the presence also of accessory components, 
such as the MUNC proteins. In particular MUNC18 and MUNC13 promote the interaction of 
the core complex and synthaxins 99. Of note is the phenotype of Munc13-2 mice lacking a 
sensor of Ca2+ and DAG that displays accumulation of mucus in the goblet cells in the 
airways 102.  
 
Inflammation and infection in Cystic Fibrosis 
Colonization of the purulent material by opportunistic bacteria represents one of the hallmarks 
of Cystic Fibrosis. In fact, CF patients are particularly susceptible to infection with 
Pseudomonas aeruginosa. Hypotheses have been postulated to justify the frequent 
association of P. aeruginosa and CF lungs. One is that CFTR is also a specific receptor for 
internalization of the bacteria; therefore, loss of CFTR causes a reduction in the bacterial 
clearance from the airways 103. Another is that CFTR, and in particular F508del-CFTR, 
influences the adherence of the bacteria to the epithelial cells 104. The persistence of bacterial 
infection is associated with the evolution of the strain into a mucoid phenotype, which is 
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extremely hard to eradicate. The chronicity of the infection is the main trigger of the 
inflammatory state, characterized by neutrophil accumulation and IL-8 release. Neutrophil 
chemoattraction and degranulation is mediated by IL-8, IL-17 and macrophage derived 
cytokines. Neutrophil degranulation causes release of proteases such as MMP-9 (matrix 
metalloprotease 9) and elastase. The imbalance between protease production and 
antiprotease defenses leads to remodeling and structural weakening of the airways, and 
finally to bronchiectasis and bronchomalacia 105. 
Infection is regarded as the main trigger of the inflammatory state. However, there is evidence 
pointing to an inflammatory response that is independent of infection. Adam et al, suggested 
that CFTR traffic defect causes ER stress and activation of the nuclear factor kappa-light-
chain-enhancer of activated B cell (NF-KB) 
106. Constant lung inflammation and progressive 
release of oxidants and enzymes cause epithelial surface damage and ultimately decline of 
the pulmonary function 3, 107. The sequence of events at the onset of pulmonary infection and 
inflammation is still controversial and not yet fully characterized. Several studies have 
reported CF patients with normal lungs at birth 108. In studies on newborn CF piglets no 
differences were observed between bronchoalveolar lavage (BAL) samples at 6h or 12h in 
terms of IL-8 release and leukocytes count 109. However, cultured BAL of newborn CF piglet 
showed host-defense defects and impaired ability to eradicate bacteria. Several other studies 
reported neutrophil accumulation and elevated levels of IL-8 and elastase in bronchoalveolar 
lavage of CF compared to healthy controls 110. To date the chicken-and-egg conundrum on 
whether inflammation or infection comes first in CF is still an open question. 
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Aim of the study 
My research has focused on understanding the cellular functions and regulation of 
TMEM16A/F. Therefore, the role of TMEM16 proteins as modulators of intracellular Ca2+ 
signaling was investigated and is outlined in Chapter 2. The interaction between TMEM16A 
and CFTR, their regulation by Ca2+ and cAMP, and the mechanisms behind this crosstalk is 
described in Chapter 3 and is further expanded in Chapter 4. A novel concept that identifies 
TMEM16A as a major player in membrane exocytosis and the underlying molecular 
mechanisms are summarized in Chapter 5. Finally, in Chapter 6 a novel therapeutic strategy 
for the treatment of CF lung and intestinal disease is proposed, which is based on 
repurposing a FDA-approved drug for the inhibition of TMEM16A. 
 
Differential effects of anoctamins on intracellular calcium signals 
  
Chapter 2 
Differential effects of anoctamins on intracellular calcium signals 
 
Abstract 
The Ca2+ activated Cl- channel TMEM16A (Anoctamin 1 / ANO1) is homologous to yeast Ist2 
and has been shown to tether the cortical endoplasmic reticulum (ER) to the plasma 
membrane. We therefore examined whether ANO1 and other members of the Anoctamin 
family affect intracellular Ca2+ signals. It is shown that expression of ANO1 augments Ca2+ 
store release upon stimulation of G-protein coupled receptors (GPCR), while knockdown of 
ANO1, or lack of Ano1 expression in Ano1-/- animals as shown in an earlier report, inhibits 
Ca2+ release. ANO 5, 6, 10 show similar effects, while expression of ANO4, 8, 9 attenuate 
filling of the ER store. The impact of ANO1 and ANO4 were examined in more detail. ANO1 
colocalized and interacted with IP3R, while ANO4 colocalized with SERCA Ca
2+ pumps and 
interacted with ORAI1 channels, respectively. ANO1 chloride currents were rapidly activated 
exclusively through Ca2+ store release and remained untouched by influx of extracellular Ca2+. 
In contrast expression of ANO4 caused a delayed activation of membrane localized ANO6 
channels, solely through store operated Ca2+ entry (SOCE) via ORAI. Ca2+ signals were 
inhibited by knocking down expression of endogenous ANO1, 5, 6, 10, and were also reduced 
in epithelial cells from Ano10 null mice. The data suggest that anoctamins affect intracellular 
compartmentalized Ca2+ signals, which may explain some of the cellular defects related to 
Anoctamin mutations. 
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Introduction 
Anoctamins form phospholipid scramblases and ion channels 61, 63, 111-114. They are expressed 
and functional in all types of tissues and have a central role in many different diseases 112. 
ANO1 is essential for chloride transport in epithelial tissues, controls smooth muscles 
contraction and arterial blood pressure and has various functions in neuronal and sensory 
cells 112, 115-118. Many cellular functions of anoctamins, like effects on proliferation, tissue repair, 
bone mineralization and immunological processes are only poorly understood 119-124. 
Recent studies suggest a role of anoctamins in controlling compartmentalized Ca2+ signals 
elicited by activation of G-protein coupled receptors (GPCRs): i) The yeast ANO1 homologue 
Ist2 tethers the endoplasmic reticulum (ER) to the plasma membrane, by means of anchoring 
in the ER membrane and binding of its polybasic C-terminus to the plasma membrane 125. ii) 
In dorsal root ganglia, ANO1 has been shown to be activated exclusively by Ca2+ released 
from the ER. This is achieved by tethering of ANO1-containing plasma membrane to the ER 
membrane via ANO1/IP3R interaction 126. iii) Mid-range Ca2+ signaling requires coupling 
between store-operated Ca2+ entry (SOCE) and IP3-dependent store release 127. iv) Freshly 
isolated intestinal crypt cells from mice lacking Ano1 expression demonstrated abrogated 
GPCR-triggered Ca2+ signals 128. v) Anoctamin-homologous transmembrane channel-like 
protein 8 (TMC8, EVER2) controls GPCR-induced intracellular Ca2+ signaling 129. Here we 
identified a differential role of anoctamins in GPCR-induced Ca2+ signaling: They affect Ca2+ 
release via IP3R as well as the Ca2+ store content, possibly by operating as leakage channels 
or by controlling ORAI or the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA). 
These results may help to explain the ever-growing number of anoctamin-related cellular 
defects and diseases.  
 
Materials and Methods 
Animals, cells, cDNA, RT-PCR, siRNA. Generation of animals with a floxed Ano10 allele 
has been described in an earlier report128. Tissue specific renal tubular knockout was 
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achieved by crossbreeding ANO10loxp/loxp and Pax8Cre+ or Six2Cre+ mice. Offsprings were 
genotyped and tubular ANO10 knockout was verified by RT-PCR and Western blot analysis 
in isolated proximal tubular epithelial cells. All animal experiments were approved by the local 
ethics commission of the University of Regensburg and the University Münster and were 
conducted according to the guidelines of the American Physiological Society and the German 
law for welfare of animals. For isolation of renal proximal tubular epithelial cells, kidneys were 
removed and kept in ice cold PAN, PO4-41250 medium. Cortices were cut off, cells were 
isolated using collagenase type 2 (Worthington, S9H11286) and passed through a sieve. 
After washing, centrifugation and resuspension, cells were run though a percoll gradient (45% 
percoll, 55% 2X PBS-Glucose). Cells were resuspended in media and kept on ice until use. 
HEK293 were grown in DMEM-F12 (GIBCO, Karlsruhe, Germany) supplemented with 10% 
fetal bovine serum at 37°C in the absence of antibiotics in a humidified atmosphere with 5% 
CO2. HeLa cells were grown as described earlier. For expression of anoctamins, cells were 
plated on fibronectin- and collagen-coated 18 cm diameter coverslips and co-transfected with 
cDNA encoding either hTMEM16A, D, E, F, G, H, J, K, or empty pcDNA3.1 vector (mock) 
along with P2Y2 receptor and CD8. Transfected cells were detected by binding of anti-CD8 
labeled beads. Construction of expression plasmids has been described earlier 130. RT-PCR 
analyses were performed using standard conditions and appropriate primers as described 
earlier 130. For semi-quantitative RT-PCR total RNA (1 µg) was isolated from HeLa, reverse-
transcribed using a random primer and M-MLV reverse transcriptase (Promega, Mannheim, 
Germany). The RT-PCR reaction contained sense and antisense primers 130. Knockdown of 
anoctamins by siRNA was reported in our previous study 131. All experiments were performed 
48h after the transfection. 
Immunocytochemistry. Transfected HeLa cells were fixed for 10 minutes with 4% (w/v) PFA 
at RT. Bovine serum albumin (BSA) was added and left for 30 min at RT. Cells were 
incubated for 1 h with primary goat anti-GFP antibody (1:200; Rockland, Philadelphia, USA), 
rabbit anti-IP3R or mouse anti-SERCA (all 1:200; Abcam, UK) in PBS supplemented with 1% 
BSA at 4°C. Cells were washed three times with cold PBS and incubated with the secondary 
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antibody Alexa Fluor 488 conjugated Donkey Anti-Goat IgG (1:500; Molecular Probes, 
Invitrogen, Germany) and 0,1 μg/ml Hoechst 33342 (1:200; Aplichem, Darmstadt, Germany) 
for 1 h. Actin was labeled by Alexa Fluor 647-phalloidin (1:100; Molecular Probes, Invitrogen, 
Germany) and Fluor 555-conjugated donkey anti-rabbit IgG (1:500) or Alexa Fluor 546 
conjugated donkey anti-mouse IgG (1:500; Molecular Probes). Cover slips were mounted with 
fluorescence mounting medium (DAKO Cytomation, Hamburg, Germany). For quantitative 
assays ANO1-GFP and ANO4-GFP transfected HeLa cells were fixed with 4% 
paraformaldehyde in PBS for 10 min, permeabilized with 0,1% Triton X-100 for 10 min at RT 
and incubated with primary antibodies goat anti-GFP, rabbit anti-human IP3 receptor (Abcam, 
UK), or mouse anti-SERCA (Abcam, UK) at 4°C overnight. Secondary antibodies were Alexa 
Fluor 488 goat anti rabbit IgG, Alexa Fluor 555 conjugated donkey anti- rabbit IgG or Alexa 
Fluor 546 conjugated donkey anti- mouse IgG (Molecular Probes, Invitrogen, Germany). 
Nuclei were counterstained with Hoechst 33342 (Sigma-Aldrich, Taufkirchen, Germany). 
Immunofluorescence was detected using an Axiovert 200 microscope equipped with an 
ApoTome and analyzed with the profile measurement tool of Carl Zeiss AxioVision software 
AxioVs40 V4.8.2.0 (Zeiss, Jena, Germany). 
COIP and Western blotting. HeLa cells overexpressing ANO4-GFP or ANO1-GFP were 
collected using 1% CHAPs lysis buffer. 500 µg protein was incubated with antibody at 4°C for 
1h by spinning on a rotator, followed by incubation with pre-cleaned protein G agarose (60 µl) 
at 4°C. Afterward, beads were centrifuged and washed three times with 1% CHAPs lysis 
buffer containing 1X proteinase inhibitor (Roche). Immune complexes were eluted by 2x 
sample buffer. IP samples were analyzed by Western blotting. Samples were separated by 
8.5% and 12.5% SDS-PAGE and transferred onto PVDF membrane. Membrane was blocked 
with 5%NFM/TBS-T or 5%NFM/PBS-T for 1h at RT and incubated overnight at 4°C with rabbit 
anti-ORAI1 (1:1000 in 0.25% BSA/TBS-T), rabbit anti-IP3R (1:1000 in 1% BSA/TBS-T), rabbit 
anti-DOG1 (1:500 in 1% NFM/TBS-T) (Novus,USA), goat anti-GFP (1:1000 in 1% NFM/TBS-
T), mouse anti-SERCa2 (1:1000 in 0.25% BSA/TBS-T) and mouse anti-actin (1:750 in 5% 
NFM/PBS-T) (Santa Cruz, USA). The membrane was incubated with HRP-conjugated goat 
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anti-rabbit IgG (1:10,000 in 1% NFM/TBS-T) for 2 hrs, HRP-conjugated donkey anti-goat IgG 
(1:2,000 in 3% NFM/TBS-T) for 1 h and HRP-conjugated goat anti-mouse IgG (1:5,000 in 1% 
NFM/TBS-T or PBS-T) for 2 hrs at RT. Signals were detected using SuperSignal West Pico 
chemiluminescence substrate (Pierce, USA). Experiments were performed in triplicates. 
Measurement of [Ca2+]i: The plasma membrane bound calcium sensor GCAMP2 was 
modified by the addition of a N-terminal signal peptide (20 aa) from Neuromodulin (Pl-G-
CaMP2 132). Addition of this peptide results in posttranslational palmitoylation of the protein, 
which facilitates anchoring of the protein to the plasma membrane 133. HEK293 cells were 
transfected on coated glass cover slips with pcDNA31 Pl-G-CaMP2 and were mounted in a 
perfusion chamber 48h after transfection. ER Ca2+ signals were detected after expression of 
the Ca2+ sensor ER-LAR-GECO1. Cells were perfused with ringer solution at a rate of 8 
ml/min at 37˚C. Cell fluorescence was measured continuously with an inverted microscope 
Axiovert S100 (Zeiss) using an x40 objective (Fluar 40x/1.3 Oil, Zeiss) and a high-speed 
polychromator system (VisiChrome, Visitron, Puchheim, Germany). Pl-G-CaMP2 was excited 
at 485 nm and 405 nm. Emission was recorded between 520 and 550 nm using a CCD-
camera (CoolSnap HQ, Visitron). Control of experiments, imaging acquisition, and data 
analysis were done with the software package Meta-Fluor (Universal imaging, New York, 
USA). Alternatively, cells were loaded with Fura-2 and intracellular Ca2+ concentrations were 
determined as described earlier 134. 
Patch Clamping. Cells were seeded and patch clamped on glass cover slips. If not indicated 
otherwise, patch pipettes were filled with a cytosolic-like solution containing (in mM): KCl 30, 
K-gluconate 95, NaH2PO4 1.2, Na2HPO4 4.8, EGTA 1, Ca-gluconate 0.758, MgCl2 1.03, D - 
glucose 5, ATP 3, pH 7.2. The Ca2+ activity was 0.1 µM. Cells were perfused with a 
bicarbonate free Ringer bath solution (in mM; NaCl 145, KH2PO4 0.4, K2HPO4 1.6, D-glucose 
6, MgCl2 1, Ca-gluconate 1.3, pH 7.4). Coverslips were mounted in a perfused bath chamber 
on the stage of an inverted microscope (IM35, Zeiss) and kept at 37 °C. The bath was 
perfused continuously with Ringer solution at a rate of 8 ml/min. Patch clamp experiments 
were performed in the fast whole cell configuration. Patch pipettes had an input resistance of 
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2–4 M when filled with the cytosolic like (physiological) solution. Currents were corrected for 
serial resistance. The access conductance was measured continuously and was 60–140 nS. 
Currents (voltage clamp) and voltages (current clamp) were recorded using a patch clamp 
amplifier (EPC 7, List Medical Electronics, Darmstadt, Germany), a LIH1600 interface and 
PULSE software (HEKA, Lambrecht, Germany) as well as Chart software (AD Instruments, 
Spechbach, Germany). Data were stored continuously on a computer hard disc and analyzed 
using PULSE software. In regular intervals, membrane voltage (Vc) was clamped in steps of 
20 mV from -100 to +100 mV. Current density was calculated by dividing whole cell currents 
by cell capacitance.  
Materials and statistical analysis. All compounds used were of highest available grade of 
purity and were from Sigma, Tocris Bioscience, or Merck. Mouse monoclonal anti- calreticulin 
and rabbit anti- actin were from Abcam and Sigma-Aldrich, respectively. Anti- ORAI1 was a 
generous gift from Prof. Dr. Veit Flockerzi (Institute for pharmacology, University of 
Saarlandes). Osmolarity of all solutions was measured using an osmometer. Data are 
reported as mean ± SEM. Student’s t-test for unpaired samples or ANOVA were used for 
statistical analysis. A p-value < 0.05 was accepted as significant difference. 
Results 
Cl- transport affects GPCR-controlled local Ca2+ increase. 
The Ca2+ sensitive dye Fura-2 detects global Ca2+ signals throughout the cell. Activation of 
the purinergic receptors (P2Y2) by ATP induced the typical intracellular Ca
2+ peak and plateau 
increase, indicating a fast release of Ca2+ from the ER (peak), followed by Ca2+ influx through 
store operated Ca2+ influx channels (SOCE) (Fig 2.1A). Fura-2 detects both parts of receptor 
triggered Ca2+ signals, as it distributes more or less homogenously through the cytosol. In 
contrast, the Ca2+ sensor Pl-G-CaMP2 binds to the plasma membrane and detects 
preferentially Ca2+ signals in close proximity of the cell membrane. We found that Pl-G-
CaMP2 detects Ca2+ release from IP3-sensitive ER stores (peak), but not Ca2+ influx (SOCE; 
plateau) (Fig 2.1A). Using GCAMP2 as Ca2+ monitor, we did not detect any Ca2+ rise in the 
ER store depletion protocol after adding CPA or after re-adding Ca2+ in the presence of CPA 
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(Fig 2.1B,C). Interestingly, a negative transient peak was detected by GCAMP2 upon re-
addition of extracellular Ca2+ indicating a transient dip in the local Ca2+ concentration in close 
proximity to the store release site (IP3 receptor). This transient peak may somehow reflect 
refilling of the store, although the mechanisms remain currently obscure. 
 
Fig 2.1 Receptor-mediated increase in intracellular Ca
2+
 is Cl
-
 dependent. 
A) Increase in intracellular Ca
2+
 in HeLa cells by stimulation with ATP (100 µM) was detected by Fura-2 
or by the membrane bound Ca
2+
 sensor Pl-G-CaMP2, fused to a N-terminal signal peptide from 
neuromodulin. While Fura-2 detects Ca
2+
 release from ER (peak) and Ca
2+
 influx through store 
operated Ca
2+
 entry (SOCE; plateau), GCAMP2 detects only ER store release Ca
2+
, indicating local 
separation of store release and Ca
2+
 influx. B, C) Ca
2+
 store release/depletion by stimulation with ATP 
(100 µM) and cyclopiazonic acid (CPA; 10 µM), as detected by Fura-2 (upper panels) or by PI-G-
CAMP2 (lower panels). D) Concentration dependent increase in intracellular Ca
2+
 (arbitrary units; au) 
by ATP. Thimerosal (100 µM), a sensitizer of IP3 receptors was enclosed to detect maximal store 
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release. E,F) Anoctamin inhibitors Niflumic acid (NFA) and CaCCinhAO1 (AO1; both 20 µM) inhibited 
baseline Ca
2+
 and abolished ATP-induced Ca
2+
 release (ΔCa
2+
). G) Summary of ATP-induce Ca
2+
 
increase in the presence of physiological extracellular Cl
-
 concentration (145 mM) or low (5 mM) 
extracellular Cl
-
. H) Western blot indicating knockdown of endogenous expression of ANO1 in CAL27 
cells. I) ATP induced Ca
2+
 signal (measured by PI-G-CAMP2), which was abolished by knockdown of 
ANO1. J) Summary of Ca
2+
 peak and plateau induced by ATP in CAL27 cells. Mean ± SEM (number of 
cells). # significant inhibition by NFA and AO1, and augmented Ca
2+
 release in the presence of 5 Cl
-
 
(ANOVA). 
 
ANO1 is a membrane localized ion channel that probably accumulates in specific cholesterol-
rich membrane compartments, called lipid rafts 79, 135. As ANO1 is preferentially, if not 
exclusively, activated through ER store release 126, and because store release (but not 
SOCE) is picked up well by Pl-G-CaMP2, Pl-G-CaMP2 is probably colocalized together with 
ANO1 in a raft compartment that does not contain elements of the SOCE. Thus, there is a 
spatial separation between Ca2+ release and activation of ANO1, and SOCE influx pathways, 
as nicely demonstrated in an earlier report by Courjaret and Machaca 127. In the present 
experiments maximal store release was achieved at 100 µM ATP (Fig 2.1D). Blockers of 
anoctamins such as NFA or AO1 strongly reduced baseline Ca2+ concentrations and 
completely abolished Ca2+ store release, suggesting a role of Cl- transport through 
anoctamins for Ca2+ signaling (Fig 2.1E,F). Cl- dependence was further supported by the 
finding that ATP-induced Ca2+ increase was augmented in the presence of a low (5 mM; 5Cl- ) 
extracellular Cl- concentration (Fig 2.1G). Possible artifacts of these inhibitors and of 5Cl- on 
intracellular pH, fluorescence intensity or absorbance were excluded in control experiments. 
Moreover, both NFA and AO1 slightly hyperpolarized (11.2 ± 1.6 mV (n=13; NFA) and 12.2 ± 
1.9 mV (n=9; AO1) the membrane voltage. Hyperpolarization of Vm is generally augmenting 
GPCR-mediated Ca2+ signaling, but in our experiments NFA and AO1 inhibited Ca2+ signaling, 
suggesting a role of Cl- conductance for ATP induced Ca2+ transients. 5Cl- depolarized Vm by 
13.4 ± 1.8 mV (n=11). Depolarization of Vm is generally inhibitory on GPCR-mediated Ca2+ 
signaling 136. However, in our experiments 5Cl- augmented Ca2+ increase (Fig 2.1G), arguing 
against an artifact, but supporting the role of Cl- / Cl- conductance for ATP induced Ca2+ 
transients. We observed that siRNA-knockdown of endogenous expression of ANO1 in the 
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head and neck cancer cell line CAL27, inhibited GPCR-mediated Ca2+ increase (Fig 2.1G-J). 
We therefore examined in detail the impact of ANO1 and other anoctamins on intracellular 
Ca2+ signaling. 
 
Anoctamins affect compartmentalized Ca2+ signals. 
We analyzed if anoctamins affect compartmentalized Ca2+ signals triggered by GPCRs in 
HeLa cells. We found that expression of some anoctamins (ANO1, 5, 6, 10; green) 
augmented Ca2+ store release detected by Pl-G-CaMP2, while others (ANO4, 8, 9; red) 
largely reduced Ca2+ signals (Fig 2.2 A,B). ANO4, 6, 8, and 10 were found to be expressed 
endogenously in HeLa cells (not shown). When endogenous Ca2+-enhancing ANO6 and 
ANO10 were knocked down by siRNA, ATP-induced Ca2+ signals were strongly attenuated 
(Fig 2.2 C). Effects of anoctamins on ATP-induced Ca2+ signals or ionomycin induced ER Ca2+ 
store depletion were only partially detected when Fura-2 was used as a global cytosolic Ca2+ 
sensor (data not shown). It appears unlikely that ANO1 affects hydrolysis of PIP2 and 
generation of IP3, when examining fluorescence changes during ATP stimulation of cells 
expressing GFP-tagged PLCδ1PH 137 (Supplementary Fig 2.2 A,B). 
Immunofluorescence labeling of IP3 receptors (IP3R) and overexpressed ANO1 suggested 
colocalization of ANO1/IP3R in close proximity to the plasma membrane (Fig 2.2 D). In 
contrast SERCA colocalized with ANO4 in a cytosolic compartment, but did not co-localize 
with ANO1 (Fig 2.2 E,F). Colocalization of proteins is supported by scanning red (IP3R, 
SERCA) and green fluorescence (ANO1, ANO4) (Fig 2.2 D-F, lowest panels). Moreover, 
fluorescence labeling of the ER protein calreticulin suggested the presence of cortical ER 
close to ANO1, which is located in the plasma membrane, while most ANO4 localized to 
intracellular calreticulin (Supplementary Fig 2.1 C,D). Compounds known to deplete biological 
membranes of cholesterol and to disrupt lipid rafts like methyl-ß-cyclodextrin (MβCD) 138 or 
filipin 139, abolished the inhibitory effects of ANO4 on Ca2+ signaling (Supplementary Fig 2.1E). 
As ORAI1 was detected as the main isoform, ANO4 may be co-localized with ORAI1 in a raft 
population separate from the one containing ANO1.  
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Fig 2. 2: Anoctamins affect intracellular Ca
2+
 signals.  
A) Ca
2+
 store release detected by Pl-G-CaMP2 fluorescence in HeLa cells overexpressing different 
anoctamins. B) Summary of ATP (100 µM) induced Ca
2+
 signals (arbitrary units; au) in the presence of 
different anoctamins, which augmented (ANO1, 5, 6,19; green) or reduced (ANO4, 8, 9; red) Ca
2+
 store 
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release. C) Summary of Ca
2+
 signals in cells treated with scrambled RNA or after knockdown of 
different endogenous anoctamins, which abolished (arbitrary units; au) enhancing (ANO6, ANO10) and 
inhibitory (ANO4, ANO8) effects of anoctamins on Ca
2+
 signals. Successful knockdown of anoctamins 
by siRNA is shown in Supplementary Fig 2.1F. D-F) Immunofluorescence of IP3 receptor, SERCA, 
ANO1 and ANO4 in HeLa cells (upper panels). Scanning of fluorescence intensities (arbitrary units, 
lowest panels) indicated colocalization of cortical IP3R (red) and ANO1 (green) close to the plasma 
membrane (D), but lack of colocalization of SERCA and ANO1 (F). ANO4 was found to be colocalized 
with SERCA (F). Mean ± SEM (number of cells). # significant increase (ANO1,5,6,10; green) and 
inhibition (ANO4,8,9; red) of Ca
2+
 signals by overexpression of anoctamins (ANOVA). § significant 
inhibition of Ca
2+
 signals and mRNA expression by siRNA-knockdown of anoctamins (ANOVA). 
 
Differential interaction of ANO1 and ANO4 with IP3R and ORAI. 
ANO1 augmented but ANO4 strongly inhibited ATP-induced currents. While ANO1 is strictly 
plasma membrane localized, ANO4 is expressed intracellularly in an ER compartment. We 
therefore decided to examine the cellular functions of these anoctamins in more detail. 
Immunocytochemistry may suggest a differential molecular interaction of ANO1 with IP3R and 
ANO4 with ORAI or SERCA 126. This assumption was supported by coimmunoprecipitation of 
ANO1 and IP3R in overexpressing HeLa cells (Fig 2.3 A). In contrast, SERCA (or ORAI; data 
not shown) could not be coimmunoprecipitated with ANO1 (Fig 2.3 B). Moreover, while ANO4 
and ORAI coimmunoprecipitated (Fig 2.3 C), no evidence was found for an interaction of 
ANO4 with IP3R or ANO4 with SERCA (data not shown). This result indeed suggests a 
differential interaction of ANO1 and ANO4 with IP3R/ORAI and suggests that ANO1 and 
ANO4 may control different Ca2+ sources. ANO1 may be activated only by store release Ca2+, 
but not by SOCE, while ANO4 is activated by SOCE, and not by store release. Remarkably, 
and in contrast to Fura-2, store release induced by CPA or Ca2+ influx through SOCE after re-
adding extracellular Ca2+ was not at all detected by GCAMP2 targeted to the IP3R/ANO1 
compartment (not shown). Thus the data strongly suggest that in mammalian cells Ca2+ pools 
(store release Ca2+ and SOCE) are spatially separated, as demonstrated recently in 
experiments in Xenopus oocytes 127 (Fig 2.5 G). 
Differential effects of anoctamins on intracellular calcium signals 
 
44 
       
 
Fig 2.3 Coimmunoprecipitation of ANO1 and ANO4 with IP3 receptor and SERCA in HeLa cells. 
 A) ANO1 was coimmunoprecipitated with IP3R, while IP3R was pulled down with ANO1. B) 
Immunoprecipitation of ANO1 did not pull down SERCA, and no pull down of ANO4 was seen by 
immunoprecipitation of SERCA. C) ORAI was coimmunoprecipitated with ANO4, while 
immunoprecipitation of ORAI pulled down ANO4. D) Control experiment in which ANO1 was pulled 
down and the pulled down protein was detected by ANO1 Western blotting. Experiments were 
performed in triplicates. 
 
We demonstrated earlier that ANO4, similar to ANO1, induces Ca2+ activated Cl- currents 
when overexpressed in HEK293 cells 114. Also in the present study we found that whole cell 
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currents were activated by ATP in ANO1 and in ANO4 expressing HEK293 cells, but not in 
mock transfected cells (Fig 2.4 A-D, I, J). Currents were strongly inhibited by removal of 
extracellular Cl- indicating activation of Cl- currents. Remarkably, ATP-induced Ca2+ increase 
activated ANO1 instantaneously (fast Ca2+ store release), while activation of ANO4 was slow 
(delayed SOCE). This suggests an exclusive crosstalk of store release Ca2+ and ANO1 (Fig 
2.4 E). But how is it possible that expression of ANO4 leads to delayed-activated whole cell 
Cl- currents although ANO4 is expressed in an intracellular compartment? It is known from 
earlier studies that ANO6 is expressed in the plasma membrane and produces delayed Ca2+ 
activated Cl- currents 114, 140, 141. ANO6 has also been shown to be activated through Ca2+ 
influx 140. We therefore speculated that ANO4 may facilitate activation of ANO6 by emptying 
the ER store or by inhibiting filling of the ER store and thereby enhancing Ca2+ influx (SOCE), 
which activates ANO6. We examined mock transfected cells or ANO4-expressing cells 
without or with simultaneous siRNA-knockdown of endogenous ANO6. In mock transfected 
cells (no ANO4), ATP did not activate a current and simultaneous siRNA-knockdown of ANO6 
had only a minor effect. In ANO4-overexpressing cells, a whole cell current was activated by 
ATP, which was largely suppressed by simultaneous knockdown of ANO6. The data indicate 
that expression of ANO4 (intracellular) induces an ATP-induced whole cell current that 
requires plasma membrane localized ANO6 (Supplementary Fig 2.5 D, F, G, H).  
ANO6 is obviously activated by SOCE, while ANO1 is activated by IP3R-mediated Ca2+ 
release. In fact, removal of extracellular Ca2+ did not compromise activation of ANO1, but 
completely abolished activation of ANO6 (in ANO4 expressing cells) (Fig 2.4F). Vice versa, 
inhibition of IP3R with Xestospongin C 142 (IP3R-inhibitor A in Fig 2.4G) or low molecular 
weight heparin (IP3R-inhibitor B in Fig 2.4 G) 
143 blocked activation of ANO1 but had no effect 
on ANO4-induced currents (Fig 2.4). Finally, inhibition of ORAI by YM8483 (ORAI-inh. A)144 or 
GSK-7975A (ORAI-inh. B) 145 completely blocked ANO4 activation, without affecting ANO1. 
These results were validated by performing comparable experiments in HeLa cells, which 
produced essentially identical results (Supplementary Fig 2.2A-D). Taken together, these 
results strongly suggest differential coupling of ANO1 and ANO6 to IP3R and ORAI, 
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respectively (Fig 2.4).  
 
 
Fig 2.4 ANO1 and ANO4 Cl
-
 currents are activated by different Ca
2+
 sources. 
 A) Patch clamp recording of ATP (100 µM) activated whole cell currents in an ANO1-expressing 
HEK293 cells. Inhibition of currents by removal of extracellular Cl
-
 (5Cl
-
). B) Corresponding 
current/voltage relationships. C) Patch clamp recording of ATP activated whole cell currents in an 
ANO4-expressing HEK293 cell. Inhibition of currents by removal of extracellular Cl
-
 (5Cl
-
). D) 
Corresponding current/voltage relationships. E) Current activation during Ca
2+
 peak and plateau. Time 
course for ATP-activation of whole cell currents: Fast activation of ANO1, but delayed activation of 
ANO4. F) Activation of whole cell currents by ATP in ANO1 and ANO4 expressing cells, in the presence 
of high (1 mM) or low (0.1 µM) extracellular Ca
2+
 concentration. Activation of ANO4 requires influx of 
extracellular Ca
2+
 while activation of ANO1 is independent of the extracellular Ca
2+
 concentration. G) 
Effects of compounds inhibiting Ca
2+
 signaling and activation of ANO1 and ANO4. Activation of ANO1 is 
suppressed by inhibition of IP3R with xestospongin C (1 µM/30 min; IP3R-Inh. A) and low molecular 
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weight heparin (1 mM/30 min; IP3R-Inh. B), but not by the ORAI inhibitor YM8483 (5 µM; ORAI-Inh. A). 
In contrast activation of ANO6 (in ANO4-expressing cells) is abolished with YM8483 and GSK-7975A (5 
µM; ORAI-Inh. B), but not by Xestospongin C. The TRPM7 inhibitor NS8593 (10 µM) and the TRPC 
inhibitor SKF-96365 (100 µM) had no effects on activation of ANO4. ORAI inhibitors, NS8593, and 
SKF-96365 were applied acutely, cells were pre-incubated with Xestospongin C and heparin for 10 
min. H) Demonstration of expression of ANO1 (plasma membrane) and ANO4 (intracellular) in HEK293 
cells. I, J) Control experiments in mock transfected cells. ATP did not activate any whole cell currents. 
Mean ± SEM (number of cells). # significant inhibition by low extracellular Ca
2+
 and inhibitors, 
respectively (unpaired t-test and ANOVA). 
 
ANO4, 8, 9 probably lower filling of the ER Ca2+ store.  
ATP-induced Ca2+ peaks and plateau were larger in ANO1-expressing cells, but were small 
and very transient in ANO4 expressing cells, which might be due to reduced store Ca2+ in 
ANO4 expressing cells (Supplementary Fig 2.2 E). In the presence of extracellular Ca2+ free 
solution, the SERCA inhibitor CPA emptied ER Ca2+ stores, leading to a transient Ca2+ 
increase. The results from this store release protocol suggested that expression of ANO4, 8 
and 9 lowered Ca2+ store content, as Ca2+ release was small and quickly collapsing, while 
expression of ANO1, 5, 6 and 10 did not affect store content (Supplementary Fig 2.2 F, G). 
These results are supported by several additional Ca2+ store release protocols described 
above. Taken together, the results suggest that ANO1, 5, 6, and 10 facilitate local ER Ca2+ 
release in close proximity to the plasma membrane. In contrast ANO4, 8, and 9 seem to lower 
the Ca2+ store content. It is likely that localization of ANO4 (and maybe ANO8, 9) in the ER 
membrane leads to a Ca2+ leakage out of the ER, thereby reducing ER store content. In fact 
ANO4 (and other anoctamins) have been described as leaky Cl- channels that are also 
permeable for cations such as Ca2+ 114, 146. Remarkably, augmented ATP-induced Ca2+ signals 
in ANO1-expressing cells, and reduced ATP-induced Ca2+ signals in ANO4 or ANO9 
expressing cells could also be monitored by expression of the Ca2+ activated K+ channel 
hSK4 (KCNN4). ATP-activated hSK4 currents were strongly attenuated in cells expressing 
either ANO4 or ANO9, while expression of ANO1 augmented ATP-activation of hSK4 
(Supplementary Fig 2.2 H-K). 
 
Ca2+ signaling is attenuated in epithelial cells from Ano10-/- mice.  
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It appears essential to demonstrate the role of anoctamins for Ca2+ signaling also in original 
tissues. This has been shown already for Ano1 in intestinal epithelial cells from Ano1 
knockout mice 128. We found a pronounced inhibition of ATP induced Ca2+ signals after siRNA 
knockdown of endogenous ANO10 and, inversely, a strong augmentation of Ca2+ signals in 
ANO10 overexpressing cells (Fig 2.2). Moreover, our earlier study indicated a role of ANO10 
for Ca2+ signaling also in macrophages 122. We therefore further validated the effects of Ano10 
on intracellular Ca2+ signaling by generating renal tubular specific Ano10 knockout mice (Fig 
2.5 A, B). Ano10 was found to be localized in an intracellular compartment below the brush 
boarder membrane (Fig 2.5 C). This compartment is likely to correspond with the 
endoplasmic reticulum, as localization of ANO10 in the ER has been demonstrated earlier 122. 
Proximal tubular epithelial cells were isolated from Ano10+/+ and Ano10-/- mice, primary 
cultured and loaded with Fura-2. Cells were stimulated with ATP, which induced the typical 
peak/plateau response. In Ano10-/- cells, baseline Ca2+ as well as ATP-induced peak and 
plateau responses were attenuated (Fig 2.5 D-F). Despite the changes in Ca2+ signaling, we 
did not observe any overt phenotype in renal Ano10 null mice, and renal serum and urine 
parameters were not different to wt animals (Supplementary Figs. 2.3,2.4). However, we 
noticed an upregulation of ANO6 expression in tubular epithelial cells from Ano10 null mice, 
which could somehow compensate for the lack of ANO10 (Supplementary Fig 2.4 D).  
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Fig 2.5 Attenuated Ca
2+
 signals in isolated epithelial cells from Ano10
-/-
 mice. 
 RT-PCR A) and Western blotting B) demonstrating lack of expression of Ano10 in proximal tubular 
epithelial cells from ANO10
-/-
 mice. C) Immunohistochemistry of Ano10 in proximal tubular epithelial 
cells. Ano10 is located underneath the brush boarder membrane in a cytosolic compartment. Bar 
indicates 50 µm. d) ATP (100 µM) induced Ca
2+
 increase measured by Fura-2 in mouse primary 
cultured proximal tubular epithelial cells. Summary traces showing reduced basal Ca
2+
 and attenuated 
ATP-induced Ca
2+
 peak and plateau in cells isolated from Ano10
-/-
 mice. Summaries for basal Ca
2+
 E) 
and ATP-induced Ca
2+
 peak and plateau F) in cells from wt (
+/+
) and Ano10 knockout (
-/-
) mice. # 
significantly reduced Ca
2+
 plateau and Ca
2+
 increase in Ano10 knockout cells (unpaired t-test). Mean ± 
SEM (number of cells). G) Model for the differential effects of ANO1 and ANO4 on receptor operated 
Ca
2+
 signaling. Two well-separated cytosolic Ca
2+
 pools exist in mammalian cells, caused by store 
release (red dots) and Ca
2+
 entry (violet dots). Plasma membrane localized ANO1 tethers ER Ca
2+
 
stores to raft compartments and augments compartmentalized Ca
2+
 signals and activation of ANO1 (or 
other Ca
2+
 dependent channels such as SK4). This compartment also contains the Ca
2+
 sensor Pl-G-
CaMP2. ER-localized ANO4 possibly operates as a Ca
2+
 leakage channel, thereby reducing Ca
2+
 store 
filling which activates/augments ORAI-mediated Ca
2+
 influx. Ca
2+
 entry activates ANO6 whole cell 
currents. This compartment does not contain the Ca
2+
 sensor Pl-G-CaMP2. Fura-2 detects global Ca
2+
 
signals throughout the cell. 
 
Discussion 
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TMEM16A/ANO1 has been reported as a protein that confers receptor-activated calcium-
dependent chloride conductance 113. In their paper the authors showed data indicating that 
ANO1 is much more activated through phospholipase C coupled GPCRs than through direct 
large Ca2+ rises induced by Ca2+ ionophores 113. These results suggest a cellular 
compartment containing GPCR, ANO1, and components of intracellular Ca2+ signaling that 
allow efficient activation of ANO1. Notably, an inhibitory role of PIP2 on TMEM16A encoded 
calcium-activated chloride channels has been demonstrated in rat pulmonary artery, which 
further substantiates the functional coupling of Ano1 to GPCRs 147. This functional coupling 
leads to augmented Ca2+ store release via IP3R. Apart from the ER-store/plasma membrane 
tethering function the present data also suggest that chloride transport through ANO1 is 
crucial for this effect, as suggested by the use of ANO1 inhibitors. Although currently unclear, 
Cl- exit and change of local submembranous Cl- concentrations may determinate store 
release. As an alternative ANO1 may be partially located in the ER where it may function as a 
counter ion channel, facilitating electroneutrality during Ca2+ exit 148. Clearly more work will be 
required to fully understand the effects of ANO1 on Ca2+ signaling.  
 Subsequent reports supported the existence of such functional compartments in Xenopus 
oocytes as well as dorsal root ganglia 126, 127, 149. These signaling compartments are essential 
for efficient activation of ANO1, and may allow local Ca2+ concentrations that are much higher 
than global cytosolic Ca2+ levels detected by standard (Fura-2) fluorescence techniques 79. 
Tethering of the ER to the plasma membrane by means of ANO1/IP3R interactions is 
therefore an essential mechanism to concentrate Ca2+ signals at the plasma membrane. ER 
tethering has also been well described for the yeast ANO1 homologue Ist2 150. In contrast to 
ANO1, the present data support the concept that ANO6 (through expression of ANO4, which 
lowers ER Ca2+ and thereby facilitates capacitive Ca2+ entry) is activated by SOCE through 
ORAI and maybe other Ca2+ influx channels 140 (Fig 1 G). Moreover, earlier studies showed 
that ANO6 is only weakly activated through GPCRs, but strongly activated by ionomycin 114.  
In intact cells ANO1 requires Ca2+ concentrations in the higher µmolar range to be fully 
activated, because the negative membrane voltage interferes with binding of Ca2+ to the 
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channel 79. These signaling compartments appear to be well shielded, as Ca2+ influx through 
voltage gated Ca2+ channels or store operated channels does not reach these compartments 
and therefore does not activate ANO1 126. The present results directly demonstrate the role of 
ANO1 (and ANO5, 6, 10) for GPCR-activated local Ca2+ signaling and suggested a different 
role for ANO4, 8, 9. ANO4, 8, 9 lower ER store Ca2+, possibly as Cl- bypass channels to allow 
Ca2+ leakage out of the ER or by operating directly as ER Ca2+ leakage channels, thereby 
activating Ca2+ influx and thus activation of plasma membrane localized Ca2+ sensitive Cl- 
channels (ANO6) or K+ channels (SK4) (Figs. S2.1F, S2.2, 2.4). Cytosolic Ca2+ increase by 
ATP, CPA or ionomycin-induced ER-store release was reduced in ANO4 expressing cells, 
while store filling was attenuated when measured by the ER Ca2+ sensor ER-LAR-GECO1, 
pointing to store depletion by ANO4 (and ANO8, 9) (data not shown).  
The physiological role of ANO1 Cl- currents in the context of Ca2+ signaling has been 
demonstrated in small nociceptive neurons from rat dorsal root ganglia 151. Stimulation by the 
pain-inducing hormone bradykinin activates ANO1, which depolarizes the membrane voltage 
thus increasing firing of action potentials. In airway and intestinal smooth muscles, ANO1 
maintains baseline contraction, muscle tone and coordinated intestinal contraction by very 
similar mechanisms 152-155. Inhibitors of ANO1 lower airway smooth muscle tone and 
intracellular calcium, which has a large therapeutic potential in asthma. Pharmacological 
modulation of ANO1 changes contractile activity and intestinal fluid secretion 68, 156. A 
functional interaction has been demonstrated between ANO1 and TRPV4 in epithelial cells 
from the choroid plexus 157. The microdomains in which Ano1 functionally interacts with Ca2+ 
channels and transporters may be therefore cell specific. E.g., in intestinal epithelial cells 
ANO1 is predominantly in the basolateral membrane, while in renal proximal tubule, 
pancreatic and salivary gland acini or in airway epithelial cells, ANO1 is resides in the apical 
membrane. Finally, regulation of ANO1 by store operated Ca2+ entry in eccrine sweat glands 
was reported recently 158. Thus ANO1 may couple to different Ca2+ transporting proteins in a 
tissue specific manner. Notably, attenuated agonist-induced Ca2+ signaling has also been 
demonstrated recently in large intestine of ANO10-/- mice 159. 
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Notably, in intestinal epithelial cells where ANO1 is expressed on the basolateral side of the 
epithelium, it augments Ca2+ signals that activate Ca2+ sensitive hSK4 K+ channels 128. These 
K+ channels maintain a negative membrane voltage that is required to drive Cl- secretion at 
the apical side of the epithelium. Thus ANO1 supports Cl- secretion not as a secretory Cl- 
channel, but indirectly by activating K+ channels. In airway epithelial cells ANO1 may have a 
similar role by facilitating Ca2+ signals in close proximity of the Cystic Fibrosis transmembrane 
conductance regulator (CFTR) Cl- channel160. CFTR is known as protein kinase A and ATP 
regulated Cl- channel, but it requires also Ca2+ dependent kinases to be fully activated 161. In 
fact, most of the apparent Ca2+ activated Cl- secretion may actually occur through CFTR 162. 
Thus anoctamins control physiological functions through compartmentalized Ca2+ signaling, 
which may explain their role in many cellular functions and diseases 160 (Fig 2.5 G). 
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Supplementary material 
 
Supplementary Figure 2.1 Role of ANO1, ANO4, and ANO6 for Ca
2+
 signaling and whole cell 
currents.  
A) HeLa cells expressing PLCδ1PH-GFP to monitor PIP2 hydrolysis by stimulation with ATP (100 µM, 
20 min) in the absence or presence of ANO1. ATP reduced membrane binding of PLCδ1PH-GFP and 
thus decreased membrane GFP fluorescence by ATP-induced PIP2 hydrolysis. Typical examples out of 
20 measured cells are shown. Bar indicates 10 µm. B) Decrease in membrane fluorescence was 
comparable in mock transfected and ANO1 expressing cells. C) Predominant membrane expression of 
ANO1-GFP in HeLa cells and colocalization with cortical actin. D) Predominant intracellular expression 
of ANO4. The endoplasmic reticulum (ER) is demonstrated using the ER marker calreticulin. Bars 
indicate 10 µm. E) HeLa cells were incubated with 1 mM methyl-ß-cyclodextrin (MβCD) at 37 °C/2-4 
hrs to remove cholesterol from the plasma membrane, or treated with the membrane disrupter filipin 
(37 °C/30’) to dissolve lipid rafts. Summary of the ATP induced Ca
2+
 increase in mock transfected 
control cells, and ANO4 expressing cells in the absence or presence of MβCD or Filipin. The results 
suggest that the inhibitory effect of ANO4 on Ca
2+
 signaling requires intact rafts. F) Whole cell currents 
in ANO4 expressing cells are due to activation of endogenous ANO6. Activation of whole cell currents 
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by ATP (100 µM) in ANO4 expressing cells was almost abolished by simultaneous siRNA knockdown of 
endogenous ANO6. No currents were activated in the absence of ANO4. G) Western blots indicating 
knockdown of ANO6 and ANO10 by siRNA. For ANO4 and ANO8 knockdown is shown by quantitative 
RT-PCR, which was 80.1% ± 7.9 % (n = 8, siANO4) and 74.1 ± 5.3 % (n = 6, siANO8). H) Expression 
of GFP-tagged ANO5, 6, 8, 9, and 10 in Hela cells. Bars indicate 10 µm. Mean ± SEM (number of 
cells). 
# 
significant inhibition by ANO4 or siANO6 (ANOVA). 
* 
significant increase by ATP (paired t-test). 
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Supplementary Figure 2.2 Anoctamins control activation of ion channels through regulation of Ca
2+
 
levels. 
 A) Whole cell currents activated by ATP (100 µM) in ANO4 expressing HeLa cells. B) Complete 
suppression of activation of whole cell currents by the ORAI inhibitor YM8483 (5 µM). C,D) Summary 
current / voltage relationships of the experiments shown in a,b. E) ATP (100 µM) induced Ca
2+
 increase 
measured by Fura-2. Summary recordings for Ca
2+
 store release (ER) and store operated Ca
2+
 entry 
(SOCE) indicate an increase by ANO1 but decrease by ANO4. F) Ca
2+
 stores emptying by inhibition of 
SERCA with cyclopiazonic acid (CPA; 10 µM) in the presence of Ca
2+
 free extracellular buffer. G) Ca
2+
 
store content was not affected by overexpression of ANO1, 5, 6, 10, but was significantly reduced by 
overexpression of ANO4, 8, 9. H,I) Whole cell patch clamp currents in HeLa cells overexpressing hSK4 
or coexpressing hSK4 with ANO9. Activation of hSK4 by ATP was much reduced in the presence of 
ANO9. J) Current voltage relationships indicate reduced activation of hSK4 in cells coexpressing 
ANO9. K) Current densities indicating inhibition or amplification of Ba
2+
 sensitive ATP-activated 
currents, by coexpression of ANO9/ANO4 or ANO1, respectively. Mean ± SEM (number of cells). * 
significant activation ATP (paired t-test). # significantly different from mock and hSK4 (ANOVA). 
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Supplementary Figure 2.3 Representative periodic acid-Schiff stainings of kidneys from Ano10
+/+ 
and 
Ano10
-/- 
animals.  
Scale bars indicating 500 µm in overview and 100 µm in detailed view. Mean ± SEM (n = 8-9). 
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Supplementary Figure 2.4 Phenotypic characterization of mice with renal tubular specific Ano10 
knockout.  
Nephron-specific knockout was achieved by crossbreeding Ano10
loxp/loxp
 with Six2Cre mice. Knockout 
mice (
-/-
) were compared to their Cre-negative littermate controls (+/+). A) Individual weight gain of 
+/+
 
(blue) and 
-/-
 (red), (circles, female; triangles, male). B) Serum concentrations for sodium, potassium, 
creatinine and urea nitrogen (each n = 3). C) Urine concentrations for potassium, sodium and 
normalized protein in spontaneous urine (each n = 10). D) RT-PCR analysis of anoctamin expression in 
tubular epithelial cells isolated from kidneys of +/+ and -/- animals. Mean ± SEM (n = 8-9), 
#
indicates 
statistical significance (p<0.05). 
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Chapter 3  
Epithelial chloride transport by CFTR requires TMEM16A 
 
Abstract 
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) is the secretory 
chloride/bicarbonate channel in airways and intestine that is activated through ATP binding 
and phosphorylation by protein kinase A, but fails to operate in Cystic Fibrosis (CF). 
TMEM16A (also known as Anoctamin 1, ANO1) is thought to function as the Ca2+ activated 
secretory chloride channel independent of CFTR. Here we report that tissue specific knockout 
of the TMEM16A gene in mouse intestine and airways not only eliminates Ca2+ activated Cl- 
currents, but unexpectedly also abrogates CFTR-mediated Cl- secretion and completely 
abolishes cAMP-activated whole cell currents. The data demonstrate fundamentally new roles 
of TMEM16A in differentiated epithelial cells: TMEM16A provides a mechanism for enhanced 
ER Ca2+ store release, possibly engaging Store Operated cAMP Signaling (SOcAMPS) and 
activating Ca2+ regulated adenylyl cyclases. TMEM16A is shown to be essential for proper 
activation and membrane expression of CFTR. This intimate regulatory relationship is the 
cause for the functional overlap of CFTR and Ca2+ dependent chloride transport. 
 
 
 
 
 
 
 
Keywords: Cystic Fibrosis transmembrane conductance regulator (CFTR); TMEM16A, 
anoctamin 1, airway transport; intestinal transport  
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Introduction 
The Cystic Fibrosis transmembrane conductance regulator (CFTR) and the calcium-activated 
chloride channel TMEM16A (Anoctamin 1) are the two major secretory anion channels in 
intestinal and airway epithelia and therefore provide the critical regulation of mucus hydration 
at these sites8, 112, 163, 164. TMEM16A and a third anion channel, SLC26A9, have been shown 
to be upregulated and particularly relevant during airway inflammation and asthma152,165. 
TMEM16A and SLC26A9 attenuate airway inflammation in Cystic Fibrosis (CF)166 , prevent 
mucus obstruction during airway inflammation and attenuate the intestinal obstructive 
phenotype in CF mice165, 167. In CF, TMEM16A and its regulator CLCA1 have been proposed 
as potential drug targets to compensate for the abrogated CFTR function in CF patients, while 
in asthma it may help to solubilize excess inflammatory mucus which may otherwise lead to 
airway obstruction168, 169. Previous in vitro studies suggested a functional relationship between 
calcium-activated TMEM16A and cAMP-regulated CFTR by some unknown mechanism170-172. 
Inhibition of TMEM16A by activated CFTR was suggested, while others reported similar 
pharmacological and functional properties for both Ca2+ and cAMP-activated Cl- currents173-
175. A recent study in human airway epithelial cells suggested CFTR as the principal chloride 
secretory pathway for both cAMP and purinergic (i.e. Ca2+ enhancing) agonists162. Similarly, 
muscarinic stimulation was shown to activate CFTR via increase in intracellular cAMP, and 
both Src and Pyk2 tyrosine kinases176. Collectively, these data suggest that CFTR may 
function as a chloride channel that is activated by both cAMP and Ca2+. 
Earlier work showed that mice lacking expression of TMEM16A in the airways present with a 
CF-like lung phenotype, suggesting that TMEM16A is essential for chloride secretion and 
maintenance of the airway surface liquid in mouse airways164, 177. However, these results were 
obtained in conventional TMEM16A-deficient mice that exhibit multiple organ failures, 
requiring studies being performed on compromised newborn pups. We therefore generated 
mouse lines in which TMEM16A expression was selectively deleted in intestinal villus and 
crypt epithelial cells (using Vil1-Cre-TMEM16Aflox/flox mice) or ciliated airway epithelial cells 
(using FOXJ1-Cre-TMEM16Aflox/flox mice). This approach allowed for the first studies of adult 
mice with TMEM16A deficiency and demonstrated that TMEM16A expression is responsible 
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for the calcium-activated chloride anion current in the intestine and lower respiratory airways 
and is essential for CFTR function at both of these mucosal sites.  
Material and Methods 
Animals, cells, isolation of crypts. All animal experiments were approved by the local 
ethics committee of the Government of Unterfranken/Würzburg (AZ: 55.2-2532-2-328) and 
were conducted according to the guidelines of the American Physiologic Society and the 
German law for the welfare of animals. Generation of Vil1-Cre-TMEM16Aflox/flox mice and 
isolation of intestinal epithelial cells have been described earlier128. Knockout of TMEM16A in 
mouse airways way achieved by crossbreeding Vil1-Cre-TMEM16Aflox/flox mice with FOXJ1-
Cre transgenic mice generated as described previously178. Generation and culture of human 
Cystic Fibrosis bronchial epithelial cell lines (CFBE) is also described in previous reports179, 
180. CFBE cells have been originally generated by Dr. D.C. Gruenert (Cardiovascular 
Research Institute, UCSF, San Francisco, USA) in accordance with the local guidelines and 
regulations. Cells were grown in minimum essential medium supplemented with 2 mM 
glutamine and 2.5 µg/ml puromycin. For Ussing chamber measurements, the cells were 
grown on permeable supports (Corning® Costar® Snapwell™, Life Science, Tewksbury, MA). 
Respiratory epithelial cells were isolated from mice as described181 and were grown in 
AECGM plus supplement (Promocell, Heidelberg, Germany) that contained bovine pituitary 
extract 13 mg/ml, EGF 10 ng/ml, epinephrine 0.5 μg/ml, hydrocortisone 0.5 μg/ml, retinoic 
acid 0.1 ng/ml, transferrin 10 μg/ml, and triiodo-l-thyroxine 6.7 ng/ml. Media were further 
supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin, 3 μg/ml fungizone, 50 μg/ml 
chloramphenicol, 0.1 mg/ml kanamycin. All media were supplemented with 10% fetal calf 
serum. Cells were incubated in 5% CO2 at pH 7.4. siRNA for hTMEM16A was transfected into 
CFBE cells using standard methods (Lipofectamine, Invitrogen, Darmstadt, Germany). Cells 
were studied 48h after transfection. cDNAs and RT-PCR. For semi-quantitative RT-PCR, total 
RNA from mouse tracheal epithelial cells, crypts from mouse jejunum, proximal and distal 
colon and CFBE cells were isolated using NucleoSpin RNA II columns (Macherey-Nagel, 
Düren, Germany). Total RNA (1µg/50µl reaction) was reverse-transcribed using random 
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primer (Promega, Mannheim, Germany) and M-MLV Reverse Transcriptase RNase H Minus 
(Promega, Mannheim, Germany). Each RT-PCR reaction contained sense and antisense 
primer (0.5 µM, see supplementary table 1), 0.5 µl cDNA and GoTaq Polymerase (Promega, 
Mannheim, Germany). After 2 min at 95°C cDNA was amplified 30 cycles for 30 s at 95°C, 30 
s at 57°C and 1 min at 72°C. PCR products were visualized by loading on peqGREEN 
(Peqlab,VWR, Germany) containing agarose gels and analysed using Meta Morph Vers. 6.2 
(Molecular Devices, USA). Human and mouse Primers for RT-PCR were (5´-3´, s-as):  
 
hTMEM16A CGACTACGTGTACATTTTCCG, GATTCCGATGTCTTTGGCTC; 
hCFTR CATCTTTGGTGTTTCCTATG, GGAGTCTTTTGCACAATGG; 
mTMEM16A GTGACAAGACCTGCAGCTAC, GCTGCAGCTGTGGAGATTC; 
mCFTR GAATCCCCAGCTTATCCACG, CTTCACCATCATCTTCCCTAG; 
GAPDH GTATTGGGCGCCTGGTCAC, CTCCTGGAAGATGGTGATGG. 
 
Ussing chamber experiments. Isolated tracheas were put into ice cold bath solution 
containing (in mM/l) 145 NaCl, 0.4 KH2PO4, 1.6 K2HPO, 4.6 D-glucose, 1 MgCl2 1.3 Ca
2+ 
gluconate; pH 7.4). After isolation of tracheas connective tissue was removed. Tissues were 
mounted into an Ussing chamber with a circular aperture of 0.785 mm2. Luminal and 
basolateral sides of the epithelium were perfused continuously at a rate of 5 ml/min. Luminal 
and basolateral solutions were heated to 37 °C, using a water jacket. Experiments were 
carried out under open-circuit conditions. Data were collected continuously using PowerLab 
(AD Instruments, Spechbach, Germany). Values for transepithelial voltages (Vte) were 
referred to the serosal side of the epithelium. Transepithelial resistances (Rte) were 
determined by applying short (1s) current pulses (I = 0.5 µA). Rte and equivalent short 
circuit currents (Isc) were calculated according to Ohm’s law (Rte = Vte/I, Isc = Vte/Rte). 
Intestinal organoids. The protocol for the small intestinal organoids isolation and culture was 
adopted from182. In brief crypts from the small intestine were isolated in Ca2+ free chelating 
buffer, and the crypts pellet was resuspended in Advanced DMDM/F12 (Thermo Fisher 
Scientific, Waltham, MA, USA) supplemented with 2mM glutathione, 100 U/ml penicillin, 100 
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μg/ml streptomycin, 10mM Hepes and mixed with ice- cold Matrigel TM (Corning® Matrigel® 
Matrix, Life Sciences, Tewksbury, MA). The Matrigel TM was overlayed with basal minigut 
media supplemented with Noggin and recombinant Rspo-1 (PeproTech, Hamburg, Germany). 
Patch Clamping. Primary-culture of mouse tracheal epithelial cells and CFBE cells were 
grown on coated glass cover slips for patch clamp experiments. Isolated intestinal crypts were 
immobilized on polylysine coated glass cover slips. If not indicated otherwise, patch pipettes 
were filled with a cytosolic-like solution containing in mM: KCl 30, K-gluconate 95, NaH2PO4 
1.2, Na2HPO4 4.8, EGTA 1, Ca -gluconate 0.758, MgCl2 1.03, D - glucose 5, ATP 3, pH 7.2. 
The Ca2+ activity was 0.1 µM. Coverslips were mounted in a perfused bath chamber on the 
stage of an inverted microscope (IM35, Zeiss) and kept at 37 °C. Transfected cells were 
identified by cotransfection of pIRES and antibody bound beads (Sigma Taufkirchen, 
Germany). The bath was perfused continuously with Ringer solution at a rate of 8 ml/min. 
Patch clamp experiments were performed in the fast whole cell configuration. Patch pipettes 
had an input resistance of 2–4 M when filled with cytosolic like solution. Currents were 
corrected for serial resistance. The access conductance was monitored continuously and was 
60–140 nS. Currents (voltage clamp) and voltages (current clamp) were recorded using a 
patch clamp amplifier (EPC 7, List Medical Electronics, Darmstadt, Germany), the LIH1600 
interface and PULSE software (HEKA, Lambrecht, Germany) as well as Chart software (AD 
Instruments, Spechbach, Germany). Data were stored continuously on a computer hard disc 
and analyzed using PULSE software. In regular intervals, membrane voltage (Vc) was 
clamped in steps of 20 mV from -100 to +100 mV from a holding voltage of -100 mV. Current 
density was calculated by dividing whole cell currents by cell capacitance. 
Measurement of [Ca2+]i. The plasma membrane bound calcium sensor GCaMP6 was fused 
to the N-terminus of CFTR. HEK293 cells grown on coated glass cover slips were transfected 
with GCaMP6-CFTR, and were mounted in a perfusion chamber 72h after transfection. Cells 
were perfused with ringer solution at a rate of 8 ml/min at 37˚C. Cell fluorescence was 
measured continuously with an inverted microscope Axiovert S100 (Zeiss) using a x40 
objective (Fluar 40x/1.3 Oil, Zeiss) and a high speed polychromator system (VisiChrome, 
Visitron, Puchheim, Germany). GCaMP6-CFTR was excited at 485 nm and 405 nm. Emission 
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was recorded between 520 and 550 nm using a CCD-camera (CoolSnap HQ, Visitron). 
Control of experiments, imaging acquisition, and data analysis were done with the software 
package Meta-Fluor (Universal imaging, New York, USA). Alternatively, cells were loaded with 
Fura-2 and intracellular Ca2+ concentrations were determined as described earlier134. 
Western Blotting, COIP, biotinylation. Protein was isolated from parental CFBE cells and 
from CFBE cells expressing wt-CFTR or F508del-CFTR using a sample buffer containing 50 
mM Tris-HCl, 150 mM NaCl, 50 mM Tris, 100 mM dithiothreitol, 1% Nonidet P-40, 0.5% 
deoxycholate sodium, and 1% protease inhibitor mixture (Sigma, Taufkirchen, Germany). For 
co-immunoprecipitation CFBE cells (wt and dF508) were collected and lysed in 0.5% CHAPs 
lysis buffer containing 1X protease inhibitor cocktail. Protein (500 µg) was incubated with 6 μg 
of antibody (North American CFF, #596) and pre-cleaned protein G agarose (60 µl) on a 
rotator at 4°C overnight. Afterward, beads were centrifuged and washed three times with 
0.5% CHAPs lysis buffer containing 1X protease inhibitor cocktail. The immunocomplexes 
were eluted by 2x sample buffer. For biotinylation CFBE cells (90-100% confluent) in T75 cm2 
flasks were washed twice with ice-cold PBS (+Ca2+/Mg2+), followed by incubation with Sulfo-
NHS-SS-Biotin (Thermo Scientific, Waltham, MA USA) at 4°C for 30 min according to the 
manufacturer’s instructions. Cells were lysed and homogenized in lysis buffer containing 
complete protease inhibitor cocktail (Roche, Penzberg, Germany) on ice for 30 minutes and 
centrifuged at 10,000g at 4°C for 2 min. Biotin labeled surface proteins were captured on 
neutravidin agarose resin (Thermo Scientific, Waltham, MA USA) at room temperature for 1h. 
The resins were washed 5 times with wash buffer containing protease inhibitor. Proteins 
bound to the resin were eluted with SDS PAGE sample buffer, and analysed by western 
blotting. Sample was separated by 8.5 % SDS-PAGE and transferred to PVDF membrane 
(GE Healthcare, Munich, Germany). The membrane was blocked with 5 % NFM/TBST or 5 % 
NFM/PBST at RT for 1h and incubated overnight 4 °C with rabbit polyclonal anti-TMEM16A 
AB (1:1000, 1 % NFM/TBST), mouse monoclonal anti-CFTR AB (1:500, 3 % NFM/PBST), 
rabbit polyclonal anti-Na+/K+-ATPase α AB (1:1000, 1 % NFM/TBST) or mouse monoclonal 
anti β-actin AB (5 % NFM/PBST). Subsequently, the membrane was incubated with HRP-
conjugated donkey anti-rabbit or goat-anti mouse IgG at RT for 2h. Immunoreactive signals 
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were visualized using supersignal chemiluminescence substrate detection kit (Pierce 
Biotechonology, Rockford, USA). 
Chemiluminescence. CFBE wtCFTR and F508del-CFTR were tagged with an extracellular 
FLAG epitope and stably expression in CFBE cells using a doxycycline-inducible gene 
expression system. Surface CFTR expression was detected using monoclonal anti-FLAG M2-
Peroxidase (Sigma, Taufkirchen, Germany) after 48 hr of doxycycline application. Cells were 
fixed in 4% paraformaldehyde, blocked in 5% BSA and incubated with anti-FLAG M2-
Peroxidase (1:1000). Chemiluminescene was detected using a SuperSignal West Pico 
chemiluminescence substrate (Thermo Scientific, Darmstadt Germany) and measured using 
plate reader NOVOstar (BMG Labtach, Offenburg, Germany). 
Immunocytochemistry. Mouse intestine, lungs and trachea were fixed by perfusion with 4 % 
paraformaldehyde (PFA) and post-fixed in 0.5 mol/l sucrose, 4 % PFA solution. Cryosections 
of 5 μm were incubated in 0.1 % SDS for 5 min, washed with PBS, and blocked with 5 % 
bovine serum albumin (BSA) and 0.04 % Triton X-100 in PBS for 30 min. Sections were 
incubated with primary antibodies (Alomone Labs, #ACl 006) in 0.5 % BSA and 0.04 % Triton 
X-100 overnight at 4 °C and with Alexa Fluor 488 labeled donkey anti rabbit IgG (Invitrogen). 
Sections were counterstained with Hoe33342 (0.1 μg/ml PBS, Aplichem, Darmstadt, 
Germany).  
Immunofluorescence was detected using an Axiovert 200 microscope equipped with 
ApoTome and AxioVision (Zeiss, Germany). CFBE cells were grown on glass coverslips and 
fixed for 10 min with 4% (w/v) PFA at room temperature. After washing, the cells were 
permeabilized and blocked with 2% (w/v, PBS) bovine serum albumin and 0.04% (w/v, PBS) 
Triton-X-100 and incubated with primary anti-CFTR rabbit antibody (1:100, Alomone labs, # 
ACl- 006) and anti-TMEM16A rabbit antibody (1:100, Geneway GWB-MP178G) over night at 
4 °C. Binding of the primary antibody was visualized by incubation with a secondary antibody 
conjugated with Alexa 488 (Life Technologies, A-21206). Nuclei were stained with Hoe33342 
(0.1 μg/ml PBS, Aplichem, Darmstadt, Germany). Cells were mounted on glass slides with 
fluorescent mounting medium (DAKO Cytomation, Hamburg, Germany) and examined with 
an ApoTome Axiovert 200 M fluorescence microscope (Zeiss, Göttingen, Germany). 
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Materials and statistical analysis.  All animal experiments were approved by local 
authorities and were conducted according to the guidelines of the American Physiological 
Society and the German law for welfare of animals. All compounds used were of highest 
available grade of purity. Data are reported as mean ± SEM. Student’s t-test (for paired or 
unpaired samples as appropriate) or ANOVA were used for statistical analysis. A p-value < 
0.05 was accepted as significant difference. 
Results 
Intestinal epithelial cell knockout of TMEM16A eliminates CFTR currents. 
An intestinal epithelial cell-specific TMEM16A gene knockout mouse (Vil1-Cre–
TMEM16Aflox/flox) was generated from Vil1-Cre and TMEM16Aflox/flox mice (Fig S3.1) to 
determine TMEM16A function in the adult mouse intestinal epithelium. In contrast to reports 
of conventional TMEM16A-defiicent mice164, 177, the Vil1-Cre–TMEM16Aflox/flox mice did not 
show any difference in birth rate or lifespan, or manifest any baseline intestinal abnormalities 
(including intestinal obstruction or change in faecal water content) compared to control 
TMEM16A wild-type (wt) mice (Vil1-Cre–TMEM16Awt/wt) (Fig S3.2). Micro-perfused Ussing 
chamber experiments were used to assess ion transport of colonic epithelium by determining 
transepithelial voltage (Vte) under open circuit conditions and calculating equivalent currents 
(Isc). Perhaps as expected, carbachol-stimulated Ca
2+-activated anion transport was no longer 
present in colonic epithelia from Vil1-Cre–TMEM16Aflox/flox compared to Vil1-Cre–
TMEM16Awt/wt control mice (Fig 3.1A,B). In addition, and rather unexpectedly, cAMP-activated 
anion transport was also markedly attenuated in intestinal epithelia from Vil1-Cre–
TMEM16Aflox/flox mice (Fig 3.1C,D). This decrease in transport function was not accompanied 
by any change in the level of CFTR expression in colonic epithelial cells based on TMEM16A 
western blotting (Fig S3.1D). In contrast, the pattern of CFTR expression in colonic epithelium 
of Vil1-Cre–TMEM16Aflox/flox mice was different, with clearly compromised apical CFTR 
expression (Fig S3.1A). cAMP (IBMX and Forskolin) stimulation failed to expand the luminal 
cavity in intestinal organoids from Vil1-Cre–TMEM16Aflox/flox mice compared to wild-type 
control mice, indicating that the defect in intestinal cAMP-activated anion transport in Vil1-
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Cre–TMEM16Aflox/flox mice was accompanied by decreased secretion (Fig 3.1E,F). Consistent 
with these results, both carbachol and cAMP stimulation of ion currents determined by whole 
cell patch clamping were lost in freshly isolated mouse colonic epithelial cells from Vil1-Cre–
TMEM16Aflox/flox mice compared to wild-type control mice (Fig 3.1G-R). Ca2+ and cAMP 
activated currents were identified by blockade with inhibitors for TMEM16A (CaCC-AO1) and 
CFTR (CFTRinh172)156, 183 (Fig 3.1M,O-R; Fig 3.2G,H). However, as indicated below crosstalk 
of both, Ca2+ and cAMP signalling pathways may lead to a cross-inhibition by both inhibitors. 
Together, the results show that calcium-activated as well as cAMP-stimulated CFTR-
dependent chloride secretion in mouse intestinal epithelial cells depends on TMEM16A 
expression. 
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Fig 3.1 Intestinal epithelial knockout of TMEM16A eliminates CFTR currents. 
 A) Original recordings of the transepithelial voltage Vte and the effect of carbachol (CCH, 100 µM) in 
colonic epithelia from mice with intestinal epithelial knockout of TMEM16A (Vil1-Cre–TMEM16A
flox/flox
 ; 
TMEM16A
-/-
) and wild-type mice (TMEM16A
+/+)
. B) Summary of the calculated CCH-induced short 
circuit currents (Isc). C;D) Original recordings of Vte and summary of cAMP (IBMX 100 µM/Forskolin 2 
µM)-induced Isc in +/+ and -/- colonic epithelia. E, F) cAMP-induced secretion in intestinal organoids 
from 
+/+ 
and 
-/-
 intestines (upper panel) and summaries of luminal area increase (lower panel). (G-J) 
Activation of whole cell currents by CCH and inhibition by CaCCinhAO1 (AO1; 10 µM) in isolated 
intestinal epithelial cells from 
+/+
 mice. Original recordings (G), individual experiments (H) and 
current/voltage relationships (I). J-L) Corresponding experiments in intestinal epithelial cells from -/- 
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mice. (M-O) Activation of whole cell currents by cAMP and inhibition by CFTRinh172 (CFTRinh; 10 µM) 
in isolated intestinal epithelial cells from 
+/+
 mice. P-R) Corresponding experiments in intestinal 
epithelial cells from 
-/-
 mice. Mean ± SEM; * significant activation by cAMP or CCH (paired t-test). 
# 
significant difference between
 -/-
 and 
+/+
 (unpaired t-test). (number of mice or cells, respectively). 
 
Respiratory epithelial knockout of TMEM16A eliminates CFTR currents. 
We next examined the effect of TMEM16A-deficiency in respiratory airway function by 
generating an epithelial ciliated cell-specific knockout of the TMEM16A gene (FOXJ1-Cre-
TMEM16Aflox/flox mice) derived from FOXJ1-Cre and TMEM16Aloxp/loxp mice (Fig 3.2,S3.3 A-C). 
TMEM16A was partially colocalized with CFTR in ciliated epithelial cells, but was absent in 
knockout airways (Fig S3.3 D,E). Notably, the TMEM16A antibody may have only detected 
larger expression levels. Like Vil1-Cre-TMEM16Aflox/flox mice, the FOXJ1-Cre-TMEM16Aflox/flox 
mice developed normally with birth rates and lifespans similar to wild-type control mice. 
Particle transport was assessed in isolated mouse tracheas as an index of mucociliary 
clearance (MCC)164. It was not compromised, but unexpectedly even enhanced under basal 
conditions in tracheas from FOXJ1-Cre-TMEM16Aflox/flox mice, compared to wild-type control 
tracheas. However, stimulation by ATP or carbachol did not further enhance MC in FOXJ1-
Cre-TMEM16Aflox/flox cells, in contrast to wild-type control cells (Fig S3.2 E). No mucus 
plugging was observed in the lungs of FOXJ1-Cre-TMEM16Aflox/flox mice or wild-type control 
mice. Experiments with micro-perfused Ussing chambers showed that luminal ATP- or 
basolateral CCH-induced voltage deflections (Vte) and calculated Isc were both attenuated 
in tracheas from FOXJ1-Cre-TMEM16Aflox/flox mice compared to wild-type control mice (Fig 
3.2A-D). As observed in cells from Vil1-Cre-TMEM16Aflox/flox mice, also in tracheas from 
FOXJ1-Cre-TMEM16Aflox/flox mice cAMP activated transport was inhibited (Fig 3.2 E,F). 
Moreover, whole cell patch clamp experiments on primary-cultured mouse tracheal epithelial 
cells demonstrated large ATP-activated Cl- currents in cells from wild-type tracheas, which 
were absent in cells from FOXJ1-Cre-TMEM16Aflox/flox tracheas, indicating that Ca2+ 
dependent Cl- currents in mouse respiratory epithelial cells are entirely due to TMEM16A (Fig 
3.2 G, H). cAMP activated whole cell Cl- currents were small but detectable in wild-type airway 
cells, and were significantly inhibited by CFTRinh172. In contrast, in cells from FOXJ1-Cre-
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TMEM16Aflox/flox tracheas no currents were activated by cAMP, and CFTRinh172 had no 
effects (Fig 3.2 I, J). Taken together, in both intestine and airways knockdown of TMEM16A 
strongly inhibited cAMP-activated, i.e. CFTR-related Cl- transport in addition to the abolished 
Ca2+ dependent chloride secretion. 
  
 
Fig 3. 2 Respiratory epithelial knockout of TMEM16A eliminates CFTR currents.  
A) Original recordings of the transepithelial voltage Vte and the effect of ATP (100 µM) in tracheas from 
FOXJ1-Cre-TMEM16A
wt/wt
 (
+/+
) and FOXJ1-Cre-TMEM16A
flox/flox
 (
–/–
) mice. B) Summary of the 
calculated ATP-induced short circuit currents (Isc). C, D) Original recordings of Vte and summary of 
CCH-induced Isc in +/+ and -/- tracheas. E, F) Original recordings of Vte and summary of cAMP (IBMX 
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100 µM/Forskolin 2 µM)-induced Isc in +/+ and -/- tracheas. G) Original recordings of whole cell 
currents activated by ATP in primary-cultured tracheal epithelial cells from TMEM16A
+/+
 and TMEM16A
-
/-
 mice. Experiments were performed in the presence of an inhibitor of Ca
2+
 activated K
+
 channels, 
TRAM-34 (100 nM). H) Corresponding current/voltage relationships of whole cell currents activated by 
ATP in TMEM16A
+/+
 and TMEM16A
-/-
 cells. I) Original recordings of whole cell currents activated by 
cAMP in primary cultured respiratory epithelial cells from TMEM16A
+/+ 
and TMEM16A
-/-
 mice. J) 
Corresponding current/voltage relationships of whole cell currents activated by cAMP in TMEM16A
+/+
 
and TMEM16A
-/-
 cells. Mean ± SEM; *significant activation by cAMP or ATP (paired t-test). 
#
significant 
difference between 
-/-
 and 
+/+
 (unpaired t-test). (number of mice or cells, respectively). 
 
Cl- currents by CFTR and TMEM16A in human airway epithelial cells are linked. 
To translate the results obtained in mouse airways to humans, we studied Cystic Fibrosis 
bronchial epithelial (CFBE) cell lines engineered to stably express wt-CFTR or the most 
frequent mutant form F508del-CFTR, when compared to the parental cell line that does not 
express CFTR (Fig 3.3 A, Fig S3.5 A) 180. Although all three cell lines expressed comparable 
levels of TMEM16A (Fig 3.3 A, Fig S3.5 A), the Ca2+-dependent whole cell currents activated 
by ATP were large in CFBE/wt-CFTR cells, but were small for CFBE/F508del-CFTR and 
parental cells (Fig 3.3 B,C). As expected, cAMP-dependent currents were large in CFBE/wt-
CFTR, but were essentially absent in CFBE/F508del-CFTR cells (Fig 3.3 D, E). Because 
large cAMP-dependent (CFTR) currents were paralleled by large TMEM16A currents, we 
knocked down TMEM16A gene expression in CFBE/wt-CFTR cells to see whether this affects 
CFTR currents (Fig 3.3 F). Strikingly, elimination of ATP-activated TMEM16A whole cell 
currents (Fig 3.3 G, upper panel), also abolished cAMP-activated CFTRinh172-inhibitable 
currents, despite expression of CFTR remained unaffected by TMEM16A-knockdown (Fig 3.3 
G, lower panel, Fig S3.5 B). The results reproduce the functional interaction between 
TMEM16A and CFTR, and identify TMEM16A as the Ca2+ activated anion channel in human 
airway epithelial cells. There was also a considerable pharmacological overlap between 
CFTR and TMEM16A, as both currents were inhibited by the TMEM16A inhibitor AO1 and the 
CFTR blocker CFTRinh172 (Fg. 3.3 H). Finally, when CFBE/wt-CFTR and CFBE/F508del-
CFTR cells were grown to polarized epithelia on permeable supports and examined in Ussing 
chambers, the results were analogous: Vte and Isc induced by either cAMP or ATP were large 
in CFBE/wt-CFTR epithelia, but were almost absent in CFBE/F508del-CFTR tissues. 
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Moreover, CFTRinh172 blocked both CFTR (cAMP) and CaCC (ATP)-induced transport (Fig 
12i-k). 
  
 
Fig 3.3 Cl
-
 currents by CFTR and TMEM16A in human airway epithelial cells cannot be strictly 
separated.  
A) Western blot demonstrating wt-CFTR expression in CFBE/wt-CFTR cells, but not in CFBE parental 
cells. Both cells lines express similar levels of TMEM16A. B) ATP (100 µM) -activated whole cell 
currents in CFBE parental cells and CFBE cells expressing wt-CFTR or F508del-CFTR. C) 
Corresponding current / voltage relationships. D) Whole cell currents activated by cAMP (100 µM 
IBMX/2 µM Forskolin) in CFBE cells expressing wt-CFTR or F508del-CFTR. E) Corresponding current 
/ voltage relationships. F) Western blot indicating suppression of TMEM16A in CFBE/wt-CFTR cells by 
siRNA G) Summary of ATP (100 µM) -activated whole cell currents in CFBE/wt-CFTR cells treated with 
scrambled RNA or after siRNA-knockdown of TMEM16A (upper panel). Inhibition by CaCCinh-AO1 (10 
µM). Summary of cAMP-activated whole cell currents in control (scrambled) and TMEM16A-
knockdown cells, and effect of CFTRinh172 (10 µM). H) Remaining currents after inhibition with 
Epithelial Chloride Transport by CFTR Requires TMEM16A 
 
74 
       
CaCCinh_AO1 and CFTRinh172. Both blockers inhibit ATP- and cAMP-activated whole cell currents. I) 
Transepithelial voltages recorded in polarized grown CFBE/wt-CFTR and CFBE/F508del-CFTR cells. 
Voltage deflections induced by cAMP or ATP. J) Transepithelial voltages recorded in the presence of 
CFTRinh172 (10 µM). K) Summaries of the corresponding calculated short circuit currents (Isc). Mean ± 
SEM; * significant activation by ATP and cAMP, or currents inhibition by AO1 and CFTRinh, 
respectively (paired t-test). 
# 
significant difference between scrambled and siTMEM16A or between wt-
CFTR and F508del-CFTR, respectively (paired t-test). (number of cells). 
 
TMEM16A activates CFTR by enhancing Ca2+ store release. 
The present results establish that CFTR and TMEM16A currents are functionally linked and 
interdependent. To determine the mechanism for TMEM16A enhancement of CFTR activity, 
we analysed the effect of additional (exogenous) TMEM16A expression on CFTR function in 
CFBE/wt-CFTR cells. We found that additional TMEM16A enhanced ATP-activated 
TMEM16A currents in parental cells as expected, but in addition also enhanced cAMP-
activated CFTR currents in CFBE/wt-CFTR and even in CFBE/F508del-CFTR cells (Fig 3.4 
A). To determine the molecular mechanism for TMEM16A regulation of CFTR, we examined 
whether TMEM16A-driven release of ER store calcium might be responsible since TMEM16A 
is reported to enhance ER calcium store release79, 80, 160. This mechanism may cause CFTR 
activation in response to stimulation of purinergic and other phospholipase C coupled 
receptors162, 176. We found that activation of wt-CFTR was markedly decreased when Ca2+ 
was chelated by BAPTA-AM (Fig 3.4 B). Moreover, release of Ca2+ from the ER store (peak) 
was significantly reduced in tracheal epithelial cells from FOXJ1-Cre-TMEM16Aflox/flox mice 
(Fig 3.4 C,D). Correspondingly, ATP-induced Ca2+ store release was inhibited with siRNA-
mediated knockdown of TMEM16A in airway epithelial cells (Fig 3.4 E, F). Notably, after 
knockdown of TMEM16A, a whole cell current could only be activated by cAMP in the 
presence of the Ca2+ ionophore ionomycin, confirming the role of Ca2+ and/or ER store 
release for activation of CFTR (Fig S3.5 C, D). To measure Ca2+ signals in close proximity of 
CFTR, the Ca2+ sensor GCAMP6 was fused to the C-terminus of CFTR and was expressed in 
HEK293 cells. TMEM16A enhanced ATP-stimulated Ca2+ release under control conditions 
and in the presence of cAMP (Fig 3.4 G, H).  
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Role of Ca2+ regulated adenylate cyclases. 
Enhanced Ca2+ store release in the presence of TMEM16A may support activation of CFTR 
through Ca2+ dependent adenylate cyclases161, 162. In support of this, we found that the IP3 
receptor inhibitor Xestospongin C markedly inhibited activation of CFTR by IBMX and 
Forskolin (Fig S3.5 E), while the TMEM16A inhibitor CaCCinhAO1 (AO1) blocked basal and 
ATP-induced Ca2+ increase (Fig S3.5 F). AO1 also blocked cAMP-induced fluid secretion in 
organoids from T84 intestinal epithelial cells (Fig S3.5 G, H). Moreover, ST034307 and KH7, 
both inhibitors of Ca2+ dependent adenylate cyclases, potently inhibited ATP-activated Cl- 
currents in CFBE/wt-CFTR cells (Fig 3.5 J). Because TMEM16A enhances ER Ca2+ store 
release, it is possible that compartmentalized increase in intracellular cAMP is induced by a 
mechanism recently identified as store operated cAMP signaling (SOcAMPs)184. SOcAMPs, 
i.e. increase of cAMP by ER store emptying, was shown to contribute to Ca2+-dependent 
activation of Cl- secretion in T84 colonic epithelial cells185. Ca2+-refill of ER stores, was shown 
to terminate SOcAMPs, and occurs through store operated Ca2+ entry (SOCE) via ORAI 
channels. Remarkably, the ORAI channel blocker YM58483 or Ca2+ removal caused 
prolonged activation of Cl- currents activated by ATP, which strongly suggests a contribution 
of SOcAMPs to activation of Cl- secretion (Fig 3,5 K).  
Epithelial Chloride Transport by CFTR Requires TMEM16A 
 
76 
       
 
Fig 3.4 TMEM16A provides Ca
2+
 for activation of CFTR. 
 A) Summary of whole cell currents activated by increase in intracellular Ca
2+
 (ATP; 100 µM) and cAMP 
(IBMX 100 µM/Forskolin 2 µM) in parental cells, CFBE/wt-CFTR and CFBE/F508del-CFTR cells, with 
or without (mock) additional expression of exogenous TMEM16A. Additional TMEM16A augments ATP-
induced currents in all cell lines, enhances cAMP-activated currents in CFBE/wt-CFTR cells, and 
induces cAMP-activated currents in CFBE/F508del-CFTR cells B) cAMP-activated whole cell currents 
in CFBE/wt-CFTR cells were inhibited by the Ca
2+
 chelator BAPTA-AM. C, D) Mean recordings of ATP-
induced rise in intracellular Ca
2+
 (Fura-2) in primary airway epithelial cells form TMEM16A
+/+
 (black) 
and TMEM16A
-/-
 (red) mice (upper panel). Summary of peak and plateau Ca
2+
 increase (lower panel). 
E, F) Mean recordings of ATP-induced rise in intracellular Ca
2+
 (Fura-2) in CFBE/wt-CFTR cells (upper 
panel) and summary of peak and plateau Ca
2+
, which were reduced after siRNA-knockout (red) of 
TMEM16A (lower panel). G, H) Recordings of ATP-induced Ca
2+
 peaks in HEK293 cells expressing 
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GCAMP2-tagged CFTR. The ATP-induced Ca
2+
 peaks are larger in cells TMEM16A (red) coexpressing 
cells (upper panel). Summaries of Ca
2+
 peaks in the absence or presence of cAMP (lower panel). J) 
Western blot indicating knockdown of TMEM16A expression by siRNA. (J) Inhibition (in %) of ATP-
activated Cl
-
 currents by two different inhibitors of Ca
2+
-dependent adenylate cyclases, ST034307 (30 
µM) and KH7 (10 µM). K) Time courses for activation of whole cell currents by ATP (100 µM) under 
control conditions, in the presence of the ORAI-inhibitor YM58483, and in the absence of extracellular 
Ca
2+
. Mean ± SEM; *significant activation by ATP or cAMP (paired t-test). 
# 
significant difference when 
compared to mock, +/+, scrambled, absence of TMEM16A, or con, respectively (unpaired t-test). 
(number of cells or assays). 
 
Control of CFTR membrane expression by TMEM16A. 
To further define the mechanisms for regulation of CFTR by TMEM16A, we examined 
membrane expression of CFTR. The results suggested a cellular mislocalization of CFTR in 
TMEM16A knockout tissues (Fig S3.1 A, B). We quantified the amount of plasma membrane 
CFTR in CFBE cells by chemiluminescence, using an extracellular FLAG epitope. Very little 
background luminescence was found in non-expressing parental cells (con), while a robust 
signal was detected in CFBE/wt-CFTR-FLAG cells (Fig 3.5 A). siRNA knockdown of 
TMEM16A (si16A) lowered membrane expression of CFTR (Fig 3.5 A), while additional 
expression of TMEM16A further enhanced luminescence (Fig 3.5 B). Cellular distribution of 
CFTR was analysed in CFBE cells in the presence or absence of TMEM16A. Membrane and 
cytosolic expression were quantified by analysing fluorescence intensities in the regions of 
interests (ROI) and are shown as proportions of membrane versus cytoplasmic fluorescence. 
CFTR was detected either by cherry fluorescence (Cherry-CFTR) in live imaging (Fig 3.5 
C,D), or by using an anti-CFTR antibody in fixed cells (Fig 3.5 E, F). Both methods supplied 
comparable results and showed a shift of CFTR from the cell membrane towards a cytosolic 
perinuclear localization. Using cell membrane surface biotinylation, we found membrane 
expression of CFTR and TMEM16A in CFBE/wt-CFTR cells, while neither CFTR nor 
TMEM16A could be biotinylated in CFBE/F508del-CFTR cells (Fig 3.5 G). Knockdown of 
TMEM16A in CFBE/wt-CFTR cells attenuated membrane expression of CFTR (Fig 14h).  
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Fig 3.5 TMEM16A enhances membrane expression of CFTR. 
 A, B) Membrane expression of CFTR detected by chemiluminescence in CFBE/wt-CFTR cells 
expressing CFTR containing a FLAG tag in the first extracellular loop and a N-terminal cherry tag. Cells 
were exposed to a primary FLAG antibody (Sigma Taufkirchen, Germany, # F3165) and a secondary 
peroxidase-conjugated antibody. Luminescence was detected in CFBE/wt-CFTR cells but not in control 
parental cells (con). siRNA-knockdown of endogenous TMEM16A reduced chemiluminescence in 
CFBE/wt-CFTR cells A), while additional expression of exogenous TMEM16A enhanced 
chemiluminescence B). Very little background chemiluminescence was observed in the absence of 
CFTR (con). Mean ± SEM, (n) number of assays. 
#
significant difference when compared to mock 
(unpaired t-test). C,D) Life imaging of cherry-CFTR in CFBE/wt-CFTR cells with and without siRNA-
knockdown of TMEM16A, as detected by cherry fluorescence. Summary of fluorescence intensity 
ratios (plasma membrane/cytosolic fluorescence) indicating redistribution of the fluorescence towards 
cytoplasm by siRNA-TMEM16A. E, F) Antibody-staining of CFTR in CFBE/wt-CFTR cells with and 
without siRNA-knockdown of TMEM16A. Summary of fluorescence intensity ratios (plasma 
membrane/cytosolic fluorescence) indicating redistribution of the fluorescence towards cytoplasm by 
siRNA-TMEM16A. G) Membrane biotinylation of CFBE/wt-CFTR and CFBE/F508del-CFTR cells, and 
detection of membrane and cytosolic fractions of CFTR and TMEM16A using Western blot. H) Effect of 
TMEM16A-knockdown on biotinylation (membrane expression) of CFTR and TMEM16A. Mean ± SEM; 
#
significant difference when compared to scrambled (paired t-test). (Number of cells). Assays were 
performed in triplicates. 
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Molecular interaction of CFTR and TMEM16A and a possible role of PDZ-interacting 
motifs. 
The present results show a functional interaction of CFTR and TMEM16A. Both proteins may 
therefore be colocalized in a functional compartment or may even physically interact, possibly 
through adapter proteins like post-synaptic density protein/Drosophila disc large tumour 
suppressor/zonula occludens (PDZ) proteins 172. In support of this, we found that wt-CFTR 
and F508del-CFTR could be coimmunoprecipitated with TMEM16A in CFBE cells (Fig 3.6 
A,B). Notably, TMEM16A pulled down the fully glycosylated form of wt-CFTR (band C), and 
the core glycosylated form of F508del-CFTR (band B). Coimmunoprecipitation was not 
observed for wt-CFTR and the TMEM16A-paralogue TMEM16F (Fig 3,6 C, D). Molecular 
interaction may require the PDZ-interacting motifs present at C-terminus of CFTR and 
TMEM16A186, 187. In support of this we found that deletion of PDZ-interacting motifs in either 
CFTR or TMEM16A reduced membrane expression of each protein (Fig S3.5 A,B). 
Membrane expression of both proteins was further inhibited by simultaneous deletion of both 
PDZ-interacting motifs (Fig S3.9 C). Taken together, control of CFTR through TMEM16A 
appears largely Ca2+ dependent, which also affects membrane expression of CFTR and may 
require anchoring of these proteins in a functional compartment by the help of PDZ proteins. 
 
Fig 3.6 Molecular interaction of TMEM16A and CFTR.  
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A, B) Coimmunoprecipitation of CFTR and TMEM16A overexpressed in HEK293 cells. CFTR was 
pulled down by anti-CFTR antibody (Alomone labs, # ACl 006), while TMEM16A was pulled down by 
mouse monoclonal TMEM16A-antibody (Geneway GWB-MP178G). Both wt-CFTR and F508del-CFTR 
were found to interact with TMEM16A. Assays were performed in triplicates. C, D) No 
coimmunoprecipitation was detected for CFTR and TMEM16F when experiments were performed 
under identical conditions using a TMEM16F antibody (Davids technology, Regensburg). White lines in 
the right blot indicate that lanes for unbound protein present on the same gel, have been relocated. 
Mean +/- SEM; #indicates significant difference (p<0.05; unpaired t-test). (number of experiments). 
 
Discussion 
We demonstrate a complete absence of cAMP-activated Cl- transport and a lack of Ca2+-
dependent Cl- secretion in large intestine and trachea from adult conditional TMEM16A 
knockout mice. A disturbed cAMP-dependent transport was not found in airways of 
conventional TMEM16A knockout pups164, 177, confirming the somewhat different physiology of 
neonatal vs. adult airways188. Somewhat surprising the complete absence of Cl- currents in 
TMEM16A knockout tissues did not cause any overt phenotype. Mouse airways lacking 
TMEM16A did not show any mucus accumulation, which may support the concept that airway 
Na+ transport is physiologically more relevant than Cl- secretion in mouse airways188. The 
data show that most (Ca2+ and cAMP-dependent) murine airway Cl- secretion depends on 
TMEM16A, with little contribution of CFTR175, 188. This is somewhat surprising since 
TMEM16A is expressed at very low levels in (non-inflamed) murine airways152, 189.  
Ruffin and coworkers found reduced TMEM16A-currents in mouse and human CF bronchial 
epithelium190. Our data obtained in human CFBE cells demonstrate a pronounced inter-
dependence between CFTR and TMEM16A, in terms of membrane expression as well as 
activation of ion currents (Figs. 3.4,3.5,). Moreover, we were not able to discriminate clearly 
between CFTR and TMEM16A current based on ion channel inhibitors. The data demonstrate 
a remarkable overlap of cAMP and Ca2+-dependent signaling and are in line with studies 
reporting Ca2+-activated secretion through CFTR161, 162, 176, 191 and cAMP-depending Ca2+ 
signaling controlling CFTR-mediated serous cell fluid secretion in porcine and human 
airways192. 
Although ATP might be released during activation of CFTR and may activate P2Y2 receptors, 
this is unlikely to explain the present results, as activation of CFTR was not inhibited by the 
Epithelial Chloride Transport by CFTR Requires TMEM16A 
 
81 
       
P2Y2 blocker suramin (100 µM), or by hydrolyzing extracellular ATP with apyrase (2 U/ml) 
(data not shown). In fact, the present data demonstrate a mechanism through which 
TMEM16A facilitates local Ca2+ signals that are required for activation of apical CFTR (and 
probably basolateral K+ channels) 79, 80, 160. Because TMEM16A facilitates ER Ca2+ store 
release, it may induce store-operated cAMP signaling184, which has been shown to control 
Ca2+ activated Cl- secretion in T84 colonic epithelial cells185 (Fig 4j). Moreover, further 
evidence is provided for a central role of Ca2+ activated adenylate cyclases162 (Fig 3.4 K). 
In contrast to mouse airways expression of CFTR is pronounced in mouse large intestine, 
where it was found to be fully dependent on the presence of TMEM16A. Intestinal knockout of 
TMEM16A eliminated cAMP and Ca2+ activated Cl- currents in colonic epithelial cells, again 
without causing intestinal obstructions. This is explained by the fact that cAMP-activated Cl- 
currents were still present in the jejunum. Jejunal epithelial cells do not express TMEM16A 
and do not produce Ca2+ dependent, i.e. CCH induced Cl- currents (Fig S3.6) 188. Jejunal 
epithelial cells obviously do not require TMEM16A for activation or membrane insertion of 
CFTR, which may suggest the role of another TMEM16 protein. Noteworthy, cAMP-activated 
currents were found to be reduced in jejunal epithelial cells from TMEM16K-/- mice193. Our 
results also explain Ca2+ dependent Cl- and HCO3
- transport by CFTR in mouse intestine and 
other tissues194-197.  
The present data suggest that TMEM16A is required for proper expression of CFTR in the 
plasma membrane (Fig 3.5, Fig S3.1, 3.3). Interaction of TMEM16A and CFTR in a functional 
signaling compartment at the plasma membrane may require the help of PDZ-proteins198 (Fig 
S3.5 C-F). TMEM16A has been shown to interact with IP3 receptors in a functional 
compartment also containing G-protein coupled receptors 80, 126. The present data add CFTR 
to such a compartment as it may be colocalized and interact directly or through PDZ proteins 
with TMEM16A. Due to the functional interaction of both proteins and cAMP/Ca2+-crosstalk, 
inhibitors for TMEM16A (e.g. CaCC-AO1) and CFTR (e.g. CFTRinh172) may be of limited 
use to dissect signaling pathways and the contribution of each channel to Cl- transport in 
highly differentiated tissues162, 199. 
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Supplementary Figure 3.1 Expression of TMEM16A and CFTR in intestinal epithelial cells from Vil1-
Cre-TMEM16A
wt/wt
 (
+/+
) and Vil1-Cre-TMEM16A
flox/flox
 (
-/-
) mice. 
 A) Immunocytochemistry of TMEM16A and CFTR in large intestinal epithelial cells from wild type mice 
(
+/+)
 and mice with an epithelial cell specific knockout of TMEM16A (
-/-
) (upper panel). Differential 
interference contrast images of the tissues (lower panels). Note that deletion of TMEM16A caused a 
cellular redistribution of CFTR away from the apical and towards the lateral plasma membrane and 
cytosolic compartments. Bar indicates 20 µm. B) RT-PCR analysis of expression of TMEM16A and 
CFTR in isolated large intestinal epithelial cells. C) Semiquantitative analysis of mRNA expression 
(relative to GABDH). D) Western blots of TMEM16A and CFTR from isolated intestinal crypts of (
+/+
) 
and (
-/-
) mice. Mean ± SEM, (n) number of animals (wt/KO). # significant difference when compared to 
+/+ (unpaired t-test). 
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Supplementary Figure 3.2 Lack of pathology in Vil1-Cre–TMEM16A
wt/wt
 (
+/+
) and Vil1-Cre–
TMEM16A
flox/flox
 (
-/-
) mice. 
 A) Size of wild-type mice (
+/+
) and mice with an intestinal epithelial specific knockout of  
TMEM16A (
-/-
). B) Overall appearance of the intestine without obvious abnormalities in -/- mice. C) 
Weight increase in (
+/+
) and (
-/-
) mice. D) Percentage stool water content in samples from (
+/+
) and (
-/-
) 
mice. E) Mucociliary clearance (MC) measured by particle transport in isolated mouse tracheas placed 
in humidified chambers, as described earlier 
131
. MC was assessed under control conditions and after 
stimulation with 100 µM ATP (luminal) or 100 µM carbachol (basolateral). Mean ± SEM, (n) number of 
animals. * significant increase by CCH (paired t-test). 
# 
significant difference when compared to (
+/+
) 
mice. 
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Supplementary Figure 3.3 Expression of TMEM16A and CFTR in airway epithelial cells from 
TMEM16A
+/+
 and TMEM16A
-/-
 mice.  
A) Scheme indicating the loxP sites to generate 
-/-
 mice. B, C) Genotyping protocol and RT-PCR 
analysis of TMEM16A (16A) expression in epithelial cells. D) Immunocytochemistry of TMEM16A and 
CFTR in TMEM16A
+/+
 and TMEM16A
-/- 
mice. Note the more diffuse staining of CFTR in TMEM16A
-/-
. E) 
Immunocytochemistry of TMEM16A/CFTR and acetylated tubulin suggesting heterogeneous 
expression of TMEM16A and CFTR and partial colocalization. Bar indicates 20 µm. 
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Supplementary Figure 3.4 CFTR and TMEM16A (16A) dependent Cl
-
 transport cannot be separated. 
 A) Western blots of 16A and wt-CFTR or F508del-CFTR in stably expressing bronchial epithelial cells 
(CFBE). Expression levels for 16A are similar in both wt-CFTR or F508del-CFTR expressing cells. B) 
siRNA-knockdown of 16A (si16A) in CFBE cells does not affect expression of CFTR as shown by 
Western blotting. C, D) Continuous recording of whole cell current density in CFBE cells with siRNA-
knockdown of 16A (si16A). Note that both IBMX/Forskolin (100 µM/2 µM; cAMP) and ionomycin (C, 1 
µM; Iono) or ATP (D, 100 µM) induced currents are inhibited by knockdown of TMEM16A (16A). In the 
presence of ionomycin, cAMP is able to activate whole cell currents, which are inhibited by 
CFTRinh172. E) IBMX/Forskolin (100 µM/2 µM) activated CFTR currents are inhibited by the IP3R-
inhibitor Xestospongin (50 µM; Xesto). F) ATP (100 µM) induced Ca
2+
 transients as measured by 
GCAMP6 fused to CFTR, were completely suppressed by TMEM16A inhibitor AO1 (10 µM). Original 
recording (left) and summary of ATP induced Ca
2+
 changes (right). G, H) Organoids grown from T84 
colonic epithelial cells demonstrate secretion upon stimulation with cAMP. Secretion is inhibited by AO1 
(10 µM) as well as CFTRinh172 (10 µM). Mean ± SEM, (n) number of cells. 
# 
significant difference when 
compared to absence of blocker (unpaired t-test). 
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Supplementary Figure 3.5 Plasma membrane expression of CFTR depends on TMEM16A (16A) 
containing a PDZ-binding domain.  
A, B) Immunocytochemistry of Cherry-CFTR and GFP-TMEM16A (16A) expressed in CFBE parental 
cells. Expression of wild type CFTR and TMEM16A (16A), respectively, or expression of truncated 
proteins, in which the C-terminal PDZ-binding motifs DTRL (PDZ-CFTR) and GGVL (PDZ-16A) were 
removed. Plasma membrane expression (PM) and cytoplasmic expression (CP) of wt and truncated 
proteins (PDZ) were quantified by measuring fluorescence intensities in the region of interest, and 
ratios (PM/CP) were calculated. Plasma membrane expression of PDZ-CFTR and PDZ-16A were 
significantly reduced when compared to wt-proteins containing PDZ-binding motifs. C) Coexpression of 
PDZ-CFTR and PDZ-16A leads to further decrease in membrane expression of CFTR and 
TMEM16A. Mean +/- SEM; #indicates significant difference compared to wt (p<0.05; unpaired t-test). 
(number of experiments). 
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Supplementary Figure 3. 6 TMEM16A and CFTR in jejunum of Vil1-Cre–TMEM16A
wt/wt 
(
+/+
) and Vil1-
Cre–TMEM16A
flox/flox
 (
-/-
) mice.  
A, B) Whole cell patch clamp recordings with isolated jejunal epithelial cells. Carbachol (CCH, 100 µM) 
does not activate Cl
-
 currents in cells from wt or (
-/-
) mice in the presence of TRAM-34 (50 nM), an 
inhibitor of Ca
2+
 activated K
+ 
currents. C, D) Activation of whole cell currents by increase in intracellular 
cAMP (100 µM IBMX, 2 µM Forskolin) in jejunal epithelial cells. Mean ± SEM, (n) number of assays. 
*indicates significant activation by cAMP (paired t-test). E) RT-PCR analysis in isolated jejunal 
epithelial cells indicating the absence of TMEM16A mRNA in 
+/+
 and 
-/-
 cells. The somewhat reduced 
cAMP-activated currents in 
-/-
 cells might be explained by the lower levels of CFTR expression. 
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Chapter 4 
 Compartimentalized Crosstalk of CFTR and TMEM16A (ANO1)Through EPAC1 and 
ADCY1 
Abstract 
Airway epithelial cells express both Ca2+ activated TMEM16A/ANO1 and cAMP activated 
CFTR anion channels. Previous work suggested a significant crosstalk of intracellular Ca2+ 
and cAMP signaling pathways, leading to activation of both chloride channels. We 
demonstrate that in airway epithelial cells, stimulation of purinergic or muscarinic G-protein 
coupled receptors (GPCRs) activates TMEM16A and CFTR. Additional expression of Gq/11 
and phospholipase C coupled GPCRs strongly enhanced the crosstalk between Ca2+- and 
cAMP-dependent signaling. Knockdown of endogenous GRCRs attenuated crosstalk and 
functional coupling between TMEM16A and CFTR. The number of receptors did not affect 
expression or membrane localization of TMEM16A or CFTR, but controlled assembly of the 
local signalosome. GPCRs translocate Ca2+-sensitive adenylate cyclase type 1 (ADCY1) and 
exchange protein directly activated by cAMP (EPAC1) to particular plasma membrane 
domains containing GPCRs, CFTR and TMEM16A, thereby producing compartmentalized 
Ca2+ and cAMP signals and significant crosstalk. While biosynthesis and membrane 
trafficking of CFTR requires a functional Golgi apparatus, maturation and membrane 
trafficking of TMEM16A may occur independent of the Golgi. Ca2+ activated TMEM16A 
currents are only transient. Thus, efficient Cl- secretion by airway epithelial cells requires 
CFTR. The present data explain why receptor-dependent activation of TMEM16A is more 
efficient than direct stimulation by Ca2+. 
 
 
 
 
Key words: CFTR, TMEM16A, anoctamin 1, Ca2+ activated Cl- channel, cAMP, Ca2+ 
sensitive adenylate cyclase 1, ADCY1, exchange protein directly activated by cAMP, EPAC1 
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Introduction 
 
TMEM16A (Anoctamin 1, ANO1) is a Ca2+ activated chloride (Cl-) channel 55, 56, 113. In their 
groundbreaking publication Yang et al. reported receptor-activated and Ca2+-dependent Cl- 
currents conferred by TMEM16A 113. We regularly observed larger ATP-activated TMEM16A 
currents in the presence of additional purinergic P2Y2 receptors, although ATP-induced 
increase in intracellular Ca2+ was not changed by additional receptors 149. This suggests i) 
that ATP-induced Ca2+ signals take place within a well shielded plasma membrane 
domain/compartment and ii) that additional mechanisms for receptor-channel coupling may 
exist in such a compartment. 
We reported earlier that in Xenopus oocytes the Cl- ion channel Cystic Fibrosis 
transmembrane conductance regulator (CFTR) is activated through stimulation of purinergic 
P2Y2 receptors 
191. Recent work also demonstrated activation of CFTR by purinergic 
stimulation of airway epithelial cells 162, 200. Thus CFTR may serve as Cl- secretory pathway 
for Ca2+ enhancing agonists, probably via Ca2+-sensitive adenylate cyclase 162, 200. Also other 
G-protein coupled receptors (GPCRs) such as muscarinic receptors can activate CFTR via 
increase in intracellular cAMP, by the help of tyrosine kinases 176. An intimate relationship 
between TMEM16A and CFTR has been suggested earlier 172, and was demonstrated 
recently in TMEM16A-knockout mice, which exhibit both compromised Ca2+-dependent and 
cAMP-activated Cl- transport 200. Here we provide for the first time evidence for a 
colocalization of GPCRs, CFTR and TMEM16A in functional membrane 
compartments/microdomains together with Ca2+-sensitive adenylate cyclase type 1 (ADCY1) 
and exchange protein directly activated by cAMP (EPAC1). Compartmentalization of these 
signaling molecules will provide intense crosstalk between Ca2+ and cAMP signals, and 
explains parallel activation of the chloride channels CFTR and TMEM16A.  
 
Materials and Methods  
Cells, cDNA, transfection, RT-PCR. CFBE cells stably overexpressing WT-CFTR or 
F508del-CFTR and expressing endogenous TMEM16A were cultured in MEM-Eagle’s 
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Minimum Essential Media with L-Glutamine supplemented with 10% (v/v) heat inactivated 
fetal bovine serum (FBS) and 2 µg/ml puromycin (Invitrogen).  
Cells were transfected with cDNA for purinergic P2Y2 receptors (P2Y2R) or muscarinic M3 
receptors (M3R) or siRNA for P2Y2R as described earlier. For semiquantitative RT-PCR, total 
RNA was isolated from CFBE cells using NucleoSpin RNA II columns (Macherey-Nagel, 
Düren, Germany). Total RNA (1 µg / 50 µl reaction) was reverse-transcribed using random 
primers and M-MLV reverse transcriptase (Promega, Mannheim, Germany). Each RT-PCR 
reaction contained sense and antisense primers for the respective gene (0.5 µM) or for 
GAPDH (0.5 µM), 0.5 µl cDNA and GoTaq Polymerase (Promega, Mannheim, Germany). 
After 2 min at 95°C cDNA was amplified during 30 cycles for 30 s at 95°C, 30 s at 56°C and 1 
min at 72°C. PCR products were visualized by loading on agarose gels containing 
peqGREEN DNA/RNA Dye (Peqlab Biotech) and analysed using Meta Morph Vers. 6.2 
(Molecular Devices, USA). Experiments were performed 48h or 72h after the transfection. 
Immunocytochemistry. Transfected CFBE cells were fixed for 10 min with 
methanol/acetone (4:1) (v/v) at -20 ºC. Cells were washed 3 times with PBS and afterwards 
incubated for 30 min at 37ºC with PBS supplemented with 1% Bovine serum albumin (BSA) 
and 0.04% Triton-X to block and permeabilize the cells, respectively. Cells were incubated for 
1h at room temperature with primary rabbit DOG1 antibody (Novus Biologicals, # 
NP_060513) diluted to 1:200 in PBS supplemented with 1% BSA. Cells were washed 3 times 
with PBS and incubated with the secondary antibody Alexa Fluor 488–conjugated donkey 
anti-rabbit IgG (1:300; Thermo Fisher Scientific) and 0.1 mg/ml Hoechst 33342 (1:200; 
Aplichem, Darmstadt, Germany) for 1h at room temperature. Coverslips were mounted with 
fluorescence mounting medium (Dako Cytomation, Hamburg, Germany). 
Immunofluorescence was detected with an Axiovert 200 microscope equipped with an 
ApoTome and analyzed with the profile measurement tool of AxioVision software (AxioVs40; 
V 4.8.2.0; Zeiss, Jena, Germany). For EPAC1 staining, a similar protocol was followed, 
though fixation was performed with PFA 4% (w/v) for 10 min at room temperature; cells were 
incubated overnight at 4ºC with primary antibody (Santa Cruz, # sc_28366) (1:100) and 
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incubated with the secondary antibody Alexa Fluor 546–conjugated donkey anti-mouse IgG 
(1:300; Thermo Fisher Scientific) and 0.1 mg/ml Hoechst 33342 (1:200; Aplichem, Darmstadt, 
Germany) for 1h at room temperature. 
Western blotting. CFBE cells were collected and lysed in 0.5% (v/v) NP40 lysis buffer. 
Proteins were separated by 7% (w/v) SDS-PAGE and transferred into Nitrocellulose 
membranes (0,45 µm; BIORAD, # 162-0115). The membranes were blocked with 5% (w/v) 
nonfat milk powder (NFM) in Tris buffer saline with 0.1 % Tween 20 (TBS-T) for 1 h at room 
temperature and incubated overnight at 4°C with rabbit DOG1 antibody (Novus Biologicals, # 
NP_060513) (1:500 in 1% (w/v) NFM/TBS-T) and rabbit anti β-Actin (1:10000 in 
1%NFM/TBS-T) (Sigma, A2066). The membranes were incubated with horseradish 
peroxidase (HRP)-conjugated goat anti-rabbit IgG (diluted 1:10000 in 1% NFM/TBS-T) for 2h 
at room temperature. Signals were detected using a SuperSignal West Pico 
chemiluminescence substrate (Thermo Fisher Scientific). Experiments were performed in 
triplicate. 
Immunoprecipitation. For immunoprecipitation (pull down) of TMEM16A by P2Y2R cell 
lysate was prepared using 1% Triton X100 in TNEV, followed by mechanical homogenization 
and centrifugation to eliminate nuclei and cellular debris. 20 µg loaded. Lysate was 
precleared by incubation of the input for 2h with Protein-A and Protein-G conjugated beads. 
15 of 50 µl (~20 µg) were loaded onto gels. 500 µg protein was subjected to 
immunoprecipitation of TMEM16A using 6 µl of anti-TMEM16A (Dog1) overnight, 15 of 50 µl 
were loaded onto the gel. Unbound protein was detected by loading the supernatant (15 µl) 
remaining after IP. 
Patch Clamping. Cells were grown on coated glass cover slips. Patch pipettes were filled 
with a cytosolic-like solution containing KCl 30, K-gluconate 95, NaH2PO4 1.2, Na2HPO4 4.8, 
EGTA 1, Ca-gluconate 0.758, MgCl2 1.03, D - glucose 5, ATP 3, pH 7.2. The intracellular 
(pipette) Ca2+ activity was 0.1 µM. Fast whole cell current recordings were performed as 
described recently 62. The bath was perfused continuously with Ringer solution containing 50 
nM TRAM34 (Abcam, ab141885) at a rate of 8 ml/min. Patch pipettes had an input resistance 
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of 2–4 M and whole cell currents were corrected for serial resistance. Currents were 
recorded using a patch clamp amplifier (EPC 7, List Medical Electronics, Darmstadt, 
Germany), the LIH1600 interface and PULSE software (HEKA, Lambrecht, Germany) as well 
as Chart software (AD Instruments, Spechbach, Germany). In regular intervals, membrane 
voltage (Vc) was clamped in steps of 20 mV from -100 to +100 mV from a holding voltage of -
100 mV. Current density was calculated by dividing whole cell currents by cell capacitance. 
Calcium measurements. CFBE cells were transfected on coated glass coverslips with 
pcDNA3.1-Pl-G-CaMP6 fused to the C-terminus of CFTR and were mounted in a perfusion 
chamber 72 h after transfection. Cells were perfused with Ringer solution at a rate of 8 ml/min 
at 37°C. Cell fluorescence was measured continuously with an inverted microscope Axiovert 
S100 (Zeiss) with a 340 objective (Fluar 340/1.3 oil; Zeiss) and a high-speed polychromator 
system (VisiChrome; Visitron, Puchheim, Germany). Pl-G-CaMP6 was excited at 485 and 405 
nm. Emission was recorded between 520 and 550 nm with a CCD-camera (CoolSnap HQ; 
Visitron, Hauppauge, NY, USA). For Fura-2 experiments, CFBE cells were seeded on glass 
coverslips and loaded with 2 mM Fura-2-AM and 0.02% Pluronic F-127 (Life Technologies, 
Germany) in ringer solution (mmol l 1: NaCl 145; KH2PO4 0,4; K2HPO4 1,6; Glucose 5; MgCl2 
1; Ca-Gluconat 1,3) for 1h at room temperature. Fluorescence was detected in cells perfused 
with Ringer’s solution at 37ºC using an inverted microscope (Axiovert S100, Zeiss, Germany) 
and a highspeed polychromator system (VisiChrome, Germany). Fura-2 was excited at 
340/380 nm, and emission was recorded between 470 and 550 nm using a CoolSnap camera 
(CoolSnap HQ, Visitron). Control of experiments, imaging acquisition, and data analysis were 
performed with the software package Meta-Fluor (Universal Imaging, New York, NY, USA). 
Measurements of global cytosolic Ca2+ concentrations by Fura-2 or measurements of 
compartmentalized Ca2+ levels in close proximity to the plasma membrane using GCAMP2, 
have been previously described in detail 80. 
cAMP measurements. cAMP direct immunoassay Kit (abcam, ab138880) was used 
following the manufacturer’s protocol. This assay is based on the competition between HRP-
labeled cAMP and free cAMP present in the sample for cAMP antibody binding sites. Briefly, 
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F508del-CFTR/CFBE cells were treated either with IBMX (100µM)/ Forskolin (2µM) or ATP 
(100µM) and then, lysate and centrifuged in order to obtain the cAMP containing supernatant. 
The supernant was incubated in the cAMP antibody coated 96-well plate for 10 min and, after 
incubation; cAMP-HRP conjugated was added. The amount of cAMP-HRP bound to the plate 
was determined by reading HRP activity at OD450nm using a NOVOstar Microplate Reader 
(BMG LABTECH GmbH, Ortenberg, Germany). The intensity of OD450 nm is inversely 
proportional to the concentration of cAMP in samples and cAMP concentration was obtained 
using a standard curve with known cAMP-HRP concentrations. 
Chemiluminescence measurements. For TMEM16A chemiluminescence, 3HA-TMEM16A-
eGFP CFBE cells were seeded on coated black 96-well plates (Corning #3631) at a density 
of 8x103 cells/well. On the following day, cells were induced with 1 µg/ml doxycycline and 
were transfected with the siRNAs targeting the genes of interest. 48h after the transfection, 
cells were washed once with ice cold PBS supplemented with 0.7 mM CaCl2 and 1.1 mM 
MgCl2. Then cells were incubated for 1h at 4˚C with monoclonal anti-HA (1:500). Then, cells 
were washed 3 times with ice cold PBS, incubated 10 min with 4% (w/v) paraformaldehyde 
(PFA) at 4°C and transferred to room temperature for the remaining staining procedure. Cells 
were then washed three times with PBS and incubated 1h at room temperature with a goat 
anti-mouse HRP-conjugated secondary antibody (1:5000). Signals were detected with 
SuperSignal West Pico chemiluminescence substrate (Thermo Fisher Scientific) using a 
NOVOstar Microplate Reader (BMG LABTECH GmbH, Ortenberg, Germany). All solutions 
were prepared in Dulbecco’s PBS freshly supplemented with 0.7 mM CaCl2 and 1.1 mM 
MgCl2. Antibody solutions contained 1% (w/v) bovine serum albumin (BSA, Sigma-Aldrich 
#A9056). For F508del/WT-CFTR chemiluminescence, a similar protocol was followed. In this 
case, CFBE mCherry-flag-F508del/Wt-CFTR were used and incubated only with anti-flag-
HRP conjugated (1:1000) for 1h at 4˚C before fixation with PFA 4% (w/v). 
Statistical Analysis. Data are reported as means ± SEM. Student’s t test (for paired or 
unpaired samples as appropriate) or ANOVA were used for statistical analysis. A value of 
P<0.05 was accepted as a significant difference. 
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Results 
 
G-protein coupled receptors control activation of the Ca2+ dependent Cl- channel 
TMEM16A.  
In human airway epithelial cells expressing wild type CFTR (WT-CFTR/CFBE) stimulation of 
P2Y2 receptors (P2Y2R) with ATP (100 µM) activates whole cell currents (Fig 4.1 A, B). 
Expectedly, siRNA-knockdown of P2Y2R (siP2Y2; Fig S 11A) inhibited activation of currents 
by ATP, but surprisingly also attenuated direct activation by the Ca2+ ionophore ionomycin 
(IONO) (Fig 4.1 C). However, increase in intracellular Ca2+ ([Ca2+]i) by IONO was not affected 
by siP2Y2R, in contrast to ATP-induced [Ca
2+]i (Fig 4.1 D,E). Overexpression of P2Y2R in 
CFBE cells expressing WT-CFTR or F508del-CFTR, dramatically enhanced Cl- currents 
activated by ATP as well as by IONO (Fig 4.1 F, G), while global cytosolic [Ca2+]i increase by 
ATP and IONO were not affected (Fig 4.1 H, I). The effect of additional P2Y2R on current 
increase was remarkably bigger in cells expressing WT-CFTR than F508del-CFTR (Fig 4.1F, 
G). Very similar results were obtained by overexpressing muscarinic M3 receptors (M3R), 
which are not expressed endogenously in CFBE cells. Expression of M3R not only induced 
carbachol-activated whole cell currents, but unexpectedly also enhanced ATP-activated 
currents (Fig S4.1 B, C). Finally, stimulation of histamine H1 receptors, another type of 
phospholipase C (PLC)- coupled GPCR, activated larger whole cell currents in cells 
overexpressing P2Y2R (Fig S4.1 D). These experiments suggest that i) expression of Gq/11 
and PLC-coupled GPCRs translocates additional signaling proteins to the plasma membrane 
(PM) to activate Cl- currents, and that ii) Ca2+-dependent whole cell current are strongly 
CFTR-dependent 200. Additional proteins are probably required to assemble the signalosome, 
such a scaffold proteins. In further preliminary experiments we found that siRNA-knockdown 
of Na+/H+ Exchanger Regulatory Factor 1 (NHERF1) attenuated both CFTR and TMEM16A-
related Cl- currents 201. 
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Fig 4.1 P2Y2 G-protein coupled receptors control activation of the Ca
2+ 
dependent Cl
-
 channel 
TMEM16A. 
 A) Whole cell currents activated by ATP (100 µM) in CFBE airway epithelial cells. B) Corresponding 
current/voltage relationships. C) Activation of TMEM16A by ATP (100 µM) or ionomycin (IONO; 0.1 
µM). Summary of current densities in cells treated with scrambled RNA (Scrbld) or siRNA for P2Y2 
receptors (siP2Y2R). ATP- and IONO-dependent activation of TMEM16A was inhibited by knockdown 
of P2Y2R. D) Increase in intracellular Ca
2+
 ([Ca
2+
]i) by stimulation with ATP or IONO, as measured by 
Fura-2 (mean curves ± SEM). E) Summary of [Ca
2+
]i indicates no inhibition of IONO-induced increase 
in [Ca
2+
]i by knockdown of P2Y2R. In contrast, ATP-induced [Ca
2+
]i increase was reduced. F) 
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Overexpression of P2Y2R largely augmented ATP (100 µM)-induced TMEM16A currents and doubled 
IONO-activated TMEM16A currents in WT-CFTR/CFBE cells. G) Overexpression of P2Y2R in F508del-
CFTR/CFBE cells caused a smaller increase in ATP/IONO-activated whole cell currents. H, I) 
Expression of additional P2Y2R did not change intracellular Ca
2+
 signals in WT-CFTR/CFBE or 
F508del-CFTR/CFBE cells. Mean ± SEM (number of experiments). # significant difference when 
compared to Scrbld or Mock (p < 0.05, unpaired t-test). § significantly smaller than in WT-CFTR (p < 
0.05, unpaired t-test). 
 
CFTR but not GPCRs affect membrane expression of TMEM16A.  
CFTR and/or P2Y2R may affect activation of whole cell currents by changing expression 
levels or PM localization of TMEM16A. However, similar levels of TMEM16A were found with 
knockdown or overexpression of P2Y2R in CFBE/WT-CFTR and F508del-CFTR/CFBE cells 
or in HEK293 cells (Fig 4.2 A, B, Fig S4.1 E). Moreover, membrane expression of TMEM16A 
was not affected by knockdown or overexpression of P2Y2R, when analyzed by 
immunofluorescence or chemiluminescence (Fig 4.2 C-H, Fig S 4.1 F). Membrane expression 
of TMEM16A was also not changed by overexpression of M3R, but was generally lower in 
F508del-CFTR/CFBE cells (Fig 4.2 C-H, Fig S4.1 G). 
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Fig 4.2 P2Y2R do not change expression and localization of TMEM16A. 
 A, B) Western blots showing expression of CFTR, P2Y2R and TMEM16A. ß-acting is shown as gel 
loading control. Similar expression levels were detected for TMEM16A in WT-CFTR/CFBE and 
F508del-CFTR/CFBE cells. siRNA-knockdown of P2Y2R or overexpression of P2Y2R had no clear 
effects on TMEM16A expression. C-F) Immunofluorescence of TMEM16A in WT-CFTR/CFBE and 
F508del-CFTR/CFBE cells. siRNA-knockdown of P2Y2R or overexpression of P2Y2R had no obvious 
effect on cellular localization of TMEM16A. G, H) Analysis of cellular distribution of TMEM16A in WT-
CFTR/CFBE and F508de-CFTR/CFBE cells by quantitative assessment of fluorescence in plasma 
membrane/cytoplasm (au; arbitrary units). Bars indicate 10 µm. Mean ± SEM (number of experiments). 
# 
significant difference when compared to WT-CFTR (p < 0.05, unpaired t-test). 
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Purinergic receptors augment CFTR whole cell currents.  
We found that the presence of P2Y2R not only enhances ATP- and IONO-activated Cl
- 
currents (Fig 4.1), but also CFTR Cl- currents stimulated with IBMX and Forskolin (I/F) (Fig 
4.3 A-D). Notably, significant I/F activated Cl- currents could even be detected in CFBE cells 
expressing F508del-CFTR, upon additional expression of P2Y2R (Fig 4.3 C,D). Expression of 
WT-CFTR and F508del-CFTR were not affected by knockdown or overexpression of P2Y2R, 
when analyzed by immunofluorescence and chemiluminescence (Fig 4.3 E-L). WT-CFTR is 
well expressed in the PM, but not F508del-CFTR, and thus I/F should be unable to activate 
F508del-CFTR. However, I/F activated a whole cell current in F508del-CFTR expressing cells 
(Fig 4.3 C,D). We found that WT-CFTR currents activated by membrane permeable 8-Br-
cAMP were largely independent of P2Y2R, in contrast to activation by I/F (Fig 4.4 A). This 
result suggests that Ca2+-dependent adenylate cyclases are translocated to the plasma 
membrane by P2Y2R. We also noticed that 8-Br-cAMP activated a small, albeit significant Cl
- 
current in CFBE cells expressing F508del-CFTR. This current demonstrated a TMEM16A-
typical time dependent activation and outward rectification (inset in Fig 19A), and is therefore 
not a CFTR-current. Activation of this current by 8-Br-cAMP was abolished by knockdown of 
P2Y2R (Fig 4.4 A). These results strongly suggest that the 8-Br-cAMP signal has been 
converted most likely by EPAC1, into a Ca2+ signal, which activated TMEM16A. EPAC1 (also 
known as RAPGEF3) functions as a guanine nucleotide exchange factor (GEF) for both Rap1 
and Rap2. EPAC1 may have been translocated to a plasma membrane compartment by 
P2Y2R. In fact, 8-substituted cAMP derivatives such as 8-Br-cAMP or 8-pCPT-2-O-Me-cAMP 
(007-AM) are known to be potent activators of EPAC1 199. The current activated by 8-Br-
cAMP or 8-pCPT-2-O-Me-cAMP (007-AM) was inhibited by the TMEM16A-inhibitor AO1 (Fig 
4.4 C). As an earlier study was unable to demonstrate a direct relation of TMEM16A by 
cAMP/TMEM16A, it is unlikely that 8-Br-cAMP directly activated TMEM16A 202. 
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Fig 4.3 P2Y2R control activation of CFTR but not CFTR membrane expression.  
A-D) Current/voltage relationships and current densities from patch clamp experiments in mock 
transfected and P2Y2R overexpressing wt-CFTR/CFBE cells and F508del-CFTR/CFBE cells. Cells 
were stimulated with 100 µM IBMX and 2 µM Forskolin (I/F). E, H) Expression of wt-CFTR and 
F508del-CFTR as detected by cherry-fluorescence (life imaging). P2Y2R was overexpressed or 
endogenous P2Y2R was knocked down by siP2Y2R. I, J) Ratios for expression of wt-CFTR or F508del-
CFTR in plasma membrane (PM) versus cytoplasm (au; arbitrary units). K, L) Membrane expression of 
wt-CFTR and F508del-CFTR as detected by chemiluminescence, using an extracellular FLAG tag 
inserted into the first extracellular loop of CFTR and an anti-FLAG antibody. Mean ± SEM (number of 
experiments). 
# 
significant difference when compared to mock (p < 0.05, unpaired t-test). Scale bar, 10 
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µm. 
 
 
Role of EPAC1 for activation of Cl- currents.  
Expression of EPAC1 was well detected in CFBE cells (Fig 4.4 B). Using the EPAC1 activator 
007-AM, whole cell Cl- currents were activated in WT-CFTR/CFBE cells that were strongly 
inhibited by removal of extracellular Cl- (5Cl-). Both TMEM16-inhibitor CaCCinhAO1 (AO1) and 
CFTR inhibitor CFTRinh172 partially inhibited 007-AM-activated Cl
- currents, suggesting that 
both (CFTR and TMEM16A) Cl- secretory pathways are activated by 007-AM (Fig 4.4 C). The 
role of EPAC1 for activation of TMEM16A and CFTR was further examined using the EPAC1-
inhibitor ESI09. While ESI09 did not block stimulation of Cl- currents by ATP or IONO in mock 
transfected wt-CFTR/CFBE and F508del-CFTR/CFBE cells, it inhibited ATP/IONO-activated 
Cl- currents in cells overexpressing P2Y2R. Inhibition by ESI09 was more pronounced in 
F508del-CFTR/CFBE cells (Fig 4.4 D). Moreover, I/F-induced currents in wt-CFTR and 
F508del-CFTR expressing cells were inhibited by ESI09 by about 50%. Additional currents in 
the presence of P2Y2R were completely inhibited by ESI09 (Fig 4.5 E). Immunocytochemistry 
detected localization of EPAC1 (in red) closer to the plasma membrane in cells expressing 
additional P2Y2R (in green) (Fig 4.5 F, G). Taken together, a significant portion of the I/F-
activated Cl- current is EPAC1-dependent and this portion is further enhanced by additional 
expression of GPCRs.  
 
Role of ADCY1 for activation of Cl- currents. 
 Because CFTR can be activated by ATP, we examined expression of the Ca2+-sensitive 
adenylate cyclases (ADCYs). ADCY1 and ADCY3 (but not ADCY8 or ADCY10) are expressed 
in both WT-CFTR/CFBE and F508del-CFTR/CFBE at approximately similar levels (Fig 4.4 H). 
We found that activation of purinergic receptors with ATP increased intracellular cAMP, and 
cAMP-increase was further enhanced by additional expression of P2YR. Remarkably, in the 
presence of P2Y2R, ATP-induced rise in intracellular cAMP was almost as high as with 
stimulation by I/F (Fig 4.4 J). Yet, expression levels for ADCY1 were not affected by additional 
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P2Y2R (Fig 4.4 I). Namkung et al. demonstrated the role of ADCY1 for ATP-activated and 
CFTR-dependent Cl- secretion in airway epithelial cells 162. We therefore used the ADCY1-
specific inhibitor ST034307 (ST034) to further examine the role of ADCY1 for IONO activated 
Cl- secretion. In the presence of additional P2Y2R, Ca
2+ activated Cl- secretion by IONO was 
strongly inhibited by ST034 (Fig 4.4 K). Remarkably, ST034 potently blocked I/F-activated 
currents in WT-CFTR/CFBE cells and inhibited I/F-induced currents in P2Y2R-expressing 
F508del-CFTR/CFBE cells, indicating the dominating role of ADCY1 for generation of cAMP 
(Fig 4.4 L, M). Taken together, an intensive crosstalk between cAMP- and Ca2+-dependent 
signaling exists in airway epithelial cells due to EPAC1 and ADCY1, converting cAMP into 
Ca2+ signals and vice versa (Fig S4.2). Intensive crosstalk prevents clear discrimination 
between adrenergic/CFTR and purinergic/TMEM16A dependent chloride secretion. This is 
further indicated by the fact that specific inhibitors for CFTR (CFTRinh172) and TMEM16 
(CACCinhAO1) inhibit both, Ca2+ and I/F-activated currents (Fig 4.4 N, O). Crosstalk and 
interaction between CFTR and TMEM16A amplify electrolyte secretion. This new insight is 
applicable to Cystic Fibrosis and the search for novel pathways to improve defective Cl- 
secretion 200. 
Compartimentalized Crosstalk of CFTR and TMEM16A (ANO1) through EPAC1 and ADCY1  
104 
       
 
Fig 4.4 EPAC1 and ADCY1 mediate cAMP/Ca
2+
 crosstalk and cross-activation of TMEM16A and 
CFTR.  
A) Summary of current densities obtained by stimulation of WT-CFTR/CFBE cells and F508del-
CFTR/CFBE cells with 8-Bromo cAMP (25 µM). Cells overexpressed P2Y2R or endogenous P2Y2R 
was knocked-down by siP2Y2R. B) RT-PCR demonstrating expression of EPAC1 in WT-CFTR/CFBE 
cells and F508del-CFTR/CFBE cells. C) Summary of current densities measured in cells stimulated 
with the EPAC1 activator 007-AM (30 µM). Replacement of extracellular Cl
-
 by impermeable gluconate 
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(5Cl
-
 ), or application of the TMEM16A inhibitor CaCCinhAO1 (AO1; 20 µM), or application of the 
CFTR-inhibitor CFTRinh172 (Inh172; 20 µM) inhibited current densities. Ca
2+
 chelating by BAPTA-AM 
(50 µM) also inhibited activation by 007-AM. D) Currents densities activated by ATP (100 µM) and 
ionomycin (IONO; 0.1 µM), respectively, and inhibition by the EPAC1 inhibitor ESI09 (10 µM) in WT-
CFTR/CFBE and F508del-CFTR/CFBE cells. E) Current densities activated by 100 µM IBMX and 2 µM 
Forskolin (I/F) in WT-CFTR/CFBE cells and F508del-CFTR/CFBE cells. Cells were mock transfected or 
overexpressed P2Y2R. Effects of the EPAC1-inhibitor ESI09. F) Immunocytochemistry of EPAC1 and 
P2Y2R in WT-CFTR/CFBE cells. G) Ratio of EPAC1 expression in plasma membrane (PM) versus 
cytoplasm in mock transfected cells and cells overexpressing P2Y2R (arbitrary units; au). H) RT-PCR 
indicating expression of the Ca
2+
-sensitive adenylate cyclases (ADCY) 1 and 3 but not 8 and 10. I) 
Relative expression of ADCY1-mRNA in mock transfected and P2Y2R-overexpressing cells. J) 
Increase in intracellular cAMP levels induced by stimulation with ATP (100 µM) and 100 µM IBMX/2 
µM Forskolin (I/F). K) Current densities activated by IONO (0.1 µM) in mock transfected and P2Y2R-
expressing WT-CFTR/CFBE and F508del-CFTR/CFBE cells, and inhibition by the ADCY1-inhibitor 
ST034307 (ST034; 30 µM). L, M) Current densities activated by I/F in mock and P2Y2R-expressing WT-
CFTR/CFBE L) and F508del-CFTR/CFBE M) cells, and inhibition by the ADCY1-inhibitor ST034. N,O) 
Inhibition of Cl
-
 currents (current densities) by CaCCinhAO1 (AO1; 20 µM) and CFTR inhibitor 
CFTRinh172 (20 µM). Mean ± SEM (number of experiments). 
# 
significant difference when compared to 
con or mock (p < 0.05, unpaired t-test). 
§ 
significant difference when compared to WT-CFTR 
expressing cells (p < 0.05, unpaired t-test). * significant inhibition by ST034 (p<0.05, paired t-test). 
 
Discussion 
The present data demonstrate the role of EPAC1 and ADCY1 for cross activation of CFTR 
and TMEM16A by cAMP and Ca2+. Our previous study indicated an intimate functional 
relationship between CFTR and TMEM16A and demonstrated cAMP-activated transport 
being almost absent in epithelia from TMEM16A knockout mice 200. TMEM16A was shown to 
be essential for proper activation as well as membrane expression of CFTR. We showed that 
TMEM16A causes ER Ca2+ store release, thereby engaging Store Operated cAMP Signaling 
(SOcAMPS) and activation of Ca2+ regulated adenylyl cyclases (ADCYs) 80. Here we show 
that cAMP-dependent and Ca2+ activated Cl- currents in airway epithelial cells strongly 
overlap due to the crosstalk of intracellular signaling molecules. The present results are in line 
with an earlier study that reported activation of CFTR via P2Y2R 
191. Notably, evidence was 
provided that TMEM16A can also be activated by a Ca2+ independent but G-protein-
dependent mechanism 131. Apart from the described crosstalk between TMEM16A and CFTR 
via Ca2+ dependent ADCY1 and cAMP-regulated EPAC1, additional crosstalk via calcium 
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dependent cAMP phosphodiesterase (PDE1), and possibly via PDE4 may take place. Such 
an additional regulatory circuit would further modulate the cooperativity between these 
channels. As our studies were performed in the presence of the PDE-inhibitor IBMX and non-
hydrolysable analogues of cAMP, subsequent studies will have to clarify the contributions of 
PDEs. 
Crosstalk of TMEM16A and CFTR is relevant in ciliated airway epithelial cells and intestinal 
epithelial cells, which are both Cl- and fluid secreting. However, TMEM16A is expressed at 
higher levels in mucus producing club cells and goblet cells. Upregulation of TMEM16A 
during inflammation will therefore increase its impact on fluid and mucus secretion. As 
expression and upregulation of TMEM16A during inflammation is much more obvious in 
mucus producing cells, the effects on mucus secretion will be more relevant. This will be even 
more so in case of Cystic Fibrosis (CF), where functional CFTR is absence and thus the 
direct impact of TMEM16A on fluid secretion (which requires functional CFTR) might be 
negligible. Nevertheless, a direct small molecule opener of TMEM16A could be beneficial in 
CF. 
This signaling/functional overlap is likely to take place in a shielded membrane compartment. 
Membrane bound ADCYs are known to colocalize with PLC-coupled GPCRs possibly in lipid 
raft-like membrane compartments 203. TMEM16A and CFTR have been both located in lipid 
rafts 126, 204, while EPAC1 was shown to colocalize with CFTR 199. EPAC1 is a known hub for 
cAMP/Ca2+ crosstalk 199, 205, 206. We found enrichment of P2Y2R in an immunoprecipitate 
against TMEM16A, further supporting the existence of such functional membrane platforms 
(Fig 4.5). Signaling occurring in such functional compartments is well shielded. The EPAC1 
activator 007-AM induced a whole cell Cl- current. Activation of this current was suppressed 
by the Ca2+ chelator BAPTA-AM, demonstrating the role of intracellular Ca2+ (Fig 4.4 C). 
Moreover, 50-60% of the whole cell current activated by I/F were inhibited by the EPAC1-
inhibior ESI09, indicating a central role of EPAC1 in regulating Cl- secretion (Fig 4.4 E). 
However, I/F did not increase global intracellular Ca2+ levels measured by Fura-2 (Fig 4.5 B). 
In contrast, local compartmentalized Ca2+ was increased by I/F and 007-AM in close proximity 
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of CFTR, which was detected by the Ca2+ sensor G-CAMP6 fused to the C-terminus of CFTR 
(Fig 4.5 C-E). 
We found earlier that extended synaptotagmins (ESYT1-3) strongly affect activation of 
TMEM16A through stimulation of P2Y2R. ESYT1-3 tethers the endoplasmic reticulum (ER) 
close to plasma membrane thereby facilitating local Ca2+ signaling 207. Thus ESYT1 stabilizes 
plasma membrane / ER microdomains to allow proper coupling of the Ca2+ sensor STIM1 to 
store operated Orai1 Ca2+ influx channels 208. It seems noteworthy that I/F-activated currents 
were also found to be ESYT1-dependent: About 50 % of the I/F-activated whole cell current 
was inhibited siRNA knockdown of ESYT1 (388.1 ± 63.4; n = 5, scrambled RNA vs. 195.5 ± 
49.3; n = 5, siESYT1). This corroborates the intimate relationship between TMEM16A and 
CFTR, and supports colocalization of signaling machines allowing Ca2+/cAMP-crosstalk. 
  
 
Fig 4.5 Compartmentalized Ca
2+
 signaling. 
A) Immunoprecipitation of TMEM16A pulled down P2Y2R. Input; cell lysate. Precleared; negative 
control obtained by incubation of Input for 2h with Protein-A and Protein-G conjugated beads. 
IP_TMEM16A; Immunoprecipitation of TMEME16A. Unbound; Supernatant remaining after IP. B) 
Global intracellular Ca
2+
 (mean ± SEM; n = 143), measured by Fura-2 in WT-CFTR/CFBE cells. I/F 
rather decreased than increased global intracellular Ca
2+
 levels. C, D) Intracellular compartmentalized 
Ca
2+
 levels close to the plasma membrane, as detected by the Ca
2+
 sensor G-CAMP6, which was 
fused to the C-terminal end of CFTR. Both I/F and the EPAC1-activator 007-AM slightly enhanced 
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compartmentalized intracellular Ca
2+
 in close proximity to CFTR. E) Control (con); absence of any 
stimulus. Mean ± SEM (number of experiments). 
 
CFTR and TMEM16A are both glycosylated 113, 209, 210. Indeed, collapsing the Golgi and thus 
blocking secretory traffic using BFA eliminated the glycosylated forms of CFTR and 
TMEM16A (Fig 4.6 A). Interestingly, membrane trafficking of CFTR was completely inhibited 
by BFA, while membrane trafficking of TMEM16A remained largely unchanged by BFA (Fig 
4.6 B-E). Astonishingly, although CFTR was completely absent from the cell membrane in 
BFA-treated cells, whole cell currents activated by I/F were still considerable (about 50 %). In 
fact I/F-induced currents remained almost unaffected by BFA in cells overexpressing P2Y2R 
(Fig 4.6 F, G). Ca2+ (IONO) activated currents were not reduced by BFA (Fig 4.6 H,I). These 
rather surprising results confirm that a significant portion of the cAMP-activated Cl- current is 
due to TMEM16A and that it appears well justified screening for more potent activators of 
TMEM16A to activate Cl- secretion in Cystic Fibrosis. In summary, we demonstrate an 
intimate relationship between TMEM16A and CFTR, which is enabled by cAMP/Ca2+ 
crosstalk due to EPAC1 and ACDY1. Future studies may supply further details regarding the 
origin of the compartmentalized submembranous Ca2+ signal, and the possible contribution of 
Ca2+ -regulated phosphodiesterases.  
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Fig 4.6 TMEM16A can compensate for the lack of CFTR in BFA treated cells. 
 A) Western blots of CFTR and TMEM16A in WT-CFTR/CFBE and F508del-CFTR/CFBE cells exposed 
to control solution (con) or the protein transport inhibitor brefeldin A (BFA; 10 µM/24h). BFA eliminated 
the glycosylated forms of CFTR (Band C) and TMEM16A (upper band at 130 kDa). B) Expression of 
CFTR (cherry fluorescence in living cells) indicating membrane localization of WT-CFTR (left upper 
panel), which was completely suppressed by BFA (left lower panel). F508del-CFTR (right panels) was 
located intracellularly, independent of BFA. C) Ratio of plasma membrane (PM) vs. cytoplasmic (CP) 
localization of CFTR, as analyzed by fluorescence intensities in regions of interest (ROI). D) 
Expression of TMEM16A (primary anti-TMEM16A (DOG1)-antibody; secondary fluorescent labeled 
antibody) indicating variable membrane localization that was not changed by BFA in either WT-
CFTR/CFBE (left panels) or F508del-CFTR/CFBE (right panels) cells. E) Ratio of PM vs. CP 
localization of TMEM16A indicating no significant changes by BFA. In F508del-CFTR expressing cells, 
less TMEM16A was membrane localized. F) Whole cell currents activated by IBMX/Forskolin (I/F; 100 
µM/2 µM) in wt-CFTR/CFBE and F508del-CFTR/CFBE cells. In WT-CFTR/CFBE cells, BFA inhibited 
only 50% of the I/F-activated current in mock transfected cells. BFA did not inhibit currents in cells 
overexpressing the purinergic receptors P2Y2R. G) In F508del-CFTR/CFBE cells, additional currents 
produced by expression of P2Y2R were not affected by BFA. H,I) Whole cell currents activated by 
Ionomycin (IONO; 100 nM) in WT-CFTR/CFBE and F508del-CFTR/CFBE cells were not affected by 
BFA. Mean ± SEM (number of experiments). 
# 
significant difference when compared to mock (p<0.05; 
unpaired Student's t test). 
§ 
significant difference when compared to con (p<0.05; unpaired Student's t 
test). 
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Supplementary material 
 
Supplementary Figure 4.1 Activation of TMEM16A by GPCR. 
 A) siRNA knockdown of P2Y2R detected by semiquantitative RT-PCR in WT-CFTR and F508del-CFTR 
expressing CFBE cells. B,C) Summary of whole cell currents activated by ATP (100 µM), carbachol 
(CCH; 100 µM) and IBMX/Forskolin (100 µM/2 µM). Summaries are shown for cells expressing empty 
plasmid (mock) or M3 receptors (M3R) in CFBE/WT-CFTR (B) and CFBE/F508del-CFTR (C) cells. D) 
Summary of current densities activated by histamine (50 µM) in mock transfected CFBE cells and cells 
overexpressing P2Y2R. E) Ratio of plasma membrane to cytoplasmic expression of TMEM16A in 
HEK293 cells by analysis of fluorescence intensities in regions of interest. Knockdown of P2Y2 
receptors does not change membrane expression. F) Membrane expression of TMEM16A in CFBE 
cells measured by chemiluminescence. CFBE cells expressed a TMEM16A construct that contained an 
extracellularly accessible HA tag in the first extracellular loop of TMEM16A. Cells were labeled using 
an anti-HA antibody and a secondary horseradish peroxidase conjugated antibody. Additional 
expression of P2Y2R did not change membrane expression of TMEM16A. G) Ratio of plasma 
membrane to cytoplasmic expression of TMEM16A in CFBE cells. Expression of M3R does not change 
membrane expression. Mean ± SEM (number of experiments). 
# 
significant difference when compared 
to mock or scrambled RNA (Scrbld) or mock transfected cells (unpaired Student's t test). 
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Supplementary Figure 4.2 cAMP/Ca
2+
-crosstalk activates CFTR and TMEM16. 
Stimulation of purinergic receptors leads to endoplasmic reticulum (ER) Ca
2+
 store release through IP3 
receptors (IP3R). Ca
2+
 not only activates TMEM16A (T16A) but also stimulates adenylate cyclase type 
1 (ADCY1) to produce cAMP and to activate CFTR via protein kinase A (PKA). Vice versa, activation of 
adenylate cyclases by IBMX/Forskolin (or through ß-adrenergic stimulation) generates cAMP and 
activates not only CFTR but also TMEM16A via exchange protein directly activated by cAMP (EPAC1), 
the small GTP-binding protein RAP, phospholipase C (PLC) and local increase in intracellular Ca
2+
. 
Receptor, TMEM16A, CFTR and signaling molecules are probably colocalized in a raft-like plasma 
membrane microdomain. 
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Chapter 5:  
TMEM16A is indispensable for basal mucus secretion in airways and intestine 
 
Abstract 
TMEM16A is the Ca2+ activated chloride channel in airways and intestine and has been 
associated with goblet cell metaplasia. Expression of TMEM16A is strongly upregulated in CF 
and asthma during mucus hypersecretion. The role of TMEM16A for mucus production or 
mucus secretion remains obscure, and whether TMEM16A affects the function of intestinal 
goblet cells is entirely unknown. Basal (unregulated) mucus secretion occurs through low 
levels of ATP. Here we report for the first time that TMEM16A is essential for basal secretion 
of mucus in airways and intestine. Airway and intestinal epithelial specific knockout of 
TMEM16A (FoxJ1-TMEM16Aflox/flox, Vil1-TMEM16Aflox/flox) leads to accumulation of mucus in 
airway club (Clara) cells and large intestinal goblet cells. Acute ATP-induced mucus secretion 
by airway club cells and colonic goblet cells is strongly compromised in the absence of 
TMEM16A. Experiments in human Calu3 airway epithelial cells show similar TMEM16A-
dependence of mucus release. In contrast, cholinergic mucus secretion due to compound 
exocytosis is independent of TMEM16A. The data demonstrate a previously unrecognized 
role of TMEM16A for membrane exocytosis and describe a novel ATP-driven pathway for 
intestinal mucus secretion. We conclude that ATP-dependent, i.e. constitutive mucus 
secretion in both airways and intestine requires TMEM16A. Providing similar regulation in 
human, the present results form the basis for a completely novel therapeutic approach for the 
treatment of mucus hypersecretion. 
 
 
 
 
 
Key words: TMEM16A; anoctamin 1; mucus secretion, Cystic Fibrosis, asthma, COPD, Ca2+ 
signaling 
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Introduction 
 
Mucus covers airways and intestine and represents the innate defense against pathogens. In 
the airways, mucus traps inhaled pathogens and particles, while intestinal mucus physically 
separates bacteria from epithelial cells and lubricates the intestinal content 211, 212. In healthy 
lungs mucus is formed by secretion and hydration of gel forming mucins from surface goblet 
and club (Clara) cells producing MUC5AC and MUC5B, and from submucosal glands 
releasing MUC5B 213. The major mucin in the gut is MUC2 214. Although clear differences exist 
between airway and intestinal goblet cells, they share common features such as low pH and 
high Ca2+ content in their secretory granules, which allows for tight packaging of the mucus 
214. Despite protective functions, mucus becomes a severe problem when hypersecreted 
upon mucous metaplasia during inflammatory lung diseases such as asthma, COPD and 
Cystic Fibrosis (CF) 215. Mucus hyperproduction causes airway obstruction, reduced 
mucociliary clearance and chronic inflammation, the predominant problems in CF 213. In CF, 
mucus is particularly viscous and adhesive due to compromised Cl- and HCO3
- secretion 
caused by defective Cystic Fibrosis transmembrane conductance regulator (CFTR) channels 
216, 217. Expression of the Ca2+ activated Cl- channel TMEM16A (anoctamin 1) is strongly 
upregulated in CF by bacterial components and in asthma by Th2 cytokines. This parallels 
goblet cell metaplasia and mucus hypersecretion 152, 218, 219. Upregulation of TMEM16A is 
predominant in mucus producing cells and to a lesser degree in ciliated epithelial cells 152, 189. 
The role of TMEM16A for mucus production or mucus secretion remains obscure, although 
both is inhibited by Niflumic acid, an inhibitor of TMEM16A and other ion channels 220, 221. 
Whether TMEM16A affects the function of intestinal mucus-producing cells is entirely 
unknown. The present study makes use of airway and intestinal selective epithelial knockout 
mice and demonstrates for the first time an indispensable role of TMEM16A for mucus 
secretion. TMEM16A provides a mechanism to enhance Ca2+ in the apical pole of mucus 
producing cells, which is essential for ATP-activated mucus release. ATP-dependent mucus 
release takes place continuously under basal conditions. TMEM16A therefore is a regulator of 
exocytosis and controls the release of proinflammatory mediators as well. The findings 
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presented here are probably correlated with the reported role of TMEM16A for cytoplasmic Cl- 
homeostasis, controlling PtdIns (4,5)P2 microdomains and membrane remodeling 222. 
 
Materials and Methods 
Cells culture, RT-PCR. HEK293 cells were grown as previously described223. Calu3 cells 
were grown in DMEM-F12 media supplemented with 1% HEPES, 1% L-glutamine, 10% FBS 
at 37ºC in the absence of antibiotics in a humidified atmosphere with 5% CO2. Total RNA was 
isolated from lungs and was reverse-transcribed using random primer (Promega, Mannheim, 
Germany) and M-MLV Reverse Transcriptase RNase H Minus (Promega, Mannheim, 
Germany). Primers used were: 5´-GTGACAAGACCTGCAGCTAC and 5´-
GCTGCAGCTGTGGAGATTC. 
TMEM16A knockout animals, ovalbumin challenge, preparation of tissues. Generation 
of mice with intestinal epithelial knockout of TMEM16A (TMEM16Aflox/floxVil1-Cre; fl/fl-Vil1) has 
been described earlier 128. Tissue specific knockout of TMEM16A in ciliated airway epithelial 
cells was achieved by crossbreeding TMEM16Aflox/flox (fl/fl) mice with FOXJ1-Cre mice 
(TMEM16Aflox/floxFoxJ1-Cre; ) and is outlined in 200. Allergen challenge of mice has been 
described earlier 224. In brief: Mice were sensitized to ovalbumin (OVA, Sigma) by i.p. injection 
of 100 µg OVA with 1 mg aluminum hydroxide gel (Sigma) on days 0 and 14. At days 21 and 
24, mice were anaesthetized (ketamine 90–120 mg/kg, xylazine 6–8 mg/kg) and challenged 
to OVA by intratracheal instillation of 50 µg OVA in 20 µl saline. Control mice were sham 
sensitized with saline and aluminum hydroxide gel (Sigma) and challenged to 20 µl saline by 
intratracheal instillation. All animal experiments complied with the ARRIVE guidelines and 
were carried out in accordance with the U.K. Animals Act, 1986 and associated guidelines, 
EU Directive 2010/63/EU for animal experiments. All animal experiments were approved by 
the local ethics committee of the Government of Unterfranken/Würzburg (AZ: 55.2-2532-2-
328) and were conducted according to the guidelines of the American Physiologic Society 
and the German law for the welfare of animals.  
Histological analysis. Intestinal sections were saved for histological analyses. Mouse 
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airways were fixed by transcardial fixation and were embedded in paraffin or were used as 
cryosections. For paraffin sections, tissues were fixed in 4% paraformaldehyde (PFA), 0.2% 
picric acid and 3.4% sucrose in PBS, and were washed in methanol before embedding in 
paraffin. Sections were stained according to standard Periodic acid-Schiff (PAS) or Alcian 
Blue methods and assessed by light microscopy. Sections were analyzed using an Axiovert 
200 microscope equipped with AxioCam ICc 1 and ApoTome (Zeiss, Germany). Cross 
sectional areas were determined using AxioVision Software and an Axiovert 200 microscope 
equipped with AxionCam. 
In vitro perfused intestine. Mice were sacrificed and excised intestines were placed 
immediately in ice-cold Ringer solution and carefully flushed to remove residual luminal 
contents. The intestinal segments were mounted and perfused vertically in a custom-
designed perfusion chamber with a constant temperature, similar to 93.  
Patch Clamping. Patch pipettes were filled with a cytosolic-like solution containing in mM: 
KCl 30, K-gluconate 95, NaH2PO4 1.2, Na2HPO4 4.8, EGTA 1, Ca -gluconate 0.758, MgCl2 
1.03, D - glucose 5, ATP 3, pH 7.2. TMEM16A was activated by high pipette Ca2+ (1 µM). 
Extracellular Cl- (145 mM) was replaced by gluconate, HCO3
- or I-. Experiments were 
performed as described earlier200. 
Electron microscopy. For transmission electron microscopy of mouse airways, deeply 
anesthetized mice were sacrificed and fixed by intracardial perfusion with 2.5% 
glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4). Lungs were treated with 1% OsO4, 0.8% 
K4[Fe(CN)6] in 0.1 M cacodylate buffer for 1.5 h, dehydrated with graded ethanol solutions 
and embedded in Epon (Roth, Karlsruhe, Germany). Semi-thin sections were stained with 
Richardson's stain. Ultrathin sections were stained with uranyl acetate and lead citrate, and 
analyzed on a transmission electron microscope (Libra, Zeiss). 
Analysis of mucus, IL-8 release, leukocytes. Tissues were fixed using 4 % 
paraformaldehyde (PFA), 0.2% picric acid and 3.4% sucrose in PBS and washed in methanol 
before embedding in paraffin. Mucus was analyzed using standard Periodic acid-Schiff (PAS) 
or alcian blue staining. MUC5AC was stained using anti-MUC5AC mouse antibody (1:200, 
Abcam, ab3649) (1h at 37°) and a secondary antibody conjugated with Alexa 488 (Life 
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Technologies, A-21206). Nuclei were stained with Hoe33342 (0.1 μg/ml PBS, Aplichem, 
Darmstadt, Germany). To measure secretion of the cytokine IL-8 by Calu3 cells Quantikine 
ELISA kits (R&D systems) were used.  
Mucociliary transport ex vivo. Tracheas were removed, fixed with insect needles onto extra 
thick blot paper (Bio-Rad, Germany) and transferred into a chamber with water-saturated 
atmosphere at 37°C. Transport was measured as described recently 200. 
CD8, luminescence, FM 4-64. Coverslips were mounted in a chamber and continuously 
perfused at 37 °C with Ringer solution containing 2 μg/ml FM 4-64. After 30 s, the cells were 
stimulated with 1 μM ionomycin for 3 min following washout. FM4-64 was excited at 546 ± 6 
nm and emission was recorded at 575/640 nm.  
Measurement of [Ca2+]I. Crypts were isolated from inverted proximal mouse colon using 
Ca2+-free Ringer solution with 1 mM DTT and 1 µM indomethacin for 20 min at 37°C. Crypts 
were loaded with 10 µM Fura-2-AM (Biotum, USA) and 1 mg/ml BSA (Sigma-Aldrich) in ringer 
solution for 1h at RT. Intracellular Ca2+ was measured as outlined in 80. 
Materials and statistical analysis. Data are reported as Mean ± SEM Student’s t-test (for 
paired or unpaired samples as appropriate) or ANOVA were used for statistical analysis. A p-
value < 0.05 was accepted as significant difference. Tissues/cells from 3 - 7 TMEM16Aflox/flox, 
TMEM16Aflox/floxFoxJ1, and TMEM16Aflox/floxVil1 mice, respectively, were examined in each 
series of experiments. 
 
Results 
 
Inhibition of basal airway mucus secretion in the absence of TMEM16A.  
Airways lacking epithelial cell specific expression of TMEM16A 200 demonstrated an 
impressive accumulation of mucus, which was not due to an increased fraction of nonciliated 
club (Clara) cells (Fig 5.1 A-C; Fig S5.1 A). TMEM16Aflox/floxFoxJ1 airways did not show signs 
of inflammation, as no infiltration by CD45 positive leukocytes was detected. Moreover, 
analysis of airway cross-sections did not provide evidence for airway constriction (Fig 5.1 
D,E). No mucus was found in the lumen of TMEM16Aflox/floxFoxJ1 airways. Basal mucociliary 
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particle transport measured in isolated TMEM16Aflox/floxFoxJ1 tracheas in vitro was enhanced, 
but was not further stimulated by ATP (Fig 5.1 F). We therefore suspected a defective basal 
mucus secretion in the absence of TMEM16A. Earlier work had shown that basal mucus 
secretion occurs at the rate of production, so that mucus does not accumulate in airway club 
cells 225. Notably, the phenotype of TMEM16Aflox/floxFoxJ1 airways was strikingly similar to that 
found in Munc2-/- knockout mice, which have a defect in basal mucus secretion 226. We 
examined if mucus accumulating in airways of TMEM16Aflox/floxFoxJ1 mice can be released by 
aerosolized carbachol (CCH) or ATP (both 100 µM). We found that CCH induced mucus 
secretion, while ATP-induced mucus release was strongly compromised (Fig 5.1 F,G). 
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Fig 5.1 Accumulation of mucus in airways of TMEM16A
flox/flox
FoxJ1 mice.  
A) Mucus staining by PAS in bronchi and tracheas of TMEM16A
flox/flox
 (fl/fl) and TMEM16A
flox/flox
FoxJ1 
(fl/fl-FoxJ1) mice, indicating accumulation of mucus in airways of fl/fl-FoxJ1 mice. Bars indicate 20 µm. 
B) RT-PCR analysis of TMEM16A in isolated respiratory epithelial cells from fl/fl and fl/fl-FoxJ1 mice. C) 
PAS positive staining in fl/fl and fl/fl-FoxJ1 airways (n = 29). D) Number of CD45 positive cells (airways) 
in fl/fl and fl/fl-FoxJ1 airways (n = 20). E) Cross sectional area of airways from fl/fl and fl/fl mice (n = 
20). F) Mucociliary clearance and effect of carbachol (CCH) or ATP (both 100 µM) assessed by particle 
tracking ex vivo in tracheas from fl/fl and fl/fl-FoxJ1 animals (n = 17). G,F) Alcian blue staining and 
quantification of mucus in fl/fl-FoxJ1 airways under control conditions and after aerosol application of 
carbachol (CCH) or ATP (both 100 µM). Mean ± SEM; *significant difference when compared to fl/fl 
(paired t-test). 
#
significant difference when compared to fl/fl-FoxJ1 (unpaired t-test). 
 
Electron microscopy images of TMEM16Aflox/floxFoxJ1 airways showed protruded club cells 
that accumulated secretory granules in the apical pole (Fig 5.2 A,B). Both the number of 
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granules per cell and their size were enhanced (Fig S5.1 B,C). Clara cell specific protein 
(CCSP) positive cells were not enhanced in TMEM16Aflox/floxFoxJ1 airways. Thus, metaplastic 
STAT-6/SPDEF pathways do not seem to be activated 227 (Fig 5.2C). Mucus accumulated 
apparently in club cells, while TMEM16A was knocked-down in FoxJ1-expressing ciliated 
epithelial cells. It is unlikely that mucus accumulates in ciliated cells, which therefore asks for 
the link between ciliated and mucus producing cells (Fig S5.1 D). The number of CCSP-
positive cells was not enhanced in fl/fl-FoxJ1, thus lack of TMEM16A is unlikely to induce a 
transdifferentiation towards mucus producing cells. We were unable to co-localize clearly 
CCSP and FoxJ1 or CCSP and acetylated tubulin in airway cells (Fig S5.1 E). As described 
further down, it is possible that ciliated cells secrete a factor that is required to release mucus 
from club cells. This could be ATP itself. However, external application of high concentrations 
(100 µM) of ATP (via aerosol) induced only little mucus secretion, suggesting a secretory 
defect in club cells. Interestingly, not only mucus accumulated in club cells from fl/fl-FoxJ1 
mice, but also CCSP itself (Fig S5.1 F). Preliminary data also suggest an accumulation of 
CLCA3 in club cells, a protein that controls membrane expression and activity of TMEM16A 
228 (not shown). Subsequent experiments will have to unmask the precise functional crosstalk 
between ciliated and club cells needed for basal mucus release.  
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Fig 5.2 Defective mucus secretion in airways of TMEM16A
flox/flox
FoxJ1 mice.  
A,B) Electron microscopic panorama (A) and higher resolution images (B) indicating accumulation of 
granules in club cells of TMEM16A
flox/flox
FoxJ1 (fl/fl-FoxJ1) airways. Bars 5 µm. C) CCSP and 
acetylated tubulin staining in TMEM16A
flox/flox
 (fl/fl) and fl/fl-FoxJ1 airways in control and OVA-sensitized 
animals. Bars 50 µm. D) Mucus induced by OVA-sensitization in airways of fl/fl and fl/fl-Fox animals, as 
detected by alcian blue staining. Exposure to ATP (100 µM) induced release of mucus in fl/fl airways, 
which was attenuated in fl/fl-Fox mice. Bars 20 µm. E) Quantification of alcian blue stainings (n = 10 - 
16). F) Number of CD45 positive cells in lungs from control and OVA-sensitized animals (n = 10 - 16). 
Mean ± SEM; 
#
significant effect of ATP or OVA, respectively (unpaired t-test); 
§
significant difference 
when compared to fl/fl (unpaired t-test). 
TMEM16A is indispensable for basal mucus secretion in airways and intestine 
123 
       
ATP-dependent but not muscarinic mucus secretion is compromised in 
TMEM16Aflox/floxFoxJ1 airways. 
 When exposed to ovalbumin, Th2-dependent goblet cell metaplasia and accumulation of 
mucus was observed in both TMEM16Aflox/flox and TMEM16Aflox/floxFoxJ1 airways, suggesting 
that TMEM16A is not required for mucus production in mouse airways (Fig 5.2 D, Fig S5.1 A). 
In TMEM16Aflox/flox airways, pronounced mucus secretion was induced by nebulized ATP, 
which was significantly reduced in TMEM16Aflox/floxFoxJ1 mice (Fig 5.2 D,E). Accumulation of 
CD45 positive leucocytes in lungs of OVA-treated TMEM16Aflox/floxFoxJ1 animals was strongly 
reduced, suggesting attenuated airway inflammation in the absence of TMEM16A (Fig 5.2 F, 
Fig S5.2). In TMEM16Aflox/flox airways, ovalbumin-sensitization upregulated expression of 
TMEM16A in epithelial and smooth muscle (ASM) cells, as described earlier 68, 152, 218, 229 (Fig 
S5.3). In TMEM16Aflox/floxFoxJ1 mice, upregulation of TMEM16A in ASM was much less 
evident, and the ASM layer was thinner (Fig S5.3, Fig 5.3A). We speculate that the release of 
mediators from epithelial cells that drive airway hyperreactivity and remodeling, could occur in 
a TMEM16A-dependent fashion 230. In contrast to ATP (Fig 5.2), cholinergic stimulation of 
mucus secretion by nebulized carbachol was uncompromised in OVA-sensitized 
TMEM16Aflox/floxFoxJ1 mice. Also muscarinic airway constriction when measured as airway 
cross-section was not different in TMEM16Aflox/floxFoxJ1 mice 231 (Fig 5.3). Thus ATP but not 
cholinergic mucus secretion requires TMEM16A. 
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Fig 5.3 Compromised mucus secretion in airways of OVA-sensitized TMEM16A
flox/flox
FoxJ1 mice.  
A) Mucus production induced by OVA-sensitization in airways from TMEM16A
flox/flox
 (fl/fl) and 
TMEM16A
flox/flox
FoxJ1 (fl/fl-FoxJ1) mice and carbachol (CCH; 100 µM) induced mucus release. Bars 
indicate 10 µm. B) Summary of alcian blue staining indicating strong increase of mucus production by 
OVA-sensitization and release of mucus by stimulation with CCH (n = 23). C) Effect of OVA-
sensitization and CCH on cross sectional area of airways from fl/fl and fl/fl-FoxJ1 mice (n = 23). Mean 
± SEM; 
#
significant difference when compared to OVA (unpaired t-test). 
§
significant difference when 
compared to fl/fl (unpaired t-test). 
 
Basal and ATP-dependent intestinal mucus release, but not cholinergic goblet cell 
secretion requires TMEM16A.  
In mice with intestinal epithelial specific knockout of TMEM16A (TMEM16Aflox/floxVil1) 200 we 
observed accumulation of mucus in both large and small intestinal goblet cells (Fig 5.4, Fig S 
5.4 A). In goblet cells from TMEM16Aflox/floxVil1 mice, the mucus content per cell was 
enhanced, while the number of goblet cells per crypt remained unchanged from wt (Fig 5.4). 
Mucus covering the intestinal epithelium appeared thinner and more irregular in 
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TMEM16Aflox/floxVil1 mice (Fig S5.4 A,B). While cellular mucus content was enhanced Muc2 
mRNA-expression was not upregulated in TMEM16Aflox/floxVil1 intestine, suggesting a 
secretory defect (Fig S 5.4 C). Goblet cells from TMEM16Aflox/flox but not from 
TMEM16Aflox/floxVil1 expressed TMEM16A (Fig 5.4 D,E). Mucus accumulation in 
TMEM16Aflox/floxVil1 intestine corresponds well to accumulation of intestinal mucus observed 
in Munc13-2 deficient mice, therefore suggesting defective basal mucus secretion 226. 
Cholinergic stimulation released mucus equally well from freshly isolated TMEM16Aflox/flox and 
TMEM16Aflox/floxVil1 intestine (Fig 5.4 D-F). This was examined in more detail by perfusing 
freshly excised colon in vitro and by collecting released mucus. We found that stimulation with 
methacholine or luminal ATP induced acute mucus secretion in TMEM16Aflox/flox colon. 
Costimulation with prostaglandin E2 was required to flush mucus out of the crypts. Identical 
results were obtained in intact (unstripped) and stripped (removal of submucosal tissue) 
colon, suggesting direct stimulation of goblet cells rather than indirect mechanisms (Fig S5.5 
A-C). Due to compromised basal secretion, mucus accumulated in goblet cells of 
TMEM16Aflox/floxVil1 colon, which was nearly completely released upon cholinergic (MCh) 
stimulation. Thus MCh-induced mucus release was much larger in TMEM16Aflox/flox when 
compared to TMEM16Aflox/floxVil1 colon (Fig 5.5 A, left). Stimulation with luminal ATP also 
released mucus in TMEM16Aflox/flox colon (Fig 5.5 A, right). To our knowledge this is the first 
observation of purinergic mucus release in naïve colon, which occurs via activation of luminal 
P2Y2 or P2Y4 receptors 
232.  
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Fig 5.4 Mucus accumulates in intestinal goblet cells of TMEM16A
flox/flox
Vil1 mice. 
 A) PAS-staining of large intestinal goblet cells from TMEM16A
flox/flox
 (fl/fl) and TMEM16A
flox/flox
Vil1 (fl/fl-
Vil1) mice. B) Number of PAS-positive cells in mucus accumulation in crypts from fl/fl and fl/fl-Vil1 mice 
(n = 40). C,D) PAS staining in small intestine of fl/fl and fl/fl-Vil1 mice (C) and effect of CCH (100 µM) 
on mucus release (D). E) Quantification of PAS staining in crypts and villi of fl/fl and fl/fl-Vil1 mice (n = 
550 – 750). F) Effect of CCH on PAS staining in fl/fl and fl/fl-Vil1 mice (n = 550 – 750). Mean ± SEM; 
#
significant difference when compared to fl/fl or control, respectively (unpaired t-test). 
 
In contrast to TMEM16Aflox/flox colon, no mucus was released by ATP in TMEM16Aflox/floxVil1 
colon (Fig 5.5 A, right). While expression of P2Y2 was unchanged, P2Y4 was upregulated in 
TMEM16Aflox/floxVil1 colon, which could be a compensatory upregulation (data not shown). 
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Thus basal and ATP-mediated mucus release in both airways and intestine are TMEM16A-
dependent.  
 
 
Fig 5.5 Compromised mucus release in TMEM16A
flox/flox
Vil1 intestine. 
A) Acute mucus secretion in perfused colon from TMEM16A
flox/flox
 (fl/fl) (black curve) and 
TMEM16A
flox/flox
Vil1 (fl/fl-Vil1) (red curve) animals. Mucus release was induced by luminal/basolateral 
perfusion with ATP (100 µM) and methacholine (MCh; 100 µM), respectively (n = 4 – 6). B,D) PAS 
stainings before and after application of MCh or ATP. Bars 50 µm. C,E) Quantification of PAS before 
and after stimulation with MCh or ATP (n = 19 – 34). Mean ± SEM; 
#
significant difference when 
compared to control (unpaired t-test). 
§
significant difference when compared to fl/fl (unpaired t-test). 
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TMEM16A controls intracellular Ca2+ signals and membrane exocytosis.  
TMEM16A controls ATP-induced compartmentalized Ca2+ signals by enhancing Ca2+ store 
release and store operated Ca2+ influx (SOCE). Both was shown to be reduced in airways 
and intestine of TMEM16Aflox/floxFoxJ1 and TMEM16Aflox/floxVil1 mice, respectively 80, 128, 200. In 
the present study we found that intestinal mucus release by ATP requires luminal Ca2+ which 
is, however, not needed for MCh-induced secretion (Fig S5.5 E,F). Ca2+ increase stimulated 
by ATP was much reduced in goblet cells of freshly isolated TMEM16Aflox/floxVil1 crypts, while 
Ca2+ increase induced by basolateral cholinergic stimulation was only slightly compromised in 
the absence of TMEM16A (Fig S5.6). Apical intracellular Ca2+ prepares granules for release 
by the exocytic machinery via the Ca2+ sensors Munc13 and Doc2B 94, 102, 233. Thus TMEM16A 
appears essential for exocytosis. A role of different TMEM16 paralogues for synaptic 
transmission has been proposed recently 67, 234, 235. We examined TMEM16A-expressing 
HEK293 cells and noticed that this enhanced membrane capacitance. Membrane capacitance 
is proportional to membrane surface and was found to be further enhanced by stimulation 
with the Ca2+ ionophore ionomycin (Fig 5.6 A-C). Using the surface marker CD8, we found 
enhanced membrane expression in the presence of TMEM16A (Fig 5.6 D,E). We analyzed 
plasma membrane lipid content using the lipophilic dye FM4-64 and found enhanced staining 
in the presence of TMEM16A. This was inhibited by the TMEM16A blocker CaCCinhAO1 and 
by the exocytosis-inhibitor tetanus toxin236 (Fig 5.6 F-J). The present data therefore suggest 
that TMEM16A controls exocytosis of mucus-filled granules by providing Ca2+ to an apical 
signaling compartment. TMEM16A is thus indispensable for basal and ATP-controlled mucus 
secretion in airways and intestine. 
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Fig 5.6 TMEM16A controls exocytosis. 
A,B) Whole cell currents and current/voltage relationships obtained in mock transfected and TMEM16A 
(T16A) expressing HEK293 cells. Stimulation with the Ca
2+
 ionophore ionomycin (Iono; 1 µM) activated 
whole cell currents in TMEM16A-expressing cells (n = 12). C) Enhanced membrane capacitance in 
TMEM16A-expressing cells under control conditions and after stimulation with ionomycin (n = 12). D) 
Chemiluminescence measured in HEK293 cells expressing the surface receptor cluster of 
differentiation 8 (CD8) (n = 8 – 16). E) Membrane expression of CD8 detected by anti-CD8-AB and 
secondary fluorescence-labeled AB in CD8 and CD8/TMEM16A coexpressing cells. F) Plasma 
membrane staining in HEK293 cells exposed to the fluorescent lipid dye FM4-64. Staining was 
enhanced by 1 and 3 min stimulation with ionomycin (Iono, 1 µM). G) Time dependent increase of 
FM4-64 fluorescence upon stimulation with ionomycin in mock-transfected and TMEM16A-expressing 
cells, and inhibition by CaCCinhAO1 (AO1; 10 µM) (n = 30). H) Summary of fluorescence increase 
induced by ionomycin (n = 30). I) Iono-induced FM4-64 fluorescence and inhibition by tetanus toxin 
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(TetTox; 20 nM) and combined application of TetTox/AO1 (n = 12). J) FM4-64 fluorescence in mock and 
TMEM16A-expressing cells (n = 50). K,L) Effect of ATP or CCH (both 100 µM) on FM4-64 fluorescence 
in cells expressing P2Y2 or M3 receptors (n = 30). Mean ± SEM. 
*
significant increase by Iono (paired t-
test). 
#
significant difference when compared to mock (unpaired t-test). 
§
significant difference when 
compared to control (unpaired t-test). Bars indicate 20 µm. 
Discussion 
Excessive airway mucus is a problem in CF, COPD, and asthma, while intestinal mucus can 
be enhanced in CF, ulcerative colitis and irritable bowel syndrome. Thus, there is a demand 
for novel drugs controlling excessive mucus secretion 237. As suggested by the present 
results, inhibitors of TMEM16A may represent a new class of drugs that reduce mucus 
secretion under basal conditions and upon stimulation by apical ATP. Notably, basal mucus 
secretion may clearly exceed stimulated (cholinergic) secretion, which is blocked by inhibitors 
of TMEM16A 225. In fact, the nonspecific inhibitor Niflumic acid (NFA) blocked mucus 
secretion and mucus production in earlier studies 220. However, inhibition of mucus synthesis 
by NFA also occurs in the absence of TMEM16A, suggesting inhibition of other channels. 
TMEM16A could contribute to mucus release by providing a secretory pathway for HCO3
-, 
which helps to unfold and solubilize mucus 217, 238. We found only a weak HCO3
- permeability 
of TMEM16A in patch clamp experiments at a cytosolic Ca2+ concentration of 1 µM (Fig 5.7 
A). However, at higher intracellular Ca2+ levels the channel has been demonstrated to be well 
permeable for HCO3
-239. 
Our data point out to an essential new role of TMEM16A for exocytosis. This function may not 
be limited to mucus release, but may also control the release of inflammatory mediators and 
secretory proteins such as CLCAs (Chloride Channel Accessory). In support of this, we found 
that LPS-induced release of IL-8 by Calu3 airway epithelial cells was significantly reduced by 
knockdown of TMEM16A (Fig S5.7 B). Attenuated release of inflammatory and chemotactic 
cytokines by airway epithelial cells lacking TMEM16A could explain the reduced leukocytic 
infiltration observed in OVA-challenged animals (Fig 5.2 F). It may also explain why 
expression of TMEM16A in ASM is lower in OVA-challenged Vil1-TMEM16Aflox/flox mice (Fig 
S5.3). Upregulated TMEM16A in airways smooth muscles (ASM) strongly supports 
bronchoconstriction 68, 152, 240. Thus, blockade of TMEM16A will inhibit release of mucus and 
TMEM16A is indispensable for basal mucus secretion in airways and intestine 
131 
       
cytokines, and will induce bronchodilation, which should be all beneficial in inflammatory 
airway disease 152, 241. In contrast, activation of TMEM16A should have adverse effects. We 
found in OVA-sensitized mice that activation of TMEM16A by Eact 
156 induced massive mucus 
release and airway contraction (Fig S5.8). 
 The present data also provide a novel regulation of basal ATP-mediated mucus release by 
intestinal goblet cells and demonstrate the crucial role of TMEM16A. In both airways and 
intestine, compound exocytosis induced by cholinergic stimulation was not compromised in 
Vil1-TMEM16Aflox/floxmice. Compound exocytosis is characterized by a fusion of secretory 
granules to a large mucin-filled vacuole, which is very different to apical single granule fusion 
triggered by ATP. It provides a mechanism for the release of deeper granules 214, 242-244. 
Muscarinic stimulation induced mucus release was independent of extracellular Ca2+, and did 
not induce exocytosis in HEK293 cells (Fig S5.5 F, Fig 5.6K). In contrast, ATP-dependent 
secretion is characterized by Ca2+ dependent single granule docking to the apical membrane 
that requires Munc13 proteins and the SNARE (soluble N-ethylmaleimide–sensitive factor 
attachment protein receptor) machinery 213. To our knowledge, this is the first report on ATP-
controlled mucus release by native intestinal goblet cells, which share similar regulatory 
properties with mucus producing airway cells.  
Knockdown of TMEM16A in airway epithelial cells eliminated both TMEM16A and CFTR 
dependent Cl- secretion 200, and abrogated mucus release. It was rather unexpected that 
these mice with complete absence of Cl- secretion did not show any signs of compromised 
mucociliary clearance or lung disease 200. We propose that mucus hypersecretion is the 
leading cause for CF lung disease, more so than the lack of Cl- secretion. Further studies are 
needed to examine if the present findings obtained in mice are applicable to human airways. 
In Calu3 human airway epithelial cells, we found that IL-13 induced production of Muc5AC is 
inhibited by the TMEM16A-blocker Niclosamide and by siRNA-knockdown of TMEM16A, and 
mucus release appeared compromised (Fig 5.7). 
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Fig 5.7 TMEM16A controls basal mucus secretion in human airway epithelial cells. 
 A) Immunocytochemistry of Muc5AC in Calu3 human airway epithelial cells. Mucus production was 
induced by the Th2 cytokine IL-13. In the presence of Niclosamide (1 µM) or after siRNA knockdown of 
TMEM16A, IL-13 induced Muc5AC was reduced and secretion was not detectable. B) Summary of 
ATP-induced Muc5AC release. Mean ± SEM. (number of experiments). Bars indicate 20 µm. 
 
The present and previous 200 data somewhat question the role of active Cl- secretion for 
maintenance of the airway surface fluid layer. Boucher and coworkers along with other teams 
provided evidence that human airways are primarily a reabsorptive tissue. Regulation of ASL 
height might be primarily dependent on Na+ absorption by epithelial Na+ channels 43, 44, 245-247. 
Thus, control of Na+ absorption by CFTR and particularly by purinergic receptors may affect 
ASL height more than electrogenic Cl- secretion. 
Blocking mucus secretion in CF by inhibiting TMEM16A may appear counterintuitive, since 
epithelial Cl- secretion will be blocked. Moreover, Cl- secretion via CFTR might also be 
compromised by inhibitors of TMEM16A, because of the known regulation of CFTR by 
TMEM16A 200. However, net secretory Cl- flux through TMEM16A is probably transient and 
rather small 248. Moreover, Cl- secretion through CFTR is already compromised in CF. Thus; 
the benefit through inhibition of mucus secretion (and probably mucus production 218, 221) may 
well exceed potential drawbacks due to inhibition of Cl- secretion. In fact, mice completely 
lacking airway Cl- secretion did not exhibit airway plugging 80. Clinical pilot studies may 
provide better insight towards the potential use of TMEM16A blockers in CF. 
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Supplementary material  
 
Supplementary Figure 5.1 Airways of TMEM16A
flox/flox
 (fl/fl) and TMEM16A
flox/flox
-FoxJ1Cre (fl/fl-
FoxJ1) mice. 
 A) Ratio of club cells (CCSP positivity) versus ciliated (acetylated tubulin positivity) cells in small 
airways. No enhanced number of club cells in fl/fl-FoxJ1 under control conditions. OVA-sensitization 
enhanced number of club cells in both fl/fl and fl/fl-FoxJ1 mice. B,C) Diameter of secretory granules in 
club cells from fl/fl and fl/fl-FoxJ1, and number of granules per cell. D) Acetylated tubulin and mucus in 
fl/fl-FoxJ1 under control conditions. E) Acetylated tubulin and CCSP in fl/fl and fl/fl-FoxJ1 airways. F) 
CCSP in fl/fl and fl/fl-FoxJ1 under control conditions. Mean ± SEM (1799 cells counted in 3 fl/fl and 3 
fl/fl-FoxJ1 animals).
 #
indicates significant difference between fl/fl and fl/fl-FoxJ1 (p<0.05; unpaired t-
test). 
§
indicates significant difference between control and OVA-treated animals (p<0.05; unpaired t-
test). 
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Supplementary Figure 5.2 Accumulation of CD45-positive leucocytes is reduced in OVA-sensitized 
lungs of TMEM16A
flox/flox
-FoxJ1Cre mice. 
Immunocytochemistry of CD45-positive cells in lungs of control and OVA-sensitized TMEM16A
flox/flox
 
and FoxJ1Cre-TMEM16A
flox/flox
 mice. Images are representatives of n = 3 animals. Bars indicate 20 
µm. 
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Supplementary Figure 5.3 Effect of OVA on expression of TMEM16A in airways of TMEM16A
+/+ 
and 
TMEM16A
-/-
 mice. 
 A) RT-PCR from whole lung of TMEM16A+/+ and TMEM16A-/- mice. Expression of TMEM16A was 
upregulated by OVA-sensitization in TMEM16A+/+ and TMEM16A-/- lungs. GAPDH served as a 
control. Representatives of n = 3 separate reactions. B) Expression of TMEM16A in TMEM16A+/+ and 
TMEM16A-/- airways under control conditions and after OVA sensitization. In control TMEM16A+/+ 
airways, TMEM16A is very weakly expressed. After OVA-sensitization, expression is reduced in airway 
smooth muscle of TMEM16A
-/-
 mice, when compared to TMEM16A
+/+
. Bars indicating 10 µm. 
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Supplementary Figure 5.4 Defective mucus secretion in small intestine of TMEM16A
flox/flox
Vil1 mice. 
A, B) PAS staining of mucus covering jejunal mucosa of TMEM16A
flox/flox
 (fl/fl) and TMEM16A
flox/flox
Vil1 
(fl/fl-Vil1) mice. The mucus layer in fl/fl-Vil1 intestine appeared thinner and more irregular. C, D) mRNA 
levels of Muc2 and TMEM16A in fl/fl and fl/fl-Vil1 colon as assessed by semiquantitative RT-PCR. E) 
Differential interference contrast image and expression of TMEM16A detected by immunofluorescence 
(green) in enterocytes and goblet cells. Bars indicating 20 µm. Mean ± SEM (n = 40 crypts analysed in 
n=3 fl/fl and n=3 fl/fl-Vil1 mice).  
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Supplementary Figure 5. 5 Induction of mucus secretion in vitro perfused colon. 
A, B) Mucus secretion induced by ATP (100 µM) or methacholine (MCh; 100 µM) requires co-
stimulation with PGE2 (1 µM) to activate CFTR dependent fluid secretion and to flush mucus out of the 
crypts. PGE2 alone did not induce mucus secretion. C) Mucus release by MCh was equal in non-
stripped and stripped (removal of serosal and submucosal layers) colon, suggesting direct stimulation 
of goblet cells by MCh. D) Dichlorophene (30 µM), an inhibitor of TMEM16A, suppressed acute MCh-
induced mucus secretion. E, F) Removal of apical Ca
2+
 in the perfusion solution inhibited mucus 
secretion by ATP but not by MCh. (n = 3 - 5 mice for each series). 
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Supplementary Figure 5.6 Purinergic Ca
2+
 signals are compromised in goblet cells from 
TMEM16A
flox/flox
Vil1 colon. 
A) Isolated crypt loaded with the Ca
2+
 dye Fura-2. Arrows indicate goblet cells used for measurement 
of intracellular Ca
2+
. B) Original recordings of Ca
2+
 concentrations in goblet cells from TMEM16A
flox/flox
 
(fl/fl) and TMEM16A
flox/flox
Vil1 (fl/fl-Vil1) mice. Activation of Ca
2+
 signals by ATP (100 µM). C) Summary 
of basal Ca
2+
 levels in fl/fl and fl/fl-Vil1 cells (n = 14). D, E) ATP induced Ca
2+
 increase (peak and 
plateau) were strongly reduced in goblet cells from fl/fl-Vil1 mice. Ca
2+
 peaks induced by carbachol 
(CCH; 100 µM) were only slightly reduced in fl/fl-Vil1 cells and plateau Ca
2+
 was indistinguishable from 
fl/fl (n = 111-126). 
# 
indicates significant difference from fl/fl (n) number of goblet cells examined for 
each series.  
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Supplementary Figure 5.7 TMEM16A is limitedly permeable to HCO3
-
, TMEM16A downregulation 
reduces IL-8 release. 
A) Anion permeability ratios for TMEM16A overexpressed in HEK293 cells (n = 7). TMEM16A was 
activated by high pipette Ca
2+
 (1 µM). Extracellular Cl
-
 (145 mM) was replaced by gluconate, HCO3
-
, or 
I-. Shifts in the reversal potentials detected in current voltage relationships were used to calculate 
permeability ratios. (Pipette solution 145 mM NaCl). TMEM16A shows only a limited permeability for 
HCO3
-
. B) IL-8 release from Calu3 human airway submucosal cells. Exposure of the cells to LPS (10 
µg/ml; 48 hrs) induced a pronounced IL-8 release that was markedly reduced upon knockout of 
TMEM16A with siRNA for TMEM16A (n = 3). C) Immunocytochemistry of TMEM16A (DOG1-antibody, 
1:200) in Calu3 cells treated with siRNA for TMEM16A or scrambled RNA, respectively. Mean ± SEM 
(number of experiments). 
# 
significant IL-8 release, 
§
significant difference to scrambled (p<0.05, 
unpaired t-tests). Bar = 20 µm.  
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Supplementary Figure 5.8 Effect of EACT on mucus release and airway contraction. 
 A) Airways from OVA-sensitized mice show pronounced mucus accumulation as demonstrated by 
alcian blue staining. Acute exposure to the known activator of TMEM16A, Eact, (4.8 µg, tracheal 
instillation) induced a rapid mucus release and airway contraction. B) PAS positive staining in control 
airways (OVA) and after application of Eact (n = 14 - 26). C) Airway cross sectional area in control 
airways and after application of Eact (n = 20 – 34). Mean ± SEM. 
#
indicates significant effect of Eact. 
Bars indicate 10 µm. 
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Chapter 6 
Niclosamide repurposed for the treatment of inflammatory airway disease 
 
Abstract  
Inflammatory airway diseases such as asthma, Cystic Fibrosis (CF) and COPD are 
characterized by airway restriction and mucus hypersecretion. CF and asthma exhibit 
enhanced expression of the Ca2+ activated Cl- channel TMEM16A in metaplastic club cells 
and airway smooth muscle, and contributes strongly to mucus hypersecretion and 
bronchoconstriction. Nonspecific inhibitors of TMEM16 proteins like Niflumic acid (NFA), 
inhibit mucus production and bronchoconstriction. Here we demonstrate that the FDA-
approved drug Niclosamide is a highly potent inhibitor of TMEM16A and TMEM16F. In 
asthmatic mice, Niclosamide inhibited mucus production and secretion, as well as 
bronchoconstriction, and showed an anti-inflammatory effect. Both TMEM16A and TMEM16F 
are essential for mucus production/secretion that is explained by augmentation of intracellular 
Ca2+ signals. TMEM16A/F supported exocytic release of mucus and inflammatory mediators, 
and are inhibited by Niclosamide. The present results unmask TMEM16A/F as pathogenic 
factors during inflammatory airway disease, and suggest Niclosamide as a potent drug for the 
treatment of asthma, CF, and COPD. 
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Introduction 
 
Inflammatory airway diseases such as asthma, Cystic Fibrosis (CF), and COPD are 
characterized by airway obstruction due to mucus hypersecretion, mucus plugging and 
bronchoconstriction 152, 213, 218, 229, 249, 250. The Cystic Fibrosis transmembrane conductance 
regulator (CFTR) chloride channel is dysfunctional in CF, leading to attenuated fluid and 
bicarbonate secretion, along with Na+ hyperabsorption and dehydration of the airway surface 
liquid (periciliary fluid layer; ASL) covering the airway epithelium 217, 251. The consequence is 
dehydrated airway mucus with abnormal rheological properties that occludes smaller airways. 
Local hypoxia, neutrophilic infiltration, accumulation of reactive oxygen species and bacterial 
superinfection cause destructive pulmonary inflammation. Whether an acidic ASL-pH further 
attenuates antimicrobial defense, and thus contributes to lung pathology, is still a matter of 
debate 252, 253. Because of the obvious lack of apical CFTR Cl- conductance in CF airways, 
alternative chloride channels were proposed to fill the gap. Thus, research focused on 
SLC26A9 and particularly on Ca2+ activated TMEM16A Cl- channels 254.  
A recent study on adult TMEM16A airway epithelial knockout (FoxJ1-Cre-TMEM16Aflox/flox) 
mice provided rather surprising results. Mice lacking airway epithelial expression of 
TMEM16A have no discernible apical airway epithelial Cl- conductance; i.e. they neither 
exhibit Ca2+ activated Cl- currents (CaCC) nor cAMP-activated CFTR Cl- currents, yet the 
animals do not develop a CF-like phenotype, and do not show attenuated mucociliary 
clearance 200. TMEM16A is expressed at low levels in ciliated cells, and at higher levels in 
mucus producing club (Clara) cells. It is strongly upregulated under inflammatory conditions 
such as CF and asthma 152, 213, 218, 229, 249, 250, 255. Our previous report demonstrates that 
TMEM16A is essential for basal secretion of mucus in both airways and intestine 255. The data 
demonstrate a previously unrecognized role of TMEM16A for membrane exocytosis and 
describe a novel ATP-driven pathway for intestinal mucus secretion. Moreover, TMEM16A is 
expressed in airway smooth muscle (ASM), where it supports contraction. TMEM16A 
therefore mediates a number of adverse events in inflammatory airway disease, which 
suggests that in CF the channel should be inhibited rather than activated.  
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TMEM16A is also weakly expressed in ciliated epithelial cells, where it may support Cl- 
secretion. However, its prosecretory effect is mainly through activation of CFTR. In the CF 
lung, where CFTR is dysfunctional, inhibition of TMEM16A is therefore predicated to have 
little or no impact on Cl- secretion 161, 162, 200. In tissue specific airway and intestinal epithelial 
TMEM16F knockout mice, we find that both TMEM16A 255 and TMEM16F are in charge of 
mucus production and secretion. We demonstrate potent inhibition of mucus secretion in 
airways and intestine by the well-known anthelminthic drug Niclosamide, which has been 
shown recently to be a potent inhibitor of TMEM16A 241. We suggest repurposing of 
Niclosamide for the use in inflammatory obstructive airway disease. Inhibition of mucus 
production/secretion along with bronchodilation is likely to be the most effective treatment of 
CF lung disease. It will normalize the imbalance between excessive mucus secretion and 
reduced ASL, and it will therefore counteract airway plugging. 
 
 
Materials and methods 
 
Animals, OVA-induced asthma. All animal experiments complied with the ARRIVE 
guidelines and were carried out in accordance with the U.K. Animals Act, 1986 and 
associated guidelines, EU Directive 2010/63/EU for animal experiments. Knockout of 
TMEM16A in ciliated airway epithelial cells (TMEM16Aflox/floxFoxJ1Cre) has been described 
elsewhere 200. Generation of mice with a floxed TMEM16F allele was described in 256. For 
knockout of TMEM16F in ciliated epithelial and intestinal epithelial cells, TMEM16Fflox/flox mice 
were crossed with FoxJ1-Cre and Vil1-Cre mice to obtained TMEM16Fflox/floxFoxJ1Cre and 
TMEM16Aflox/floxVil1Cre, respectively. Mice were sensitized to ovalbumin (OVA, Sigma-Aldrich, 
Germany) by intraperitoneal (ip) injection of 100 µg OVA with 1 mg aluminum hydroxide gel 
(Sigma) on days 0 and 14. At days 21, 22 and 23, mice were anaesthetized and challenged to 
OVA by intratracheal instillation of 50 µg OVA in 100 µl saline. Control mice were sham 
sensitized with saline and aluminum hydroxide gel (Sigma-Aldrich, Germany) and challenged 
to 100 µl saline by intratracheal instillation 224. NFA (0.5 mg/kg/day for three days, dissolved in 
Corn Oil (Sigma-Aldrich, Germany)) and Niclosamide (13 mg/kg/day for three days, dissolved 
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in Corn Oil) were administered via ip injections. In addition, Niclosamide (13mg/kg/day, 
dissolved in Corn Oil) was received via gavage. For control treatment vehicle were used.  
Cells culture, cDNA, siRNA, RT-PCR. HEK293 cells were cultured in DMEM media (GIBCO, 
Germany) supplemented with 10% FBS (Capricorn, Germany). Calu3 cells were grown in 
DMEM-F12 media (GIBCO, Germany) supplemented with 1% HEPES, 1% L-glutamine, 10% 
FBS (Capricorn, Germany). All cells where grown at 37ºC in the absence of antibiotics in a 
humidified atmosphere with 5% CO2. 
RT-PCR, siRNA. RT-PCR has been performed using RNA isolated from lungs of wt and 
TMEM16A and TMEM16F KO mice using NucleoSpin RNA columns (Macherey-Nagel, 
Germany). Total RNA (1 μg/50 μl reaction) was reverse-transcribed using random primer 
(Promega, Germany) and M-MLV Reverse Transcriptase RNase H Minus (Promega, 
Germany). Each RT-PCR reaction contained sense and antisense primer (table 1), 0.5 μl 
cDNA, and GoTaq Polymerase (Promega, Germany). After 2 min at 95 °C cDNA was 
amplified for 30 cycles for 30 s at 95 °C, 30 s at 57 °C and 1 min at 72 °C, followed by 10 min 
at 72°. PCR products were visualized by loading on peqGREEN (Peqlab,VWR, Germany) 
containing agarose gels and were analyzed using ImageJ. TMEM16F was downregulated by 
human siRNA transfection into Calu3 cells using standard methods (Lipofectamine, 
Invitrogen, Germany).  
Western blotting. Cells were collected and lysed in 1% NP40 lysis buffer containing protease 
inhibitor cocktail and DTT (Sigma-Aldrich, Germany). Protein (30–50 µg) was separated by 
8.5% SDS-PAGE and transferred to nitrocellulose membranes. Membranes were blocked 
with 5% NFM/TBST at RT for 1 h and were incubated overnight at 4 °C with rabbit polyclonal 
anti-TMEM16F (diluted 1:5000 in 5% NFM/TBST, Thermo Fisher Scientific, USA) or rabbit 
polyclonal anti-actin (diluted 1:10000 in 5% NFM/TBST, Sigma-Aldrich, Germany). 
Subsequently, membranes were incubated with secondary antibody at RT for 2 h. 
Immunoreactive signals were visualized using supersignal chemiluminescence substrate 
detection kit (Pierce Biotechonology, USA). 
IL-8 assay. To measure secretion of the cytokine IL-8 (Peprotech, Germany), Calu3 cells 
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were rinsed twice with PBS (Capricorn, Germany), placed in OPTIMEM (GIBCO, Germany) 
and exposed to LPS (10 μg/ml48h). After 48 hours, the conditioned medium was collected 
and used to quantify IL-8 using Quantikine ELISA kits (R&D systems, Germany) according to 
the manufacturer’s instructions. 
In vitro perfusion of intestine. Mice were sacrificed by cervical dislocation and excised 
intestines were placed immediately in ice-cold Ringer solution and carefully flushed to remove 
residual luminal contents. The intestinal segments were mounted and perfused vertically in a 
custom-designed perfusion chamber with a constant temperature, similar to 93, 255. After 
mounting, the serosal side was exposed to Ringer solution (NaCl 120 mM, KH2PO4 0.4 mM, 
K2HPO4 1.6 mM, D-glucose 5 mM, MgSO4 1 mM, Ca-gluconate 1.5 mM and NaHCO3 25 mM, 
pH 7.4, continuously gassed with 95% O2 and 5% CO2) and perfused luminally with glucose-
free mannitol-replaced Ringer. Perfusates were collected at a rate of 0.5 ml/min at 3 min 
intervals for an additional 27 min. Tissues were stimulated with methacholine (MCh; 100 μM) 
or ATP (100 μM) for 9 min, always in the presence of 1 μM Prostaglandin E2 (PGE2) if not 
mentioned otherwise. In luminal Ca2+ free solution, Ca2+ was substituted with equimolar 
EGTA. The amount of mucus secretion was analyzed using a periodic acid-Schiff (PAS) 
assay (Sigma-Aldrich, Germany). In brief, 50 mM dithiothreitol was pipetted into each sample 
and incubated for 1h at 37º under continuous shaking. 0.2 ml periodic acid (0.1%) was added, 
incubated for 2 hours at 37°C, and additional 30 min at 20°C after adding 0.2 ml Schiff´s 
reagent (Sigma-Aldrich, Germany). Samples were centrifuged at 500 g/5 min and OD of the 
resulting solution was measured at 540 nm. The amount of mucus per tissue and minute was 
calculated using a calibration curve from defined pig gastric mucin (Sigma-Aldrich, Germany). 
Histology, mucus staining by alcian blue and PAS, quantification. Mice were sacrificed 
by cervical dislocation. Small and large intestine were removed and cut in two sections. One 
section was kept in Ringer solution, the other section was exposed to 100 µM ATP (ROTH, 
Germany) or 100 µM CCH (carbachol; Sigma-Aldrich, Germany). Before and after each 
experiment, intestinal sections were fixed for further histological analyses. Mouse airways 
were fixed by transcardial fixation and were embedded in paraffin or frozen in liquid N2. For 
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paraffin sections, tissues were fixed in 4% paraformaldehyde (PFA), 0.2% picric acid and 
3.4% sucrose in PBS, and were washed in methanol before embedding in paraffin. For 
mucus analysis sections were stained according to standard Periodic acid-Schiff (PAS) or 
Alcian Blue methods and examined by light microscopy. A minimum of nine random images 
for each embedded tissue were acquired from a minimum of three animals (TMEM16Aflox/flox, 
TMEM16Fflox/flox,TMEM16Aflox/floxFoxJ1Cre, TMEM16Fflox/floxFoxJ1Cre, TMEM16Fflox/floxVil1Cre). 
Sections were analyzed using an Axiovert 200 microscope equipped with AxioCam ICc 1 and 
ApoTome (Zeiss, Germany) and analysed using AxioVision (Zeiss, Germany). 
Patch Clamping. Crypts from jejunum and distal colon were isolated in Ca2+-free Ringer 
solution and immobilized on poly-lysine coated glass cover slips. HEK293 cells were grown 
on glass-coated cover slips and were mounted on the stage of an inverted microscope (Zeiss, 
Germany). Experimental procedures are described in detail in 200. 
Measurement of intracellular Ca2+concentration. All measurements of intracellular Ca2+ 
concentration [Ca2+] of cell lines and isolated goblet cells have been performed using the Ca2+ 
sensitive dye Fura-2-AM (TOCRIS, Germany), as described earlier 80. 
YFP-Quencing. Quenching of the intracellular fluorescence generated by the iodide-sensitive 
enhanced yellow fluorescent protein (YFP) was used to measure anion conductance. YFP 
fluorescence was excited at 490 nm using a semi-automatic Novostar plate reader (BMG-
Labtech, Offenburg, Germany). I− influx was induced by replacing 20 mM extracellular Cl− 
with 20 mM I− in the presence of 1µM Ionomycin (Enzo Life Science). Background 
fluorescence was subtracted and autofluorescence was negligible. Changes in fluorescence 
induced by I− are expressed as initial rates of fluorescence decrease (arbitrary units/sec) and 
analyzed using MARS data analyzing program (BMG-Labtech, Offenburg, Germany).  
Materials and statistical analysis. All compounds used were of highest available grade of 
purity: Niclosamide, Eact, OVA, MCh, NFA, Dichlorophene, (Sigma-Aldrich, Germany). 
Niclosamide-ETHO, Nitazoxanide, tizoxanide (Caymann-Chemicals, USA), CaCCinhAO1 
(Tocris; Germany) IL-8, IL-13 (Peprotech, Germany). Antibodies used were purchased from 
Thermo Fisher Scientific (USA) for TMEM16F and from Bioss (USA) (MUC5AC (41M)). Data 
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are reported as mean ± SEM. Student’s t-test (for paired or unpaired samples as appropriate) 
or ANOVA were used for statistical analysis. A p-value < 0.05 was accepted as significant 
difference. 
Results 
Niflumic acid (NFA) is an inhibitor of TMEM16 and blocks airway mucus secretion. 
OVA-induced allergic asthma in mice caused pronounced airway goblet cell metaplasia. 
Exposure of asthmatic lungs to aerosolized carbachol (CCH) induced massive release of 
mucus as well as airway contraction (Fig 6.1 A-C). Pretreatment of sensitized animals for 
three days with Niflumic acid (NFA; ip and tracheal instillation), a well-known inhibitor of Ca2+ 
activated chloride currents, abolished production so that no mucus could be released by 
CCH. Moreover, airway contraction was completely inhibited as judged from airway cross 
sections. We expressed in HEK293 cells the two main TMEM16 paralogs expressed in airway 
epithelial and smooth muscle cells 257, TMEM16A and TMEM16F, and measured whole cell 
currents upon activation by the Ca2+ ionophore ionomycin (Iono). Large whole cell currents 
were activated by simulation of TMEM16A and TMEM16F with Iono, and current activation 
was potently suppressed by NFA (Fig 6.1 D-F). The data suggest TMEM16A/F being in 
charge of both mucus production and contraction of airway smooth muscle (ASM). Novel 
therapeutic strategies for the treatment of inflammatory airway diseases such as asthma, CF, 
and COPD may therefore consider the use of inhibitors of TMEM16. 
Niclosamide repurposed for the treatment of inflammatory airway disease 
150 
       
 
 
Fig 6.1 The TMEM16-inhibitor Niflumic acid attenuates inflammatory airway disease. 
 A, B) OVA-sensitization induced pronounced goblet cell metaplasia as indicated by alcian blue 
positivity. Exposure to carbachol (CCH, 25 mg/ml, nebulizer) induced release of mucus and airway 
contraction. Bars indicate 10 µm. Pre-exposure to the TMEM16A-inhibitor Niflumic acid (NFA, 0.5 
mg/kg/day) by intratracheal and intra peritoneal application for three days, strongly attenuated mucus 
production and CCH-induced airway contraction (A-C). C) Cross section of airways under the different 
conditions indicating airway relaxation by NFA. D-F) Whole cell currents obtained in HEK293 cells 
expressing TMEM16A or TMEM16F after stimulation with 1 µM ionomycin (Iono), and inhibition by NFA 
(20 µM). Mean ± SEM; *significant inhibition by NFA (paired t-test). 
# 
significant difference when 
compared to OVA (unpaired t-test). (n) number of airways analysed or number of cells examined. 
 
Niclosamide and derivatives: Potent inhibitors of anoctamins and Ca2+ signaling. 
NFA is a broadly acting and non-specific compound, which may not be appropriate for the use 
in human. The anthelmintic drug Niclosamide has been recently reported to be a potent 
inhibitor of TMEM16A that fully bronchodilates airways 241. In patch clamp experiments, we 
confirmed the inhibitory effect of Niclosamide on TMEM16A outward currents activated by 
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purinergic stimulation of HEK293 cells (Fig 6.2 A-C). Similar to TMEM16A, overexpressed 
TMEM16F was also inhibited by Niclosamide (Fig 6.2 D). We also examined the effect of 
Niclosamide on endogenous TMEM16A expressed in HT29 colonic carcinoma cells, which 
were stably transfected with iodide-sensitive yellow fluorescent protein (YFP). TMEM16A was 
activated by ionomycin and TMEM16A currents were measured as iodide quenching. 
Niclosamide and the related compounds Niclosamide-ETHO, tizoxanide, and nitazoxanide 
inhibited endogenous TMEM16A in the low nanomolar range, and were more potent than the 
well-known inhibitors CaCCinhAO1 or dichlorophen (Fig 6.2 E).  
 
Fig 6.2 Inhibition of TMEM16A and TMEM16F by Niclosamide. 
 A) TMEM16A whole cell currents in overexpressing HEK293 cells. The purinergic agonist UTP was 
used to activate TMEM16A (100 µM). B, C) Concentration-dependent inhibition of TMEM16A by 
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Niclosamide (Niclo). D) Current/voltage relationship showing inhibition of TMEM16F by Niclosamide (1 
µM). E) Inhibition of endogenous TMEM16A/F expressed in HT29 cells, as shown by iodide quenching. 
Rate of YFP quenching (arbitrary units (au/second), when applying 20 mM iodide to the extracellular 
bath solution. HT29 cells stably overexpressing YFP were stimulated with 1 µM ionomycin. 100.000 
cells were seeded/well. Mean ± SEM; (number of experiments) 
#
significant inhibition when compared to 
the absence of the inhibitor (p<0.05; unpaired t-test). * significant activation by UTP (paired t-test). 
 
Earlier studies demonstrated that expression of TMEM16 proteins augment intracellular Ca2+ 
signals, which are attenuated by the inhibitors CaCCinhAO1, NFA, and others 80. Here we 
show that Niclosamide also blocks Ca2+ signals elicited by ATP or by the TMEM16-activator 
Eact 156 (Fig S6.1). Niclosamide had also a marked effect on Ca2+ signals in freshly isolated 
goblet cells, which suggests an inhibitory effect on mucus production and secretion.  
 
Niclosamide inhibits mucus production and mucus secretion, ASM contraction, and 
inflammation. 
In fact, OVA-induced mucus production was strongly reduced by both NFA and Niclosamide 
(Fig 6.3 A, B). We reported earlier that airway epithelial knockout of TMEM16A caused a 
defect in basal, i.e. ATP-mediated mucus secretion. This resulted in an accumulation of 
mucus under control (non-inflammatory) conditions 255. Mucus synthesis under inflammatory 
(OVA) conditions and mucus release upon cholinergic stimulation, however, were not 
compromised 255 (Fig 6.3 C). In wt (TMEM16Aflox/flox) mice and mice with knockout of 
TMEM16A in ciliated epithelial cells (TMEM16Aflox/floxFoxJ1Cre) airways, application of 
Niclosamide three days before applying CCH strongly reduced mucus synthesis, so that little 
mucus was left to be secreted by CCH (Fig 6.3 C-E). Because mucus production occurs in 
the absence of TMEM16A, other TMEM16 paralogs may also be in charge of mucus 
synthesis. We analyzed expression of the three main TMEM16 paralogs in isolated airway 
epithelial cells 257, and found that TMEM16A, also TMEM16F and TMEM16K, are upregulated 
through Th2 driven goblet cell metaplasia and mucus hyperproduction after OVA – 
sensitization (Fig 6.3 F). Thus, it is likely that TMEM16F/K control mucus production, because 
they are inhibited by Niclosamide and other TMEM16-inhibitors 140. Interestingly, knockdown 
of TMEM16A in fl/fl-FoxJ1 mice way paralleled by reduced expression of TMEM16F/K, 
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suggesting a co-regulation of TMEM16 proteins as suggested earlier 258. 
In the presence of Niclosamide, not only mucus production/secretion was strongly attenuated, 
but also airways appeared much less contracted after acute application of CCH (Figs. 6.1 A, 
6.3 C). We analyzed cross sections of small airways and similar to NFA we found inhibition of 
the cholinergic reduction of the cross sectional area by Niclosamide (Fig 6.3 G). This 
corresponds well to the findings by Miner et al., who described bronchodilation by 
Niclosamide 241. Of note were also the peribronchial infiltrations by immune cells, observed 
after OVA treatment, which were strongly attenuated by Niclosamide (Fig 6.3 H). An 
attenuation of allergic lung inflammation by Benzbromarone, another TMEM16-inhibitor, has 
been reported earlier 259. 
 
Niclosamide repurposed for the treatment of inflammatory airway disease 
154 
       
 
Fig 6.3 Niclosamide attenuates inflammatory airway disease. 
 A, B) OVA-sensitization of wt mice induced pronounced goblet cell metaplasia as indicated by alcian 
blue staining. Tracheal instillation of Niflumic acid (NFA; 0.5 mg/kg/day) or Niclosamide (Niclo; 
13mg/kg/day) significantly reduced mucus production. C-E) OVA-sensitization of TMEM16A
flox/flox
 (fl/fl) 
and TMEM16A
flox/flox
FoxJ1Cre (fl/fl-FoxJ1) mice induced goblet cell metaplasia. Exposure of fl/fl and 
fl/fl-FoxJ1 mice to carbachol (CCH, 25 mg/ml, nebulizer) induced release of mucus and pronounced 
airway contraction. Pre-exposure to Niclosamide by intratracheal application for three days strongly 
attenuated mucus production and CCH-induced airway contraction. F) Expression of the three main 
TMEM16 paralogs (A, F, K) in mouse airways before and after OVA-sensitization. Bars indicate 10 µm. 
G) Airway cross section indicating airway contraction by muscarinic stimulation (aerosol) and inhibition 
of contraction by Niclosamide. H) Number of CD45 positive cells (airways) under different conditions. 
Mean ± SEM; (number of experiments) 
# 
significant effect of NFA, Niclo, and OVA, respectively 
(p<0.05; ANOVA). 
§
significant difference when compared to OVA (unpaired t-test). 
$ 
significant 
difference when compared to fl/fl (unpaired t-test). 
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Attenuation of airway inflammation by Niclosamide suggests inhibition of inflammatory 
mediators, which has been recently demonstrated for other tissues 260, 261. We exposed Calu3 
airway epithelial cells to LPS for 48h and measured release of the neutrophil attractor 
interleukin 8 (IL-8). IL-8 release was enhanced by LPS-exposure and the release was clearly 
inhibited in the presence of Niclosamide (Fig 6.4 A). Upon stimulation with the Th2 cytokine 
IL-13, Calu3 cells produced MUC5AC (Fig 6.4 B, C). IL-13 induced synthesis of Muc5AC was 
clearly inhibited when TMEM16F-expression was knocked down by siRNA (Fig 6.4 C, E). As 
observed for mouse airways, incubation with Niclosamide also largely reduced Muc5AC-
expression in Calu3 human airway epithelial cells (Figs. 6.4 B, C, Fig 6.3). Niclosamide did 
not change expression of either TMEM16A or TMEM16F (Fig 6.4D). As shown earlier, airway 
epithelial knockout of TMEM16A caused a defect in mucus secretion while mucus production 
was retained 255. In summary, Niclosamide is a potent inhibitor of both TMEM16A and 
TMEM16F, and inhibits production and secretion of mucus. Niclosamid does not affect 
expression of TMEM16A/F. We therefore suggested that TMEM16F is required for mucus 
production in mouse airways.  
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Fig 6.4 Niclosamide attenuates inflammatory airway response. 
A) Effect of Niclosamide (1 µM) on LPS (10 µg/ml) induced release of IL-8 in Calu3 cells. B, C) IL-13 – 
induced MUC5AC release and inhibition by siRNA-TMEM16F and Niclosamide (1 µM). D) Effect of 
Niclosamide on mRNA-expression for TMEM16A and TMEM16F (semiquantitative RT-PCR). E) 
Western blot indicating knockdown of TMEM16F by siRNA. Mean ± SEM; 
# 
significant difference when 
compared to control or scrambled RNA (scrbld) (unpaired t-test). 
§ 
significant difference when 
compared to DMSO (unpaired t-test). 
 
Airway epithelial knockout of TMEM16F attenuates mucus production and release 
We generated mice with a knockout of TMEM16F in ciliated epithelial cells 
(TMEM16Fflox/floxFoxJ1Cre) to examine further the role of TMEM16F for mucus production and 
mucus release in mouse. Alcian blue staining indicated accumulation of mucus in airways of 
TMEM16Fflox/floxFoxJ1Cre mice, which was not observed in TMEM16Fflox/flox littermate controls 
(Fig 6.5 A). This suggests a role of TMEM16F for basal mucus secretion in mouse airways, 
similar to TMEM16A 255. OVA-sensitization induced pronounced goblet cell metaplasia and 
mucus production, which was attenuated in the TMEM16Fflox/floxFoxJ1Cre mice when 
compared to TMEM16Fflox/flox. Acute muscarinic stimulation with aerosolized CCH released 
mucus from both TMEM16Fflox/floxFoxJ1Cre and TMEM16Fflox/flox mice (Fig 6.5 A, B). However, 
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the amount of mucus released was clearly less in TMEM16Fflox/floxFoxJ1Cre mice. The data 
suggest role of TMEM16F for basal mucus release similar to that of TMEM16A, and a role of 
TMEM16F for mucus production. 
 
Fig 6.5 TMEM16F controls mucus production. 
 A) Mucus in mouse TMEM16F
flox/flox
 (fl/fl) and TMEM16F
flox/flox
FoxJ1Cre (fl/fl-FoxJ1) airways under 
control conditions, after OVA sensitization and after exposure to carbachol (CCH, 25 mg/ml, nebulizer). 
Bars indicate 10 µm. B) Summary alcian blue staining in fl/fl and fl/fl-FoxJ1 animals. Mean ± SEM; 
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#
significant difference when compared to con (unpaired t-test). 
§
significant mucus release by CCH 
(unpaired t-test). 
$
significant difference when compared to fl/fl (unpaired t-test). (n) number of airways 
analyzed. 
 
TMEM16F is required for intestinal mucus production and secretion. 
We examined whether TMEM16F is also important for intestinal mucus secretion and 
measured acute mucus release in freshly excised colonic segments mounted in a vertical 
custom-designed perfusion chamber at 37 °C and 24 mmol/l HCO3
-/5 % CO2 
255. Secretion of 
mucus was induced by basolateral perfusion with methacholine (MCh) and by luminal 
perfusion of ATP 255. Both, MCh and ATP induced secretion of mucus in colon from 
TMEM16Fflox/flox and TMEM16Fflox/floxVil1Cre mice (Fig 6.6 A). 
Although acute perfusion with ATP induced mucus release in TMEM16Fflox/floxVil1Cre mice 
(Fig 6.6 A), a milder defect in mucus release might be present in the colon of these mice 
because i) ATP-induced mucus release was attenuated according to PAS stainings (Fig 6.6 
D,E) and ii) MCh induced release was augmented, suggesting an accumulation of mucus (Fig 
6.6 A). These data suggest a defect in basal, i.e. ATP-driven mucus secretion, upon intestinal 
epithelial knockout of TMEM16F. Albeit being milder, the effect is similar to the secretory 
defect described recently in mice lacking intestinal epithelial expression of TMEM16A 
(TMEM16Aflox/floxVil1Cre) 255. Of note, TMEM16Fflox/floxFoxJ1Cre mice showed normal 
expression of purinergic or muscarinic receptors (not shown). Like in TMEM16Aflox/floxVil1Cre 
mice, cholinergic mucus secretion was uncompromised in TMEM16Fflox/floxVil11Cre mice. 
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Fig 6.6 Production of mucus but not release is affected in TMEM16F
flox/flox
CreVil1 intestine. 
A) Acute mucus secretion in excised colon from TMEM16F
flox/flox
 (fl/fl) and TMEM16F
flox/flox
CreVil1 (fl/fl-
Vil1) animals. Mucus release was assessed in in vitro perfused colon and was induced perfusion with 
methacholine (100 µM) or ATP (100 µM) respectively. B-E) PAS staining of proximal colon before and 
after stimulation with methacholine (100 M) (B, C) or ATP (100 µM) (D, E). Bars indicate 50 µm. Mean 
± SEM; 
#
significant difference when compared to control (unpaired t-test). 
§ 
significant difference when 
compared to TMEM16A
flox/flox
 (unpaired t-test). (n) number of perfused colons and PAS stainings, 
respectively. 
 
Niclosamide blocks mucus secretion and inhibits intestinal Ca2+ signals. 
We examined whether Niclosamide inhibits intestinal mucus secretion. To this end, 
Niclosamide was added to the perfusate. This clearly inhibited mucus secretion activated by 
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luminal ATP but not basolateral MCh (Fig 6.7 A). Niclosamide was applied in vivo by 
intraperitoneal (ip) injection for three days, or was applied orally by gavage for seven days 
before intestinal perfusion. Both ip and oral application of Niclosamide completely inhibited 
ATP-induced release of mucus. Although mucus release was inhibited by Niclosamide, mucus 
did not accumulate in goblet cells, indicating again inhibition of mucus production by 
Niclosamide (Fig 6.7 B-E). 
 
Fig 6.7 Effect of Niclosamide on intestinal mucus release. 
A) Acute mucus secretion in excised wt colon activated by methacholine or ATP, respectively, and 
inhibition by acute perfusion with Niclosamide (Niclosamide; 10 µM). B-D) Effect of intraperitoneal 
injection of Niclosamide (13 mg/kg/day) on PAS staining (B, C) and acute mucus discharge induced by 
perfusion with 100 µM ATP (D). E-G) Effect of application of Niclosamide by gavage (13 mg/kg/day) on 
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PAS staining (E, F) and acute mucus discharge induced by perfusion with 100 µM ATP (G). Bars 
indicate 50 µm. Mean ± SEM; 
#
 significant difference when compared to Niclosamide (unpaired t-test). 
(n) number of perfused colons and PAS stainings analyzed, respectively.  
We reported earlier the role of TMEM16F for intracellular Ca2+ signaling 80. Here we found 
reduced Ca2+ increase upon ATP-stimulation of freshly isolated crypt cells from 
TMEM16Fflox/floxVil1Cre (Fig S6.2 A-C). In contrast, CCH-induced Ca2+ rise was not affected. It 
shows that TMEM16F is relevant for purinergic (luminal) but not cholinergic (basolateral) 
receptor signaling (Fig S6.2 D). ATP-induced Ca2+ rise was potently inhibited by low 
concentrations of Niclosamide (Fig S6.2 E). Comparable results were obtained in cells from 
large intestine (Fig 6.2 F,G). As demonstrated recently, increase in FM4-64 fluorescence in 
the plasma membrane is a marker for membrane exocytosis 255. We found that ATP-
stimulation (but not cholinergic stimulation) of HEK293 cells expressing TMEM16F, induced 
FM4-64 fluorescence, i.e. exocytosis (Fig S3). Taken together, the data demonstrate that both 
airway and intestinal mucus production and secretion depend on TMEM16F, and are potently 
inhibited by Niclosamide. 
 
Discussion 
Role of TMEM16A/F in inflammatory airway diseases. 
The present paper shows the importance of TMEM16F for mucus production and mucus 
secretion and identifies TMEM16F in vivo as a target of the anthelmintic drug Niclosamide. 
We may therefore propose TMEM16 inhibitors, and particularly Niclosamide, as a novel 
pharmacological tool to treat diseases with excessive mucus secretion, such as the 
inflammatory airway diseases asthma, COPD and CF, as well as intestinal mucus 
hypersecretion in CF. Mucus hypersecretion in airways results in mucus plugging, causing 
reduced mucociliary clearance, the predominant problem in CF lung disease 213. Pronounced 
upregulation of TMEM16A was observed in asthma during Th2-driven goblet cell metaplasia 
and mucus hypersecretion, but it was unclear if TMEM16A is required for mucus production 
or release 189. TMEM16A expression is driven via IL4/IL-13/STAT6 and by bacterial antigens 
219, 262.  
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Using T16Ainh-AO1 inhibitor, regulation of MUC5AC-expression by TMEM16A via 
STAT6/Erk1,2 was proposed 263. However, TMEM16A inhibitors, including T16AinhAO1, are 
non-specific and inhibit other TMEM16 proteins as well 140. The present results show that in 
the absence of TMEM16A goblet cell metaplasia is uncompromised (Fig 6.3 C). In contrast, 
SAM pointed domain-containing ETS transcription factor (SPDEF) activated via STAT6 is an 
essential regulator of Th2-dependent mucus production and goblet cell hyperplasia 227. The 
data shown here demonstrate a role of TMEM16F for mucus production in airways and 
intestine. Like TMEM16A, also TMEM16F (along with TMEM16K) are upregulated during 
Th2-dependent goblet cell metaplasia (Fig 6.3 F). These three proteins are among the three 
main TMEM16 paralogs expressed in human and mouse airway epithelium 130, 257. They are 
inhibited by TMEM16 blockers such as NPPB, NS3728, T16inhAO1, or NFA 122, 140.  
 
TMEM16A/F control intracellular Ca2+ signals and exocytosis. 
TMEM16A, F, K augment intracellular Ca2+ signals induced by stimulation of G-protein 
coupled receptors. This has been demonstrated in naïve mouse epithelial cells from airways, 
intestine and kidney, as well as macrophages, sensory neurons, and a number of different 
cell lines 80, 126, 128, 134, 160, 193, 200. It is also shown in the present study (Fig S6.2). Enhanced 
GPCR-triggered intracellular Ca2+ signaling induced exocytosis of mucus and increases 
plasma membrane localized signaling and membrane expression of CFTR 222, 255 200. In 
epithelial cells, TMEM16 proteins are located in apical membranes, in subapical 
compartments, in the basolateral membrane, or in intracellular compartments 80, 128, 130. Thus, 
they affect Ca2+ signals at different cellular locations and therefore have an impact on different 
cellular functions, causing various tissue defects and symptoms when mutated 52. Intracellular 
Ca2+ signals may be enhanced through tethering of the endoplasmic reticulum to the plasma 
membrane by TMEM16A, or by Ca2+ influx through TMEM16F 63, 80.  
However, He et al. described another interesting link between expression/activation of 
TMEM16A and the intracellular Cl- concentration 222. The team demonstrated that activation of 
TMEM16A affects localization of phosphatidylinositol-4,5-bisphosphate (PIP2) in the plasma 
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membrane, by changing the intracellular Cl- concentration. Plasma membrane PIP2 is 
required for proper recycling of endosomes, increase in plasma membrane surface area and 
exocytosis 222. Such a scenario would also explain enhanced purinergic Ca2+ signals and 
mucus exocytosis in the presence of TMEM16A and TMEM16F. Moreover, it could be the 
reason for the pleiotropic cellular effects induced by expression of TMEM16 and the 
pathology observed in knockout mice or patients 264. 
 
Not activation, but Inhibition of TMEM16 may improve CF lung disease  
Pharmacological activation of TMEM16A and induction of Cl- secretion is currently thought to 
improve CF lung disease 169. However, in CF activation of Cl- secretion through stimulation of 
TMEM16A may be ineffective because i) maturation/function of TMEM16A in CF tissues is 
compromised 190, 200, and ii) Ca2+ activated Cl- secretion is essentially through CFTR and not 
through transient CaCC 161, 200. Related to this, earlier trials using stabilized purinergic ligands 
(denufosol) to restore Ca2+ dependent Cl- secretion in CF, failed to demonstrate any beneﬁt 51, 
265. 
Using Niclosamide as a potent inhibitor of TMEM16 may have a number of beneficial effects 
in CF: i) It is a potent inhibitor of excessive mucus secretion as shown in the present study. ii) 
It relaxes airways and thereby reduces bronchoconstriction 241 (and present study). iii) It is a 
commonly used FDA-approved drug, which is well tolerated 266. iv) It was shown to inhibit 
Pseudomonas aeruginosa quorum sensing 267. v) Inhalable formulations of Niclosamide have 
been developed for the treatment of Pseudomonas lung infections 268. vi) It was shown to 
have broad antimicrobial effects directed against hospital-acquired bacterial infections 269. vii) 
It is anti-inflammatory 270 (and present study). viii) It has additional anti-cancer effects 271. 
Taken together all reported positive effects of Niclosamide, additional preclinical studies and 
subsequent clinical pilot studies appear indicated. 
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Supplementary material  
 
Supplementary Fig 6.1 Inhibition of Ca
2+
 signaling by Niclosamide in different cell types. 
 A-B) HT29 cells were loaded with the Ca
2+
-sensitive dye Fura-2 (5 µM/30 min). 10 µM ATP was applied 
to stimulate purinergic receptors, which increased intracellular Ca
2+
 and activated TMEM16A. 
Activation of TMEM16A was inhibited in the presence of Niclosamide (Niclo, 5 µM), which also inhibited 
ATP-induced Ca
2+
-release from the endoplasmic reticulum (peak) and blocked store operated Ca
2+
 
influx (plateau). C-D) ATP-induced Ca
2+
 increase in goblet cells of freshly isolated colonic crypts. ATP 
(100 µM) was applied in the absence (black curve) or presence (red curve) of Niclo (100 nM). D) 
Summary of ATP-induced Ca
2+
 changes in goblet cells, indicating inhibition of peak and plateau Ca
2+
 
increase by Niclo. E-F) Ca
2+
 increase in HEK293 cells expressing endogenous TMEM16F only, or 
overexpressing TMEM16A together with endogenous TMEM16F. Ca
2+
-rise by the activator of 
TMEM16A, EACT (50 µM), was inhibited by Niclo (1 µM) (n=60-70). Mean ± SEM; (number of 
experiments) 
#
significant inhibition by Niclo (p<0.05; unpaired t-test). 
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Supplementary Fig 6.2 Inhibition of intestinal Ca
2+
 signals in the absence of TMEM16F, and by 
Niclosamide.  
A) Crypt from small intestine (jejunum) loaded with the Ca
2+
 dye Fura-2 (5 µM/30 min). B) ATP (100 
µM) induced Ca
2+
 signals in crypt cells from TMEM16F
flox/flox
 (fl/fl) and TMEM16F
flox/flox
 Vil1Cre (fl/fl-Vil1) 
littermates. C, D) Summary of ATP (100 µM) and carbachol (CCH, 100 µM) induced Ca
2+
 peaks, 
respectively. E) Inhibition of ATP-induced Ca
2+
 increase by two different concentrations of Niclosamide 
(Niclo). F, G) Summary of ATP (100 µM) and carbachol (CCH, 100 µM) induced Ca
2+
 peaks in colonic 
crypt cells from fl/fl and fl/fl-Vil1 littermates. Mean ± SEM; (number of experiments) 
#
significant 
difference when compared to fl/fl (p<0.05; unpaired t-test). * significant effect of Niclosamide (Niclo; 
p<0.05; paired t-test). 
 
 
 
 
 
 
 
 
 
Niclosamide repurposed for the treatment of inflammatory airway disease 
167 
       
 
Supplementary Fig 6.3 Coupling of P2Y2 receptors but not muscarinic M3 receptors with TMEM16F.  
A) Effect of ATP (100 µM) on plasma membrane insertion of the lipid dye FM4-64, present in the 
extracellular bath solution. Increase in FM4-64 fluorescence in the plasma membrane of HEK293 cells 
can be taken as a measure for endosomal recycling/exocytosis. Cells expressing TMEM16F in addition 
to P2Y2 receptors, show stronger basal FM4-64 fluorescence, which is further enhanced by stimulation 
with ATP. Inset: FM4-64 labeled HEK293 cell. B) Effect of CCH (carbachol; 100 µM) on FM4-64 
insertion and staining of the plasma membrane in HEK293 cells expressing mock/M3R or 
TMEM16F/M3R. Lower basal FM6-64 fluorescence and lack of muscarinic stimulation of membrane 
exocytosis was observed in these cells. Mean ±SEM; (n) number of experiments. 
 
 
Discussion 
  
Discussion 
 
TMEM16 proteins control cellular functions by modulating Ca2+ signaling in 
microdomains 
 
Function of TMEM16A in smooth muscles 
 
We show that TMEM16A augments Ca2+ signals induced by stimulation of phospholipase C 
coupled GPCRs, release of 1,4,5-trisphosphate (IP3) (Chapter 2, Fig 1 I/J. Fig 2A/B). Our 
findings correlate with studies conducted in dorsal root ganglia 79 and in yeast 125. In the 
gastrointestinal tract, TMEM16A is expressed in interstitial cells of Cajal, 272 where it 
modulates their pacemaker activity. Cajal cells regulate intestinal smooth muscle contraction 
by calcium oscillation, which is an IP3 receptor mediated process 
273. This mechanism is 
triggered by adrenergic induced Ca2+ store release and leads to CaCC activation 274. 
Activation of CaCC leads to membrane depolarization and activation of voltage dependent 
calcium channels (L-type), and to further calcium influx 273. A mouse model for total knockout 
of TMEM16A showed defective smooth muscle contraction, confirming a physiological role for 
TMEM16A for proper gastric motility 229. 
In the airways and reproductive tract, TMEM16A is also found in the smooth muscle cells 152. 
Contraction of airway smooth muscles (ASM) is under the control of a number of stimuli. The 
agonist binding to the receptor triggers a signaling cascade that involves the activation of the 
Gq/11 proteins and Phospholipase C (PLC). PLC catalyzes the hydrolysis of PIP2 in IP3 and 
DAG. IP3 binding to its receptor in the ER triggers Ca
2+ store release. Emptying of the Ca2+ 
store is followed by Ca2+ influx and finally by airway contraction (Fig 7.1). Ca2+ influx can 
occur by several mechanisms. Firstly, by opening of L-type voltage gated Ca2+ channels 
(VGCCs) activated through membrane depolarization 275. Secondly, Ca2+ can enter the cell 
via receptor-operated channels (ROCs), which are activated upon binding of the agonist 276, 
277. A third mechanism for Ca2+ entry involves store operated Ca2+ entry (SOCE) triggered by 
emptying of the Ca2+ store. This concept is defined as pharmacomechanical coupling. It is a 
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mechanism for Ca2+ entry that is independent of membrane depolarization. SOCE is 
considered the predominant regulatory system in vascular smooth muscle contraction 278. In 
asthmatic patients SOCE has been shown to cause narrowing of the airways, airway 
hyperresponsiveness and hyperplasia of smooth muscle mass 279. The role of TMEM16A in 
excitable cells as a modulator of calcium signals, thereby supporting airway smooth muscle 
contraction is fascinating. But how does TMEM16A modulate Ca2+ signaling in excitable 
cells? 
 
Fig 7.1: TMEM16 proteins control cellular functions by modulating Ca
2+
 signaling in microdomains. 
Model proposing separation of Ca
2+
 pools, and colocalization of TMEM16A with IP3 in a lipid raft A) 
TMEM16A tethers the ER to the plasma membrane thereby forming a functional microdomain. Release 
of Ca
2+
 from endoplasmic reticulum (ER) store, is followed by Ca
2+
 influx through store operated Orai1 
and Orai1/TRP (Transient Receptor Potential Channels) Ca
2+
 influx channels. B) Ca
2+
 activated 
TMEM16A secrets Cl
-
 (blue) and causes depolarization of the membrane voltage, which activates 
VGCCs (voltage gated Ca
2+
 channels) and Ca
2+
 influx.  
 
Our findings show that TMEM16A forms microdomains by tethering the ER to the plasma 
membrane through interaction with IP3 receptors (Fig 1 and Chapter 2, Fig 1E/F). Noteworthy, 
the yeast homologue of TMEM16A, Ist2, was shown to tether the cortical endoplasmic 
reticulum to the plasma membrane. In these apical microdomains, Ca2+ release from the Ca2+ 
store is facilitated by activation of TMEM16A. TMEM16A mediated Cl- secretion causes 
plasma membrane depolarization; this activates the voltage operated Ca2+ channels, leading 
to further calcium influx and augmented contraction of smooth muscle cells.  
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Function of TMEM16A in airway epithelial cells 
 
We show that TMEM16A is essential for membrane insertion and activation of CFTR. Thus, 
TMEM16A and CFTR demonstrate a tight functional and molecular relationship. The 
relationship between these two proteins and its role in CF has been observed for quite some 
time, but the results were somewhat controversial. The Boucher group and other research 
laboratories reported enhanced Ca2+ activated Cl- currents in airways cells from CF patients 
280. Along these results it was reported from the Kunzelmann lab that F508del-CFTR 
increases intracellular Ca2+ signalling, leading to increased CaCC activation281, 282. However, 
other studies suggested a rather inhibitory effect of CFTR on TMEM16A 170, 171.  
Our results from Chapters 3 and 4 suggest that CFTR and TMEM16A are functionally 
coupled. TMEM16A facilitates purinergic Ca2+ release in microdomains, thereby engaging 
Store Operated cAMP Signaling (SOcAMPS). The localized Ca2+ rise activates the Ca2+ 
sensitive Adenylate Cyclase type 1 leading to cAMP production and activation of CFTR. In 
other word; increase in intracellular cAMP activates TMEM16A through activation of the 
exchange factor directly activated by cAMP 1 (EPAC1) (Fig 2).  
 Ca2+ depletion from ER stores triggers aggregation of stromal interaction molecule 1 (STIM1; 
an ER membrane localized Ca2+ sensor 283) in multiple plasma membrane puncta. STIM1 
translocates to the junctions between ER and the plasma membrane, where it binds to the 
Ca2+ channel protein ORAI1 to activate Store Operated Calcium Entry (SOCE). Calcium influx 
mediated refilling of the stores inhibits SOcAMPs 284. We show that TMEM16A is a major 
player within this process; it provides the Ca2+ required for activation of ADCY1 and for 
production of cAMP, which will then activate CFTR. Similar findings related to our results were 
reported elsewhere and it was shown that CFTR is colocalized with EPAC1 in membrane lipid 
rafts 203 204.  
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Fig 7.2 TMEM16A and CFTR are functionally dependent and interact through EPAC1 and ADCY1. 
Purinergic stimulation induces Ca
2+
 release from the ER store. Ca
2+
 not only activate TMEM16A but 
stimulates also ADCY1 (Adenylate Cyclase type 1), which produces cAMP. The intracellular messenger 
cAMP activates CFTR via protein kinase A (PKA). Activation of ADCYs (Adenylate Cyclases) by 
Forskolin generates cAMP and activates not only CFTR, but also TMEM16A via EPAC1 (Exchange 
Factor Directly Activated by cAMP 1). 
 
These findings confirm what was reported previously in primary human bronchial cells, 
namely that CFTR also mediates chloride currents induced by purinergic stimuli 162. 
Interestingly purinergic activation of CFTR was independent of protein kinase C, calmodulin 
dependent kinase and intracellular calcium, but was suppressed by inhibition of 
phospholipase C 191. These observations together with our results suggest that purinergic 
activation of CFTR is mediated mainly through TMEM16A (Chapters 3 and 4). 
We show a functional overlap between CFTR and TMEM16A in terms of both membrane 
expression and activation of ion currents. (Chapter 3, Fig 4, Fig 5, Fig 6). Functional studies 
in the TMEM16A knockout animals revealed that CFTR is fully dependent on the presence of 
TMEM16A in the intestine (Chapter 3, Fig 2). The fact that no intestinal obstructions where 
observed in the knockout models could be explained by the fact that cAMP activated Cl- 
currents were still present in the jejunum. It appears that jejunal epithelial cell do not require 
TMEM16A for activation or membrane insertion of CFTR. We speculated that another 
membrane localized TMEM16 paralog might be expressed in the jejunal epithelial to 
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compensate for the lack of TMEM16A. In unpublished data we could show that TMEM16F, 
which is expressed in jejunal epithelium, can replace the function of TMEM16A. Another proof 
for the functional link between CFTR and TMEM16 proteins was obtained in experiments, in 
which trafficking of CFTR to the membrane was disrupted. CFTR accumulated in the Golgi 
and no longer reached the plasma membrane, whereas TMEM16A traffic was undisturbed. 
Under these conditions, cAMP induced Cl- currents were still detectable even in the absence 
of CFTR from the plasma membrane, and it was shown that cAMP activated TMEM16A via 
ADCY1 (Chapter 4, Fig 6H). Our results confirm that in CF, a significant portion of the cAMP-
activated Cl- current is due to activation of TMEM16A. Therefore screening for more potent 
activators of TMEM16A to treat CF appears well justified. However, the impact of TMEM16A 
on fluid secretion is probably negligible, because Ca2+ activated chloride secretion by 
TMEM16A is very transient. For functionally appropriate chloride secretion, a sustained 
activation of a chloride current by CFTR is needed. 
TMEM16A is also expressed in salivary glands 285, in pancreatic islets 286 and in neurons 126 in 
both mouse and human tissues. Huang et al reported in 2009 that TMEM16A is expressed in 
the apical membrane of tracheal epithelial cells 229. Surprisingly and although expressed 
rather sparsely TMEM16A mediates large Ca2+ activated chloride currents in bronchial 
epithelial cells and in CFBE41o– cells 189.  
Our results confirm expression of TMEM16A together with CFTR in airway epithelia cells 
(Chapter 3, Supplementary Fig 3E). Very recently, co-localization of TMEM16A, CFTR and 
ENaC in non ciliated cells was reported 287. The authors studied a possible compensatory 
system through TMEM16A in a cftr -/- mouse and in a Scnn1b-overexpressing mouse. In the 
absence of CFTR expression, the authors found no changes in either expression or function 
of TMEM16A 287. However, this could be explained by the lack of mucus plugging in these CF 
models. At any rate, there is consensus that TMEM16A is upregulated in asthma and in other 
inflammatory conditions. Treatment of bronchial epithelial cells with IL-4 increased both 
expression and function of TMEM16A 189. Other inflammatory stimuli can trigger upregulation 
of TMEM16A, such as bacterial peptides 219, Th2 cytokines, IL-13, as well as IFN-γ 288. In 
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addition, under inflammatory conditions TMEM16A is predominantly upregulated in mucus 
producing cells 152, 189 and submucosal glands 152 when compared to ciliated cells. This 
strongly suggests that the role of TMEM16A in mucus producing cells is dominating.  
 
TMEM16A plays an essential role in mucus secretion 
Functionally, airways epithelia are characterized by the presence of fluid secreting ciliated 
cells and ionocytes that promote mucus transport through coordinated action of motile cilia 
and maintenance of the ASL layer. This operates in concert with mucus producing club and 
submucosal goblet cells. The rare Foxi1-positive ionocytes have been described only recently 
as high CFTR expressing cells 289. Under healthy conditions, mucins are continuously 
synthesized and released from the club cells. Airways specific knockout for TMEM16A 
(TMEM16A-FoxJCreflox/flox) shows intracellular mucus accumulation in club cells without signs 
of inflammation (Chapter 5, Fig 1A). Mucus accumulation suggests an imbalance between 
mucus production and mucus secretion. We therefore concluded a defect in mucus secretion 
by airway club cells form TMEM16A-FoxJCreflox/flox mice. 
The striking finding was that mucus accumulated in club cells, although the TMEM16A was 
knocked out in ciliated cells. In the airways the ratio between ciliated and secretory cells is 
slightly shifted towards more ciliated cells (60% ciliated cells versus 40% club cells). Under 
inflammatory conditions, this ratio is shifted towards more club cells 290. We therefore 
wondered whether knockout of TMEM16A could have produced an inflammatory state or a 
genetic differentiation of ciliated cells towards club cells. We labeled club cells using the 
CCSP (Clara Cell Secretory Protein) antibody and ciliated cells using acetylated tubulin. We 
observed that the number of CCSP positive cells was not increased in mice lacking 
TMEM16A (Chapter 5, Fig 2C and Supplementary Fig 1A). This suggests that knockout of 
TMEM16A did not produce an inflammation and the normal proportion between ciliated and 
secretory cells is maintained. Several studies have reported that IL-13 increases the number 
of goblet cells in cultured epithelia, while suppressing the number of ciliated cells 291, 292. A 
study that made use of a lentiviral-mediated lineage–tagging approach using the human 
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FoxJ1 promoter, proved that goblet cells in response to IL-13 treatment derived from 
progenitor cells expressing FoxJ1 cells 293. However, we did not observe colocalization 
between CCSP and FoxJ1 or CCSP and acetylated tubulin (Chapter 5, Supplementary Fig 1 
D-F). TMEM16A knockout in ciliated cells may therefore cause a defect in the paracrine 
signaling that is normally required to drive mucus secretion by club cells. Possible molecules 
involved are ATP or Clca3, which corresponds to CLCA1 in humans (Fig 3). CLCA1 is a 
human zinc-metalloproteinase reported to be upregulated during airway inflammation 294. 
Matrix metalloproteinases (MMP) are a family of zinc-dependent endopeptidase. They are 
broadly expressed and modulate inflammation by regulating bioavailability and activity of 
cytokines, chemokines, and growth factors. CLCA1 was regarded a tumor suppressor and 
reported as such in breast cancer and melanomas 295. CLCA proteins are linked to the 
development of mucous cell metaplasia and possibly airway hyperactivity in experimental 
models and in humans 296. Several studies reported that Niflumic acid (NFA) blocks mucus 
secretion caused by CLCA3 297 and reduced ATP induced exocytosis of mucin granules298. In 
addition, NFA and MSI-2216 (both CaCC inhibitors) were shown to reduce the TNFalpha-
induced mucin expression and have a strong anti-inflammatory effect 299. An earlier study 
showed that Talniflumate, a precursor of NFA, reduces intestinal mucus obstruction in a CF 
mouse model 300. Talniflumate was shown to be nontoxic in phase II of a clinical trial and was 
considered for the treatment of asthma and COPD 301. CLCA1 was reported recently to 
stabilize TMEM16A in the plasma membrane, thereby increasing the number of channels at 
the cell surface and increasing the Ca2+ activated current. Despite these interesting findings, 
several questions are still unanswered: Is CLCA1 involved in the inflammatory process 
mediated by TMEM16A, and if so, what is the link between TMEM16A and CLCA1. Does 
knockout of TMEM16A in the ciliated cells in the mouse cause defective release of CLCA3 
from ciliated cells, which in turn causes mucus accumulation in club cells? 
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Fig 7. 3: Role of TMEM16A in airway epithelial cells.  
TMEM16A mediated secretion of paracrine factors by ciliated cells, acting as secretagogues for mucus 
exocytosis/secretion by club cells. TMEM16A knockout leads to accumulation of mucus intracellularly 
due to impaired constitutive exocytosis. 
 
Apart from this indirect effect of TMEM16A on mucus secretion, studies on intestinal goblet 
cells lacking expression of TMEM16A demonstrate also a direct role of TMEM16A for 
exocytosis and mucus release. We observed that TMEM16A-Vil1flox/flox mice also showed 
enhanced intracellular mucus content in goblet cells. In addition, in both airway and intestinal 
secretory cells, knockout of TMEM16A did not compromise cholinergic mucus secretion, i.e. 
compound exocytosis. Only apical ATP-induced mucus release was found to be TMEM16A 
dependent. These data reveal a novel function of TMEM16A in regulation of ATP-mediated 
mucus release by secretory cells. 
Discussion 
176 
       
 
Fig 7. 4 TMEM16A mediates ATP dependent constitutive exocytosis in the apical side of goblet cells. 
A) Model elucidating TMEM16A mediated constitutive exocytosis of mucus in granules on the apical 
side, and cholinergic dependent compound exocytosis on the basolateral side. B) Colinergic (CCH) 
mediated compound exocytosis occurs independently of TMEM16A from the basolateral side, while 
constitutive exocytosis is impaired. 
 
TMEM16A mediates not only mucus secretion, but also the release of inflammatory 
mediators. In fact our data show that in inflammatory airways of TMEM16A knockout mice 
CD45 positive leukocytes accumulation and contraction of the airway smooth muscle layer 
(ASM) was strongly reduced (Chapter 5, Fig 5.2F and Fig S5.2, and 152). These data replicate 
the findings of several other studies in which downregulation of TMEM16A reduced 
inflammation and neuropathy-induced hyperalgesia 302-304. Similar data were recapitulated in 
Calu-3 cells, where we found that LPS-induced release of IL-8 was significantly reduced by 
knockdown of TMEM16A (Chapter 5 Fig 5.7 A-B). In addition, we observed that IL-13 induced 
Muc5AC production was inhibited by the TMEM16A-blocker Niclosamide (Chapter 6, Fig 6.4 
A-C). 
 
Targeting TMEM16 proteins to treat CF? 
Excessive mucus secretion represents one of the main clinical hallmarks in respiratory 
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diseases, as well as in ulcerative colitis and irritable bowel syndrome 305, 306. Therefore, the 
need for novel drugs to control mucus hyperproduction is compelling. We investigated the 
effect of two compounds: Niclosamide, a FDA approved drug used as anthelmintic, that was 
found to be a potent bronchodilator 241 and NFA, a known CaCC inhibitor. Niclosamide and 
NFA inhibited purinergic Cl- currents in HEK293 cells expressing TMEM16A or TMEM16F 
(Chapter 6, Fig1 A-C and Fig 2A-D). In addition, both drugs showed a marked effect on Ca2+ 
signals in in freshly isolated intestinal cells (Chapter 6, Supplementary Fig 1A-D). In asthmatic 
mice, Niclosamide and NFA reduced mucus production and attenuated bronchoconstriction 
after acute application of cholinergic stimuli (Chapter 6, Fig 3 C-E). Moreover, both inhibitors 
reduced the inflammation in asthmatic mice (Chapter 6, Fig 3H). 
Th2-induced goblet cell metaplasia occurs at the same rate in both normal asthmatic mice 
and asthmatic mice lacking expression of TMEM16A. Therefore, we speculated that not 
TMEM16A, but other members of TMEM16 family are in charge of mucus production. 
Deletion of TMEM16A in the airways (TMEM16F-FoxJCre flox/flox) displayed mucus 
accumulation similar to TMEM16A-FoxJCre flox/flox mice but showed attenuated mucus 
accumulation when compared to wild type mice (Chapter 6, Fig 5 A-B). Acute cholinergic 
stimulation induced mucus release in wt and TMEM16F-FOXJCre flox/flox mice. However, the 
amount of mucus release was clearly less in the tissue specific TMEM16F knockout mice. 
Taken together the results suggest a predominant role of TMEM16A for mucus secretion, and 
a role for TMEM16F in both mucus production and secretion. 
In the intestine, ATP induced mucus secretion was also attenuated in TMEM16F-Vil1flox/flox 
mice similarly to the TMEM16A-Vil1flox/flox mice, while, cholinergic release was augmented 
compared to wt mice (Chapter 6, Fig 6A). Interestingly, pretreatment of the mice with 
Niclosamide inhibited apical ATP-induced release, but not basolateral cholinergic induced 
mucus secretion. Since mucus accumulation was not observed, these results suggested 
inhibition of both mucus production and mucus secretion by Niclosamide (Chapter 6, Fig 7 A-
G). Freshly isolated colonic crypt from TMEM16F-Vil1flox/flox mice showed a reduced ATP 
induced Ca2+ rise while the CCH-induced increase of intracellular Ca2+ concentration was 
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unaffected (Chapter 6, Supplementary Fig 2 A-G). Taken together these results indicate a role 
for TMEM16F in mucus production and mucus secretion. We also show that TMEM16F is 
involved in purinergic (luminal) but not cholinergic (basolateral) receptor signaling. Taken 
together both TMEM16A and TMEM16F are inhibited by Niclosamide, which appears suitable 
to treat excessive mucus secretion in vivo.  
Upregulation of TMEM16A during inflammation strongly supports bronchoconstriction. The 
role of TMEM16A in provoking bronchoconstriction was further shown in asthmatic mice, by 
activating TMEM16A directly using the activator EACT. EACT induced massive mucus release 
and airway contraction (Chapter 5, Supplementary Fig 8 A-C). 
Therefore, blocking of TMEM16A activity will not only inhibit the release of mucus and 
cytokines, but will also promote bronchorelaxation. Inhibition of TMEM16A will block the 
release of inflammatory mediators and therefore which is likely to provide an additional 
beneficial effect in inflammatory airway and intestinal disease. Given the tight regulatory 
relationship between TMEM16A and CFTR, blocking TMEM16A and mucus secretion in CF 
may appear counterintuitive, because residual epithelial Cl- secretion via TMEM16A and 
mutated CFTR will also be blocked. However, we reported that the net secretory Cl- flux 
through TMEM16A is rather small and mostly occurs though CFTR. Moreover, Cl- secretion 
occurring through CFTR is already compromised in CF. Thus, the benefit through inhibition of 
mucus secretion may well exceed potential drawbacks due to potential inhibition of Cl- 
secretion. Our studies suggest that both TMEM16A and TMEM16F might play major roles in 
mucus secretion and production. Both proteins can be used as pharmacologic targets in CF 
therapy. We therefore propose inhibitors of TMEM16A as a new class of drugs that reduce 
mucus secretion in inflammatory airway diseases (an overview of TMEM16 inhibitors and 
activators is given in Table1 and Table 2 of Appendix II).  
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Conclusions and further perspectives  
 
Development of new drugs is a challenging, time consuming and expensive process. Re-
profiling of approved drugs is cost-effective, fast and saves resources. Niclosamide is a FDA 
approved drug already in use against the tapeworm Hymenolepis infestations, and is used in 
several clinical trials to treat colonic cancer and prostatic cancer. We report that Niclosamide 
is a potent inhibitor of TMEM16 proteins and may have a number of beneficial effects in CF. 
As we show in the present study it inhibits excessive mucus secretion and is a potent 
bronchorelaxant. In addition, several studies have proposed Niclosamide for the treatment of 
Pseudomonas aeruginosa lung infections. Niclosamide was proved to be a strong inhibitor of 
P. aeruginosa quorum sensing (QS) response and inhibits the production of acyl-homoserine 
lactones QS signal molecules 307. Moreover, it was reported to combat existing biofilms of 
several relevant Gram-positive bacteria, namely strains of Staphylococcus aureus, including 
methicillin MRSA, and Staphylococcus epidermidis, all common causes of hospital-acquired 
and device-associated infections 269. Taken together all reported positive effects of 
Niclosamide strongly suggest its use in inflammatory airway and intestinal disease. 
Considering the role of TMEM16A in exocytosis, it will be interesting to look into the role of 
TMEM16A in activation of immune cells and neutrophil degranulation. Exocytosis of granules 
in neutrophils requires increase in intracellular Ca2+ 308 likewise other secretory processes. We 
may therefore examine the release of neutrophil elastase and the release of other 
proinflammatory factors.  
Niflumic acid is a known COX-2 inhibitor. COX-2 (cyclooxygenase-2) is an enzyme involved in 
the conversion of arachidonic acid toprostaglandins. COX-2 is upregulated during 
inflammation and in cancer. It was shown that in pancreactic ductal adenocarcinoma (PDA), 
COX-2 upregulation is under the influence of MUC1. MUC1 upregulation increases COX-2 
and vice versa, downregulation of MUC1 attenuates COX-2. In addition, upregulation of COX-
2 via Interleukin 1β upregulates MUC5AC and MUC2 by a mechanism that dependents on 
mitogen-activated protein kinase (MAPK) 309. It is known that TMEM16A is involved in tumor 
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progression, and that this involves induction of the RAS-RAF-MEK-ERK1/2 pathway310. 
Therefore, a link between TMEM16A and COX-2 during mucus production should be further 
examined. In particular it will be interesting to learn about their role in inflammation and 
whether COX-2 is responsible for TMEM16A-mediated inflammation. In addition, recent 
studies showed that reactive oxygen species (ROS) also activate the TAK1-MAPKs/NF-κB 
pathway. This leads to induction of COX-2 and therefore MUC5AC and MUC2 accumulation. 
Along this line, ROS was shown to induce lipid peroxidation and activation of TMEM16F 
during chronic inflammation65. Along this line, a role of fatty acids during exacerbation of P. 
aeruginosa infection has been shown recently 311. It appears attractive to speculate on a 
functional role of TMEM16A and TMEM16F in modulating airways inflammation and lung 
remodeling.  
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Table 1 Appendix 1 Members of the TMEM16 family and their significance in diseases.  
TMEM16 
PROTEINS 
LOCALIZATION PATHOLOGY 
TMEM16A/ANO1 
 
Broadly expressed in 
secretory epithelia
312
 and 
skeletal muscles
313
. 
 
Upregulated in renal cancer,head and neck 
cancer, pancreatic cancer and lung cancer
314, 315
. 
 
TMEM16B/ANO2 
 
Mainly expressed in 
chemosensory neurons. 
Upregulated in colorectal cancer. 
TMEM16C/ANO3 
Expressed mainly in the 
brain, particularly in the 
putamen 
316
. 
 
 
Mutation of this protein have been associated 
with dominant craniocervical dystonia 
316
 due to 
disturbances in the Ca
2+
 signaling. 
Hypersensitivity to high temperature. Na
+
 and K
+ 
currents largely reduced. 
 
TMEM16D/ANO4 Neuronal tissue. 
 
Upregulated in patients with aldosterone 
adenomas and pheochromocytoma in the zona 
glomerulosa of the human adrenal gland. 
 
TMEM16E/ANO5 
Skeletal muscles and the 
tyroid. 
Responsible for the bone-related late-onset 
disease gnathodiaphyseal dysplasia (GDD) 
317
, 
in the Limb-girdle muscular dystrophy type 2L 
(LGMD2L) 
318
. 
 
TMEM16F/ANO6 
 
Broadly expressed.  
Upregulated in breast cancer and cervical 
cancer 
TMEM16G/ANO7 Epithelial tissues. 
 
Prostate cancer. 
 
TMEM16H/ANO8 
Upregulated in the 
substanzia nigra and in the 
cerebellum. 
Upregulated in a variety of cancer. 
TMEM16I/ANO9 
 
Gastro intestinal tract and 
pancreatic cells 
319, 320
. 
 
Upregulated in Head and Neck cancer. 
TMEM16K/ANO10 
 
Broadly expressed in 
human, while in the mouse 
is preferentially expressed 
in the pancreas and in the 
thyroid 
53
. 
 
A coding variant of Tmem16K (ANO10-R263H) 
was shown to have an impact on the human 
immune response against Borrelia. Mutations of 
TMEM16K are also causing recessive cerebellar 
ataxia
123
, epilepsy, cognitive impairment and 
coenzyme Q10 deficiency
123
. 
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Appendix II 
INHIBITORS IC50 (µM) 
5F (Ani9  derivative) 0.02 
10bm
321
 0.03 
Monna
322
 0.08 
Niclosamide
241
 0.7 
Ani9
323
 0.1 
Tannic Acid
324
 0.323 
T16A-AO1
325
 1.1 
Dichlorophen
321
 5.49 
Idebenone
326
 5.52 
Shikonin
327
 6.5 
Benzbromarone
269
 9.97 
CACC-A01
175, 328
 10 
9-Phenantrol
329
 12 
Nifumic Acid
299
 12 
Flufenamic Acid
330
 28 
Talniflumate
300
 - 
Dehydroandrographolide
331
 
20-30 
DIDS
332
 10-100 
NPPB
333
 15-150 
ACTIVATORS IC50 (µM) 
Brevenal - 
Eact
334
 3 
INO-4995
335
 5 
Denufosol
265
 10 
Cinnamaldehyde
336
 10 
Ginsenoside Rb1
337
 38.4 
Table 1 Appendix 2: Effects of TMEM16A inhibitors and activators. 
Inhibitors: Antioxidative
322
, anti-inflammatory, anti-hypertensive, bronchorelaxant, reduce cancer cell 
proliferation, reduce rotavirus-induced diarrhea
338
, reduce capsaicin-induced nocifensive behaviors
116
, 
reduced contractile tone in vascular and airway smooth muscle
249, 325, 339
, reduced intestinal motility 
327
. 
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Activators: Stimulate epithelial chloride secretion and intestinal contraction
156
, elicit pain and hitchy 
behaviour
334
, pro-proliferatory activity, induction of nociceptive responses
70
. 
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